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vMeasurement of Autonomic Function in Renal Disease and Diabetes
Renal disease and diabetes lead to dysautonomia resulting in consequences
ranging from gastroparesis to sudden death.  New technologies to detect dysautonomia,
such as 24-hr heart rate variability, are being evaluated and compared to traditional
evoked tests.  These advances have, however, lead to a lack of standardization in testing
batteries, procedures, and reporting formats.  This series of 3 studies psychometrically
assessed measures of autonomic function (AF) and explored relationships among
objective and subjective measures in healthy adults and uremic patients.
Participants underwent evoked tests that included change in heart rate with deep
breathing and Valsalva.  In addition, measures of 24-hr HRV (time-domain: SDNN,
SDANN, RMSSD; frequency-domain: total power, low and high frequency) and
symptomatology were obtained.
Study 1 examined the development and psychometric testing of the Autonomic
Symptom Checklist (ASC), an instrument designed to assess autonomic symptomatology,
with uremic patients (n=244) and healthy adults (n=34).  Findings showed the ASC was
able to differentiate among healthy and uremic patients with and without diabetes.  Test-
retest reliability was moderate to high for most categories.
Study 2 established normal, borderline, and abnormal AF values and determined
if these values could distinguish healthy (n=158) from uremic adults (n=363).  Abnormal
values were established at the 2.3 quantile of healthy adults. Uremic patients, especially
those with diabetes, had much poorer values than healthy adults. The influence of age and
gender on AF measures was attenuated in uremic as compared to healthy adults.
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Study 3 examined relationships among and the clinical utility of evoked tests, 24-
hr HRV, and the ASC.  Data were obtained from pre (n=130) and post (n=55) kidney and
kidney-pancreas transplant recipients (n=130), and healthy adults (n=22).  The frequency
of abnormal values was used to identify the most sensitive measure.  Measures of 24-hr
HRV were more sensitive than evoked measures, with frequency measures being most
sensitive.
In conclusion, this series of studies established reliability and validity for the
ASC, referent values for AF tests, devised a scoring system for AF tests, and found 24-hr
HRV measures more sensitive than evoked measures.
vii
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1Chapter 1.  Introduction
Autonomic nervous system dysfunction, dysautonomia, is responsible for
incapacitating and life threatening patient outcomes ranging from gastroparesis to sudden
cardiac death.  Depending on the nature and frequency of the symptoms, dysautonomia
can have a devastating effect on quality of life.  These conditions are prominent in
patients experiencing end-stage renal disease (ESRD), and those who also have diabetes
mellitus experience even poorer autonomic function.  Cardiovascular autonomic function
is of particular concern for patients with ESRD and diabetes as 50% of this population
die within two years of initiating maintenance hemodialysis therapy, many from
consequences of cardiovascular complications1.
In the last twenty years, a wide-variety of disciplines, including neurology,
cardiology, physiology and nursing, have examined autonomic function.  This has lead to
rapid change and development in the methods to evaluate, manage, and treat
dysautonomia.  Unfortunately, this growth has also caused a lack in standardization in
testing batteries and procedures, in addition to diversity in reporting formats.  Thus,
sharing of findings and building on the findings of other researchers both within and
among disciplines has been hampered.
Currently, numerous studies are examining objective measures of autonomic
function in a variety of populations.  However, only one study was found that examined
and documented subjective symptoms of dysautonomia.  In addition, no self-administered
instruments with established psychometric properties were available to measure
symptoms of dysautonomia.  Although symptoms of dysautonomia usually do not occur
2until objective measures are present, it is the symptoms that bring the patient to the health
care system.  Thus, symptoms of dysautonomia, particularly orthostatic hypotension and
impotence, prompt objective testing for dysautonomia and may subsequently lead to
treatment.  In order to correlate symptoms with objective measures of dysautonomia and
to evaluate interventions designed to improve autonomic function, a psychometrically
sound instrument designed to measure subjective symptoms of dysautonomia needs to be
developed and tested.
 Due to the lack of a clear methodology for autonomic measurement and a lack of
consistency in analysis and reporting of findings both within and among disciplines,
generally accepted referent values for both healthy individuals and patient populations
have not been established.  Within the literature, individual studies report normal
values2, 3, but these values are for narrowly defined groups and are frequently based on
the autonomic function of healthy adult men.  It is generally recommended that each
autonomic function lab should establish its own referent values for both healthy and
patient populations4, 5.  Thus, referent values for both healthy groups and the ESRD
population need to be established.
The rapid and diversified growth in the methods and instruments used to
objectively quantify autonomic function has further added to the confusion.  With recent
technological advances, newer methods of autonomic function testing are being evaluated
and findings reported.   Some traditionally reported measures are currently being found
less sensitive to early changes in autonomic function, while some investigators consider
the cutting-edge technology to lack validity.  The Physiologic Function Lab at our center
has been using two techniques to collect data on physiological measures of autonomic
3function, evoked and 24-hr tests of heart rate variability (HRV).  Patient reported
symptomatology data have recently been added to the repertoire of tests.  Establishment
of normal referent values, development of a score system for each group of these
measures, and subsequently examining the relationships among all measures and scores
with both ESRD patients and a group of healthy controls would permit establishment of
validity, and evaluation of sensitivity among the measures.  In addition, symptomatology
could then be correlated with objective measures of dysautonomia.  This would possibly
lead to the determination of a threshold where objective measures of autonomic function
could predict the development of symptoms.  If such a threshold could be found,
interventions could be implemented prior to the development of symptoms.
 The objective measurement of autonomic function is in a state of change and
symptomatology has not been consistently evaluated and correlated with objective
measures.  Thus, the purpose of this research was to psychometrically assess measures of
autonomic function and explore relationships among objective and subjective
measurements of autonomic function in normal healthy adults and ESRD patients.
Specifically, the aims of this investigation were to:
1. Develop a reliable and valid instrument, the Autonomic Symptom Checklist, to assess
symptomatology associated with dysautonomia.
1a)  To what extent does the Autonomic Symptom Checklist demonstrate validity by
distinguishing among known groups with and without dysautonomia?
1b)  To what extent does the Autonomic Symptom Checklist demonstrate reliability
 in patients with end-stage renal disease and in healthy adult individuals?
1c) To what extent is the Autonomic Symptom Checklist useful as an instrument for
4      autonomic symptomatology assessment?
2. Establish evoked autonomic function, 24-hr HRV, and symptomatology referent
values for healthy adult individuals and values that are characteristic of patients with
end-stage renal disease.
2a) What responses to evoked cardiovascular function testing, 24-hr HRV
 monitoring, and autonomic symptomatology are characteristic of healthy adult
 individuals and adult ESRD pretransplant patients?
2b) What are the relationships among age and measures of evoked cardiovascular
function, 24-hr HRV monitoring, and autonomic symptomatology for healthy
adult individuals and adult ESRD pretransplant patients?
2c) What are the differences among measures of evoked cardiovascular function,
24-hr HRV monitoring, and autonomic symptomatology for healthy adult men
and women and adult men and women ESRD pretransplant patients?
2d) What are the relationships among measures of autonomic function in healthy
adult individuals and adult ESRD pretransplant patients?
2e) What are normal, borderline, and abnormal values for evoked autonomic tests,
24-hr HRV, and Autonomic Symptom Checklist measures?
3. What are the correlations and sensitivities among evoked tests, 24-hr HRV
monitoring, and Autonomic Symptom Checklists?
3a) What are the correlations of within test measures of evoked tests, 24-hr heart
rate variability tests, and Autonomic Symptom Checklists?
3b) What are the correlations among evoked scores, 24-hr HRV time- and frequency-
domain scores, the 24-hr heart rate variability score, and the Autonomic Symptom
5Checklist score?
3e) What are the clinical utility and sensitivity of evoked scores, 24-hr heart
rate variability scores, and Autonomic Symptom Checklist scores?
The Autonomic Nervous System
The autonomic nervous system (ANS) performs vital regulatory functions using
primarily efferent fibers to control multiple organ systems including cardiorespiratory,
gastrointestinal, and genitourinary.  These systems are largely independent of conscious
control, but can be affected by both conscious control and emotional output.  In addition,
the body uses the ANS to maintain normal homeostasis by regulating body temperature,
blood pressure and fluid and electrolyte balance6, 7.
The multiple functions of the ANS are accomplished through a balance of
excitatory and inhibitory impulses which originate from centers in the spinal cord, brain
stem, and higher centers and which are transmitted via parasympathetic and sympathetic
pathways.  The efferent pathways arising from the craniosacral area of the spinal column
carry the parasympathetic fibers; those from the thoracolumbar region carry the
sympathetic fibers.  Both parasympathetic and sympathetic divisions have a central and
peripheral component.  In addition, in recent years the concept of a central autonomic
network, which is located in the brainstem and spinal cord and functions to integrate and
regulate the parasympathetic and sympathetic divisions, has become accepted.
The nucleus tractus solitarius located in the medulla oblongata is the area where
much of the integration between afferent and efferent fibers occurs.  This area obtains
input from an individual’s internal and external environment and reflexively controls
6body functions; thus, integrating the function of the somatic and autonomic nervous
systems7.  Other areas of the central nervous system, such as the cerebellum and cerebral
cortex, have also been shown to play a role in autonomic function7.
Within the spinal cord, all descending autonomic fibers project through the
intermediolateral or intermediomedial columns.  These neurons decrease in number with
age at approximately eight percent per decade8.  Additionally, within these columns
somatic sensory neurons release neuropeptides, such as somatostatin and vasoactive
intestinal polypeptide, which act as neuromodulators or cotransmitters to modify the
neurotransmissions of the ANS.  Thus, the somatic sensory system is intimately involved
with the ANS8.
Both sympathetic and parasympathetic pathways are composed of two types of
neurons; preganglionic, which originate in the CNS and are myelinated, and
postganglionic, which terminate in the effector organ and are generally unmyelinated6, 7.
The parasympathetic preganglionic fibers are long with short postganglionic fibers;
whereas the sympathetic preganglionic fibers are short and synapse with postganglionic
fibers in ganglia which are often located near the spinal column and at a distance from the
end-organ.  Thus, the sympathetic system has much longer postganglionic fibers than the
parasympathetic system.
Upon leaving the spinal cord, the peripheral part of the sympathetic nervous
system passes through anatomically complex ganglia located on either side of the spinal
column.  From the numerous sympathetic ganglia, fibers branch to various body organs
including the eye, lungs, heart, stomach, pancreas, liver, small and large intestine, kidney
and sex organs.  In contrast, seventy-five percent of the activity of the peripheral
7parasympathetic nervous system is accounted for by one cranial nerve, the vagus, or Xth
cranial nerve.   The vagus nerve innervates the lungs, heart, intestine, pancreas, spleen,
gallbladder, liver, kidney, bladder and sex organs.  Whereas, the other parasympathetic
fibers running through cranial nerves III, VII, and IX innervate end-organs primarily
within the facial area8.
End-organ response to stimulation from sympathetic and parasympathetic fibers is
dependent on the neurotransmitters released and the end-organ receptor.  Postganglionic
parasympathetic synapses release acetylcholine, and are therefore referred to as
cholinergic.  Postganglionic sympathetic synapses release norepinephrine (noradrenaline)
and are referred to as adrenergic.  All preganglionic sites, both parasympathetic and
sympathetic, predominantly release acetylcholine.  The end-organ receptor usually varies
primarily by system pathway.  The parasympathetic system has at least two types of
receptors, muscarinic and nicotinic, and the sympathetic system has primarily alpha and
beta receptors.
Physiologically, the body responds differently to sympathetic and
parasympathetic stimulation.  Sympathetic stimulation causes excitatory effects such as
increased sweating, heart rate, and blood pressure while inhibiting peristalsis.
Conversely, stimulation of the parasympathetic system causes a decrease in heart rate,
and little or no effect on the blood vessels while increasing peristalsis6, 7.   Alterations in
parasympathetic and sympathetic function can be quantified by HRV analysis,
particularly when using power spectral analysis.  Akselrod, Gordon, Ubel, Shannon,
Berger, and Cohen9 confirmed this in a dog model by alternately augmenting and
blocking sympathetic and parasympathetic tone with atropine or vagotomy.  The changes
8in autonomic activity were quantified into total (total neural activity), high (primarily
parasympathetic activity), and low (primarily sympathetic activity, but some
parasympathetic activity) frequency measures of power spectral analysis.  This study’s
results have been reproduced in humans10 and dogs11.
The sympathetic and parasympathetic pathways are also a part of the baroreceptor
arc.  The baroreceptor arc functions by transmitting signals through the vagal portion of
the ANS to the arterial system to enhance vasodilation and decrease blood pressure in
response to an increase in arterial pressure.  This occurs reflexively when the receptors,
primarily located within the aortic arch and the internal carotid arteries, are stretched by
an increase in blood pressure6.  Abnormalities seen within this arc result from modified
sensitivity of the arc to changes in arterial pressure.  This abnormality can be measured
by an altered heart rate response during the release phase of the Valsalva maneuver12.  In
normal individuals, a reflex bradycardia is demonstrated.
Physiologically, when the subject blows against resistance during a simulated
Valsalva maneuver, there is an increase in intrathoracic pressure that produces a decrease
in venous return with a subsequent decrease in cardiac output.  A functioning
parasympathetic system responds to the decrease in cardiac output by increasing the heart
rate.  When the patient quits blowing against the resistance, the intrathoracic pressure
decreases allowing an increase in venous return and cardiac output.  In addition,
peripheral vascular resistance can increase due to augmented sympathetic activity.  The
resulting increase in systolic arterial pressure is sensed by the baroreceptors in the aortic
arch and the carotid arteries.  To maintain the body in a homeostatic state, the
baroreceptors send out signals decreasing the heart rate.  However, if the baroreceptor
9response is blunted, which can occur in the presence of uremia and hyperglycemia, a
reflex bradycardia will not occur.  Campese and Massry13 point out that this is a complex
test, and other mechanisms could be involved in the heart rate response to the Valsalva
maneuver.  Abnormalities could be due to sympathetic dysfunction leading to
inappropriate changes in peripheral vascular resistance, derangements in the
parasympathetic pathway or an inability of the heart muscle to respond with enough force
and volume.
Similarly, a dysfunctional efferent parasympathetic pathway can be assessed by
the heart rate response to deep breathing.  In patients with uremia, the measured variation
in heart rate while breathing slowly and deeply for one minute is reduced13.  There is no
consensus on the role of the efferent sympathetic pathway in uremic patients.  Because
the ANS has such widespread influence on critical body functions, disruption of the
normal balance between the parasympathetic and sympathetic system has the potential to
threaten life and well being.
 Assessment of Autonomic Function
Dysautonomia is difficult to measure and quantify because of the dual innervation
of the ANS (sympathetic and parasympathetic systems), the numerous reflex arcs
involved, and the anatomic dispersion of autonomic nerve fibers14.  Even with these
measurement obstacles, quantification of dysautonomia using objective physiologic
measures of autonomic function has been reported in the literature since the
1950s3, 15-17.  Prior to that time, there were occasional references to clinical signs and
symptoms thought to indicate the presence of autonomic neuropathies18.  In the 1970s,
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investigators began using a battery of bedside autonomic function tests to aid in
interpretation of vague symptoms experienced by both diabetic19 and uremi20 patients.
The battery of tests has moved from the bedside to the laboratory and has lead to
improved diagnosis and treatment of autonomic neuropathies at an earlier stage than
previously diagnosed3.  In 1981, Akselrod et al.9 described power spectral analysis of
HRV as a quantitative method to evaluate autonomic regulation of the cardiovascular
system.  Currently, autonomic function is assessed in a variety of ways including
laboratory evoked measures, short-term and 24-hr heart rate variability using both time-
and frequency-domain measures, and symptomatology.  Several physiologic factors, such
as gender and age, and confounding variables, such as environmental factors and
smoking, have been identified to possibly have an effect on autonomic function21.  When
interpreting study findings these factors should be taken into consideration.
Laboratory Evoked Autonomic Function Measures
Evoked measures of autonomic function evaluate heart rate responsiveness to
postural and respiratory maneuvers.  These tests measure a complex reflex arc reflecting
a "beat to beat" balance of sympathetic and parasympathetic activity which can easily be
altered by physical and/or emotional stress5.  Previous studies of cardiac autonomic
function have relied primarily on assessment of cardiovascular reflexes using evoked
tests, such as the change in heart rate with deep breathing and heart rate variation during
Valsalva maneuver3, 22.  Numerous studies3, 20, 22-32 have used these measures to
evaluate cardiac autonomic function in normal, uremic and diabetic populations.  The
high reliability, ease of administration, and non-invasive nature of these tests make them
11
the most popular investigative tools3.  H wever, there are two major limitations to
evoked measures.  First, the patient must be willing and able to cooperate with the
protocol and second, although a procedure is standardized, stimuli could evoke alternate
mechanisms in individuals, thus the resulting measure may not always mean the same
thing33.
Improvement in autonomic function as measured by Valsalva ratio in ESRD
patients with diabetes who have undergone kidney or kidney-pancreas transplantation34
has been found.  Although improvement was also seen in the change in heart rate with
deep breathing, it was not as significant as the improvement in Valsalva ratio.
Rothschild, Weinberg, Halter, Porte, and Pfeifer25 found that the heart rate change with
deep breathing was more sensitive than the Valsalva ratio in detecting parasympathetic
ablation and is useful for early detection and follow-up of mild dysautonomia, while the
Valsalva ratio may be more useful for sequential long-term evaluation of patients with
severe dysautonomia.  However, Ziegler, Dannehl, Muhlen, Spuler, Volksw, and Gries35
found in a study of 130 patients with newly diagnosed type 1 diabetes, that the Valsalva
ratio was a more sensitive indicator of poor autonomic function than previously thought.
Opfer-Gehrking and Low32 suggested that when both measures are decreased it may
indicate that there is more cardiac adrenergic failure than previously thought.  As these
inconsistencies in findings suggest, researchers have been unable to identify one specific
measure, such as the change in heart rate with deep breathing or the Valsalva ratio, which
consistently reflects changes in cardiac autonomic function.  Because there is some
inconsistency in the physiologic underpinnings and sensitivity of evoked measures, it is
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important that both measures be included in a battery of tests designed to evaluate
autonomic function and monitor its improvement or deterioration4, 21.
Sensitive measures of autonomic function are needed because impaired vagal
activity has been linked to sudden cardiac death in experimental studies36, clinical
studies37-39, and in a small sample of kidney and pancreas-kidney transplant
recipients40, 41.  When Campese, Romoff, Levitan, Lane, and Massry12inve tigated the
genesis of dysautonomia in four groups (normal controls, predialysis patients, dialysis
patients, and patients with chronic illness and normal renal function) using the Valsalva
ratio in addition to two tests evaluating sympathetic function, they found that both the
predialysis and dialysis patients had dysautonomia with increased dysautonomia in the
predialysis group.  In addition, recent studies42, 43 show a relationship between reduced
vagal activity as measured by a lack of cardiac circadian rhythmicity and cardiovascular
events in diabetic populations.  Hjalmarson, Gilpin, Nicod, Dittrich, Henning, Engler,
Blacky, Smith, Ricou, and Ross44 suggest that the lack of an increase in nocturnal
parasympathetic function may also provide an explanation for nighttime myocardial
infarctions.
24-hr Heart Rate Variability Measures
Oscillations in heart rate, represented by variations in consecutive R-R intervals,
are modulated by sympathetic and parasympathetic outflow.  These oscillations can be
mathematically estimated by noting how the variations in R-R intervals rhythmically
decrease (primarily sympathetic influence) and increase (primarily parasympathetic
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influence) over a given time period.  These oscillations in R-R intervals can be examined
in both time- and frequency-domains (power spectral analysis).
 Twenty-four hour monitoring of heart rate variability and use of power spectral
analysis has gained interest as an alternative method to evoked tests for evaluating
autonomic function.  This method has the potential to assess earlier stages of autonomic
cardiovascular dysfunction and examine circadian rhythmicity42, 45-47.  Abnormalities
detected by this test are believed to be more sensitive indicators of autonomic
dysfunction than evoked tests, particularly in patients with diabetes who have
significantly less 24-hour R-R interval variability48.
Using power spectral analysis of heart rate variability, studies49-51are dispelling
the previously held belief that diabetic autonomic neuropathy primarily affects
parasympathetic function.  These studies report lower values in measures of sympathetic
activity, as well as parasympathetic activity.  Similar beliefs were also held regarding the
autonomic dysfunction accompanying uremia, and are being dispelled by spectral
analysis of heart rate variability52.
Short-term recordings of HRV are another technique used to provide physiologic
data on autonomic balance.  These recordings generally last only minutes (5-20 minutes)
and both time- and frequency-domain analyses can be calculated on the
electrocardiogram (ECG) recording.  Short-term recordings are normally collected while
stressing the patient either mentally or physically thus producing a reflex autonomic
change.  For example, a patient would have an ECG recording made while performing a
Valsalva maneuver, changing from a sitting to a standing position, or solving
mathematical problems.  In response to stresses such as these, a change could be seen in
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autonomic function as measured by variability in R-R intervals.  It is thought that short-
term recordings generally reflect modulation of vagal activity53.
Very little data has been gathered that compares short-term to long-term
recordings.  In one such study, Bigger, Fleiss, Rolnitzky, and Steinman54 compared
mean power spectral analysis values calculated from short-term periods (2-15 minutes)
recorded during the day as well as at night to 24-hr HRV recordings.  He found that the
short-term recording values were similar to the 24-hr values and that some correlations
were quite strong (> 0.75).  In addition, he found these short-term measures to be
excellent predictors of sudden death.
Two major advantages to short-term recordings using power spectral analysis are
a shorter data collection period and biological data can better comply with the need for
data stationarity55.  Data stationarity is an assumption made during data analysis that the
signal, heart period in this example, does not change with time56. Short-term recordings
are, however, limited in that they only collect data on short-term reflex responses and,
thus, may fail to reflect long-term trends or circadian effects on HRV, as seen in diabetic
groups57.
Long-term (24-hr) recordings examine an individual’s background autonomic
activity, providing a more complete picture of total autonomic function.  In addition,
long-term recordings analyze autonomic function at night when vagal function increases
and subtle changes in autonomic balance can be detected.  When examining
psychometric properties of 24-hr HRV measures, Camm58 found that the positive
predictive ability of 24-hr HRV measurement is higher than that of short-term recordings.
15
Symptomatology
Historically, the diagnosis of autonomic neuropathy was based primarily on
symptoms including postural hypotension, sweating abnormalities, intermittent diarrhea,
gastric fullness, impotence, and hypoglycemic unawareness18, 59, which generally occur
late in a disease process.  In the early 1940s, when these symptoms were initially
described60, limited medical treatment options were available for patients with diabetes
and uremia.  The life expectancy for patients with these conditions at that time was short,
so that many patients did not live long enough to manifest symptoms and, thus,
symptoms were thought to be uncommon.
Postural hypotension is a primary symptom of dysautonomia61, even though it
tends to be a late clinical feature59.  It possibly indicates a lesion in the baroreceptor arc
resulting in a decrease in peripheral vascular resistance12 due to a diminished response of
the sympathetic vasoconstrictor fibers to the splanchnic bed, muscle and skin18.  This
prevents normal arteriolar vasoconstriction upon postural change from a sitting to a
standing position.  Symptoms can include dizziness, faintness, visual impairment, or
syncope.  However, some patients are asymptomatic even when objective measures
document a drop of greater than 30 mmHg in systolic blood pressure upon standing18.
Although an objective test can measure the amount of postural hypotension, the
symptoms that accompany this clinical feature are not always present.
Deficiencies in thermoregulation thought to be caused by sympathetic pathway
damage result in sudomotor and vasomotor abnormalities18.  Sudomotor, or sweating,
abnormalities generally occur in a pattern of diminished or absent sweating in the lower
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extremities with compensatory increased sweating in the upper trunk and head.
Gustatory sweating, or increased sweating while eating that is unrelated to a response to
spicy foods, is a less common symptom59.  Sy ptoms of vasomotor thermoregulatory
abnormalities present vaguer symptoms of dysfunction than sudomotor abnormalities.  In
general, vasomotor complaints center around the individual’s feet being either too cold or
too hot.  These symptoms are thought to be caused by a failure to reflexively vasodilate
or vasoconstrict in response to body temperature changes18.
Hosking, Bennett, and Hampton59 reported that even when the entire
gastrointestinal system is involved with generalized hypotonic or hypertonic activity, the
patient is often asymptomatic.  The genesis of gastrointestinal dysfunctions, which can
range from esophageal atony to diarrhea, involves damage to the parasympathetic and
sympathetic nervous system18, in addition to possible autoimmune factors62.  Dia rhea
is the most prevalent symptom within this category59.  I  is fairly characteristic and can
last from hours to days, with liquid stooling up to twenty or more times a day.  Nocturnal
diarrhea and fecal incontinence are common.  Constipation is also a frequent complaint of
patients with dysautonomia, but it is unknown how this is related to autonomic nervous
system function18, or if it is related to other factors such as medications the patient is
taking.
Symptoms of urogenital system involvement primarily include changes in the
ability to control the bladder and impotence61.  Symptoms of deficient bladder control
develop insidiously, progress slowly, and are complex to differentiate from common
complications such as a bladder infection.  This makes it difficult to evaluate urinary
changes as a symptom of dysautonomia.  Damage to the parasympathetic nervous system
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causes impotence with loss of penile erection in diabetic men with a prevalence of up to
50%18, 59, 60.  Data on female sexual function is scant.  Other urogenital symptoms that
can occur include ejaculation failure and loss of testicular pain to pressure.  Both of these
symptoms are believed to result from widespread sympathetic denervation to the pelvic
area18.  Impotence is not always included as a diagnostic feature63 because of
confounding variables, such as psychogenic factors or the influence of age and
mediations59, which can affect penile erection.
Hypoglycemia unawareness is the failure of the patient to recognize symptoms of
low blood sugar.  This involves both parasympathetic and sympathetic dysfunction,
however, the symptoms associated with hypoglycemia, including tachycardia and
headache, are sympathetic in origin18.  Thus, hypoglycemia unawareness indicates the
progression of autonomic dysfunction from parasympathetic to sympathetic involvement.
It is considered a late symptom manifestation of diabetic autonomic neuropathy and can
be particularly devastating, resulting in coma and death.
With improved medical treatment options available, patients with uremia with or
without diabetes now have a longer life expectancy and reports of symptomatology are
becoming more common.  However, symptoms of autonomic neuropathy still occur late
in the course of the over-riding disease, and once they do occur, the natural course of
dysautonomia is one of continued progression with a high mortality rate61.
Factors Thought to Influence Autonomic Function
Variables that have been reported to have an affect on autonomic function are age,
gender, exercise training, and medications.  Studies have shown that increasing age is
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associated with decreased HRV27, 31, 64, 65.  The effect of gender on measures of
autonomic function is less consistent than those of age27, 31.  Braune, Auer, Schulte-
Monting, Schuerbrock, and Lucking27 studied 137 healthy individuals between 18 and
85 years of age and found that both the valsalva ratio and the change in heart rate with
deep breathing were attenuated with increasing age.  Values of both measures for subjects
over 65 years of age hardly exceeded baseline normals making it difficult to evaluate for
dysautonomia in the over 65 age group.  However, changes in both measures were not
associated with gender.  Lishner, Akselrod, Avi, Oz, Divon, and Ravid50 lso found less
pronounced differences in frequency measures between diabetic and healthy subjects
over age 65 versus subjects under age 65.
In another study of 557 normal subjects ranging in age from 10 to 83, Low, Deng,
Opfer-Gehrking, Dyck, and O’Brien31 evaluated the effect of age and gender on heart
rate response to deep breathing (n=376) and Valsalva ratio (n=425).  The results
indicated that heart rate response to deep breathing fell with increasing age and was
unaffected by gender.  In contrast, the Valsalva ratio decreased with age and was lower
for women.  The investigators suggested these findings indicated that diagnosis of
dysautonomia was possible in individuals over 80 years of age.
Cowan, Pike and Burr65 found that, in general, 24-hr HRV was significantly
lower in healthy women (n=71) compared with healthy men (n=40) in all time- and
frequency-domain measures, except for the RMSSD and the PNN50 (see Table 1).
However, resting heart rate differences between women and men were found to explain a
high proportion of the gender differences of HRV.  In addition, all the time- and
frequency-domain measures decreased with increasing age of the healthy sample.  In
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contrast, no gender effect on 24-hr HRV was seen in a group of 95 surviving sudden
cardiac arrest persons (79 men and 16 women) and only the frequency-domain measures
decreased with age.
Bigger, Fleiss, Steinman, Rolnitzky, Schneider, and Stein2 recruited 274 healthy
middle-aged individuals (57±8.2 years old, 74% men) and compared the values that were
characteristic of the healthy sample to two samples of myocardial infarction patients. One
sample of myocardial infarction patients was obtained from the Cardiac Arrhythmia Pilot
Study (CAPS) with measures taken one year post-infarction (n=278, 58±7.4 years old,
84% men).  The second sample was obtained from the Multicenter Post Infarction
Program (MPIP) with measures taken about 2 weeks post-infarction (n=684, 58±7.5
years old, 76% men).  The values established by Bigger et al. were later accepted as
normal values by the Task Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology53.  In addition to establishing normal
values for 24-hr time- and frequency-domain measures, the purpose of Bigger et al.’s
study was to clarify the extent to which age and gender affected 24-hr time- and
frequency-domain measures.  In the healthy sample, findings showed a significant
decrease in low and high frequency measures with increasing age, with low power
decreasing 22% per 10 years and high frequency decreasing 10% per 10 years.  In
contrast, when a sample of patients with chronic coronary heart disease was examined
there was little relationship found between frequency measures and age.  Patients with a
recent myocardial infarction, however, demonstrated a strong relationship between
frequency measures and age.  Thus, while normal individuals and a group with recent
autonomic dysfunction continued to demonstrate differences in autonomic function by
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age, a group with chronic autonomic dysfunction did not.  For healthy persons, low
power was significantly higher for men than for women, however, no differences were
seen for total power or high power frequency measures.  In contrast, both samples of
patients with myocardial infarction demonstrated differences in total power and low
power, but not high power frequency measures.
The effect of exercise training on cardiac autonomic function has had conflicting
results; however, this may be due to HRV measures being determined using brief
intervals of time and various analysis methods66.  Heart rate variability measures of 20
cardiac subjects were studied using 24-hr Holter monitoring and spectral analysis before
and after an 11-week cardiac rehabilitation program, which included exercise67.  This
study concluded that HRV is not changed in cardiac subjects who undergo exercise
training.  Conversely, in two cross-sectional studies, one comparing healthy male runners
(n=72) who were age matched with a sedentary healthy male cohort (n=72), the other
comparing healthy endurance trained men (n=8) with healthy age matched untrained men
(n=8), the results suggested that the physically active group had significantly higher
fitness levels which were associated with significantly higher levels of HRV.  Thus, these
two studies concluded that long-term aerobic exercise augments HRV64, 66.
Levy, Cerqueira, Harp, Abrass, Schwartz, Stratton68 initiated a 6-month exercise
training program to evaluate the effect of exercise on parasympathetic function as
measured by brief intervals of HRV.  Eleven healthy young men (ages 24-32) and 13
older men (ages 60-82) had HRV measured at rest, during supine exercise, and after the
training program.  The findings showed that training increased resting HRV by 19% in
young men and by 68% in older men.  From this, two conclusions were reached;
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parasympathetic activity (high power) decreases with age and intensive exercise training
partially reverses this age-associated change in parasympathetic function.  Thus,
strenuous exercise has been shown to improve HRV, although little data documents the
effects of a mild to moderate exercise program and no data could be found examining
how an exercise program might influence HRV for individuals with known autonomic
dysfunction secondary to chronic renal disease.
Beta-adrenergic blocking agents have been shown to increase HRV by
simultaneously decreasing adrenergic activity and increasing vagal activity69.  Anti-
arrhythmic agents, such as quinidine and amiodarone, which depress parasympathetic
activity69 have been shown to decrease HRV70 in the frequency-domain of 24-hr HRV
analysis, but not in the time-domain, even in groups on low-dose beta blockers in
combination with anti-arrhythmic medications71.  In addition, preliminary data72
obtained from kidney transplant recipients show that mycophenolate mofetil, an
immunosuppressant, may interact with beta-blockers to enhance patients’ HRV.  Further
study needs to be done to confirm these findings.
Instrumentation and Procedure
Laboratory Evoked Autonomic Function Measures
Noninvasive laboratory evoked tests of cardiovascular autonomic function are
typically performed in a temperature-controlled laboratory dedicated to performing
autonomic function tests.  The room is maintained at 25 - 27 degrees centigrade and
environmental stimuli such as noise and light are minimized.  The laboratory at our
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center is equipped with a Power Macintosh 9500 computer system and AcqKnowledge ®
III BIOPAC software for data acquisition and analysis of standard electrocardiogram
recordings and blood pressure measurements obtained from a DinamapTM XL
(CRITIKON).  The protocols (see Appendix A) used to perform the evoked tests were
modified from Mayo Clinic’s protocols73, and a brief overview follows.
Following University Institutional Review Board approval and obtainment of
informed consent (see Appendix B), patients are brought into the laboratory,
demographic information obtained, testing procedures explained, and monitoring
equipment applied. After a 10- to 15-minute period of stabilization of heart rate, blood
pressure and skin temperature, laboratory evoked autonomic function tests are performed.
Cardiovascular autonomic function is determined by two tests that primarily reflect
parasympathetic function, the heart rate change with deep breathing (HRDB) and heart
rate change with Valsalva maneuver (VR).
The first of these tests measures the change in heart rate with deep respiration
(HRDB).  This measure is obtained during a one-minute period of deep breathing (6
breaths/minute) which follows a two-minute period of regular breathing.  It is calculated
by subtracting the lowest heart rate from the highest heart rate during the 1-minute deep
breathing period (see Appendix A).  The normal HRDB is abolished by parasympathetic
blockade with atropine, but unaffected by sympathetic blockade with propranolol74.
Thus, HRDB loss is thought to primarily reflect parasympathetic dysfunction.
The second test, the VR, is derived by dividing the highest heart rate during a
forced expiration of 40 mm Hg for 15 seconds by the lowest heart rate immediately after
the maneuver (see Appendix A).  The VR can be pharmacologically blocked by atropine,
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but not with cardiac sympathetic blockade17.  Thus, it is thought to primarily reflect
parasympathetic function, but may also reflect some adrenergic function.
A lengthy and rigorous series of developmental, standardization, and
reliability/validity studies have been conducted on the evoked cardiovascular tests in
numerous centers.  Procedures have been refined3, 5, normal referent values have been
determined3, 19, 28, and reliability and validity have been established for change in heart
rate variability with deep breathing and Valsalva ratio5, 19, 63.  In one study, the
reproducibility of the HRDB was measured by calculating the difference between two
tests performed less than two months apart on the same subject.  Of the 59 diabetic
patients with abnormal results, 97% remained abnormal or borderline at the second
testing63.  Since various methodologies are employed among centers, it has been
recommended that each center establish their own referent values4, 5.  
24-hr Heart Rate Variability Measures
Heart rate variability measurements in both time- and frequency-domains are
obtained by analysis of 24-hr ambulatory Holter monitor tapes.  Our laboratory employs
Marquette Electronics Laser SXP® Ambulatory ECG Analysis and Editing Systems with
version 5.8 software program and Series 8500 Holter recording system.  Each QRS
complex is digitized, identified and labeled.  The analyzed data file is then scanned and
manually edited to locate and correct any errors in QRS labeling that would adversely
affect measurement of heart rate variability.  Tapes generally have > 23 hours of
analyzable data.  Using these data files, 24-hr heart rate variability with power spectral
analysis is calculated.
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The time-domain analysis of heart rate variability can be divided into two general
categories (see Table 1).  The first category is derived directly from the R-R intervals and
includes means and standard deviations of the interval.  Measures in this category of the
time-domain include the SDNN, SDANN, and SD.  The SDNN is the standard deviation
of all R-R intervals during the 24-hours and has been found to be associated with sudden
cardiac death37.  The SDANN is the standard deviation of the means of R-R intervals
found in successive five minute blocks over 24-hours and is considered the best measure
of overall autonomic balance and represents circadian rhythmicity of autonomic
function75.  The SD is the mean of the standard deviation of the R-R intervals of each 5-
minute block and is sensitive to variability within the 5-minute block.  The second
category of time-domain variables is based on the differences between adjacent R-R
intervals and includes the PNN50 and the RMSSD.  The PNN50 is the proportion of
adjacent R-R intervals having a difference > 50 milliseconds (ms).  The RMSSD is the
square root of the mean of the sum of squares of differences between adjacent R-R
intervals.  Both the PNN50 and the RMSSD are virtually independent of circadian
rhythms and reflect alterations in autonomic function that are primarily vagally
mediated57.
Because time-domain measurements are calculated using, in general, three
different techniques, the resulting values represent three different views of heart rate
variability.  The SDNN is based on each R-R interval over the 24-hr period and, thus, is
an easy way to calculate overall heart rate variability.  The SD and SDANN values are
both based on 5-minute periods and reflect long-term oscillatory components of heart rate
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variability.  The short-term components of heart rate variability are expressed by the
PNN50 and the RMSSD55.
Recently, it was recommended that four measures be used for time-domain HRV
assessment; SDNN, HRV triangular index, SDANN, and RMSSD53.  The HRV
triangular index is the measure reported from geometric analysis of the
electrocardiogram.  Because both the SDNN and the HRV triangular index are estimates
of overall HRV53, and the SDNN is more routinely reported in the literature37, the seri s
of studies presented in this dissertation will report SDNN in place of HRV triangular
index.  In addition, the series of studies is part of a longitudinal research protocol funded
by the National Institute of Health and is in compliance with the study measures as
defined there76.
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Table 1.  Definitions of Time- and Frequency-Domain Measures of 24-Hour Heart
Rate Variability and Their Relationship to Autonomic Function
TIME-DOMAIN
Variability of R-R intervals over 24-hours
· SDNN is the standard deviation of all R-R intervals for the entire recording.  It is
mathematically equal to total power of spectral analysis, thus, reflects all cyclic
components responsible for variability in the recording period53.
· SDANN is the standard deviation of the averages of R-R intervals calculated over
short periods, usually 5-min. blocks, for the entire recording.  This is an estimate of
the changes in heart rate due to long cycles (> 5 min.)53
· SD (also called the SDNN index) is the mean of the standard deviation of the R-R
intervals of each 5-min block for the entire recording.  This measures variability due
to short cycles (< 5 min.)53
Differences in adjacent R-R intervals  (thought to be vagally mediated, they estimate
high-frequency variation and, thus, are highly correlated53)
· PNN50 is the proportion of adjacent R-R intervals having a difference > 50
milliseconds
· RMSSD is the square root of the mean of the sum of squares of differences between
adjacent R-R intervals
FREQUENCY-DOMAIN
· total (0.01-1.00 Hz) reflects all cyclic components responsible for variability53
· low (0.04-0.15 Hz) represents primarily sympathetic activity with some
parasympathetic activity modulated by baroreflex activity77
· high (0.15-0.40 Hertz) represents primarily parasympathetic activity53
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Calculation of time-domain values is a simple process, unfortunately, when the
heart period is reduced to simple means and standard deviations information is lost.  For
example, there is no direct relationship to a time axis or anyway to differentiate between
parasympathetic or sympathetic function using frequency content. To overcome these
shortcomings, more sophisticated techniques for analysis have been developed.  One of
the newest technologies uses signal-processing methods to determine a frequency
waveform depicting heart rate variability.  It is thought that this method allows further
delineation of the beat to beat variabilities into their respective autonomic genesis, thus
allowing more in-depth physiological inquiry78, 79.
The two basic signal-processing models are fast Fourier transform (FFT) and
autoregressive (AR) analysis.  Fast Fourier transform describes a signal (heart rate
pattern) as the sum of sinusoids at fixed and equally spaced frequencies45, 79.  This
analysis is dependent on two primary assumptions, stationarity of data and smoothing.
There is well-developed nonparametric statistical theory used in FFT computations, even
though some80 consider it statistically unstable.  In contrast, AR analysis is based on a
linear prediction model derived from the signal (heart rate pattern) itself and does not
depend on the same assumptions used in FFT79.  Autoregression is a conceptually simple
algorithm, but its computational complexity is greater than FFT.  Cowan, Burr,
Narayanan, Buzaitis, Strasser, and Busch81 compared the spectral density of HRV using
both AR and FFT techniques and found that either would be methodologically acceptable
for clinical studies.  The series of studies presented here used FFT to examine periodic
oscillations in R-R intervals over a 24-hr period.
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Increases and decreases in R-R interval widths reflecting periodic fluctuations in
sympathetic and parasympathetic function are transformed by FFT into a frequency
waveform.  This technique is frequently referred to as power spectral analysis.  The
spectrum of frequencies (Hz) present over the 24-hrs is plotted and values provided
which indicate the relative amount of total (0.01-1.00 Hz), low (0.04-0.15 Hz) and high
(0.15-0.40 Hz) frequency power (see Table 1).  Low frequency waveforms estimate
sympathetic activity with some parasympathetic activity while high frequency
waveforms, also known as the respiratory frequency, represent parasympathetic activity.
The ratio of low frequency to high frequency power provides a useful quantification of
the balance between the sympathetic and parasympathetic activity.  In addition to the 24-
hour average, power spectral analysis provides an hourly sum of each 5-minute interval
throughout the day. These hourly profiles permit visual depiction of the autonomic
modulation of circadian rhythms.  Normally, low frequency activity (sympathetic
activity) predominates during waking hours and high frequency activity (parasympathetic
activity) predominates during sleep; thus, a higher ratio, as seen during the awake hours,
reflects lower vagal activity.
Correlations between Time- and Frequency-Domain Variables
Several 24-hr HRV time-and frequency-domain measures are strongly correlated
with each other46, 82.  It is thought that these strong correlations exist because of both
mathematical and physiological relationships among time- and frequency-domain
measures53.  Kleiger, Bigger, Bosner, Chung, Cook, Rolnitzky, Steinman, and Fleiss46
obtained 24-hr HRV measures from 14 healthy individuals (20-55 years of age) and
found that certain time- and frequency-domain variables are highly correlated concluding
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that they may serve as surrogates for each other.  High frequency power, RMSSD, and
PNN50, all considered measures of vagal function, were strongly correlated (r>0.9) with
each other and with SD.  Low frequency power was also strongly correlated with the
measures of vagal function (r>0.8) indicating that some parasympathetic activity is
reflected in low frequency power.
Bigger, Fleiss, Steinman, Rolnitzky, Kleiger, and Rottman82 exa i ed the
correlations between time- and frequency-domain measures in 24-hr HRV recordings
obtained 2 weeks after myocardial infarction (n=715).  They found that there were natural
groupings for several of the 24-hr measures.  From Bigger et al.’s data, Keehn deduced
that both SDNN and SDANN are essentially equivalent to total power83 (see Table 1 for
measure definitions). It was suggested82 that these measures could act as surrogates for
each other.  Similar patterns of correlation among measures of parasympathetic function
(RMSSD, PNN50, and HF) were reported in an earlier study84 and in a later, larger
study2.  In addition, the SDNN and the square root of total power are almost perfectly
correlated, and the time-domain measure, SDNN, was found to be strongly and
significantly associated with mortality in this group2, 37.
Alterations in parasympathetic and sympathetic function can be quantified by
HRV analysis, particularly when using power spectral analysis.  Akselrod et al.9
confirmed this in a dog model by alternately augmenting and blocking sympathetic and
parasympathetic tone with atropine or vagotomy.  The changes in autonomic activity
were quantified in the total (total neural activity), high (primarily parasympathetic
activity), and low (primarily sympathetic activity, but some parasympathetic activity)
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frequency measures of power spectral analysis.  This study’s results have been
reproduced in humans10 and dogs11.
Quality assurance data provided by the Marquette Electronics illustrates
mathematically correct results following submission of known electronically generated
cardiac signals83.  This technology has been successfully employed in clinical studies
evaluating alterations in autonomic regulatory mechanisms in patients with heart
disease38, cardiac transplantation85, diabetic autonomic neuropathy42, 48, 86
uremia52, 87 and kidney transplantation88. Twenty-four hour measures have been highly
stable in both normal subjects46, post myocardial infarction patients55, a d patients with
ventricular arrhythmias89.  Thus, it is thought that 24-hr measures may be ideal for
assessing intervention therapies53, such as transplantation, exercise, and deep breathing
relaxation techniques.
Before a new technology is approved by the FDA for clinical use, findings from a
sufficient number of research studies must support the new technology’s efficacy and
safety.  The psychometric properties, including validity issues of sensitivity and
specificity, need to be delineated.  Sensitivity is the probability of testing positive if the
disease is truly present, and specificity is the probability of testing negative if the disease
is truly absent90.  Another closely related test is predictive value, which is whether the
individual actually has the disease, given the results of the test.  Twenty-four hour HRV
with power spectral analysis is a potential screening test because it is relatively
inexpensive, easy to administer and imposes minimal discomfort on the patients.  The
validity of HRV is determined by its ability to do what it is supposed to do; that is, to
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distinguish between individuals with diminished cardiac autonomic function (who should
test positive) and individuals with normal cardiac autonomic function (who should test
negative).  For example, in the ESRD population, as 24-hr HRV sensitivity increases
more patients who have dysautonomia are correctly identified as such.  Using the same
example, as specificity increases fewer patients with normal autonomic function are
falsely identified with dysautonomia (false positive).  The goal with instrument design or
selection is an instrument with high sensitivity and high specificity; however, this is
usually not possible90 because of tradeoffs between sensitivity and specificity (type 1
and type 2 errors, respectively).
In a report on studies which used 24-hr HRV as a marker of prognosis after
myocardial infarction47, the sensitivity of HRV measures ranged from 33.9% to 100 %
and specificity ranged from 44.6% to 92.6%, while the positive predictive value of HRV
was about 40% when used in combination with other postinfarction risk factors.  Malik91
found when the SDNN, the standard deviation of duration of RR intervals, was <50ms,
the sensitivity was 46 % and the positive predictive value was 34% for the prediction of
24 month cardiac mortality.  These findings are congruent with Kleiger’s37 resu ts.
Thus, HRV measurements with power spectral analysis can be used as a prognostic
indicator for risk stratification of post myocardial infarction92, and p tentially with other
populations such as patients with diabetes and ESRD93, of significant autonomic
dysautonomia similar to that of myocardial infarction patients40, 87.  Diminished
measures of autonomic function are also found in uremic patients.  Only preliminary data
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on sensitivity and specificity for 24-hr HRV measures were found for the ESRD
population93.
Because 24-hr HRV monitoring with power spectral analysis is being evaluated
for clinical use, high sensitivity is required, even if the positive predictive accuracy is not
high.  In contrast to traditional methods of detecting autonomic dysfunction, 24-hr HRV
monitoring has the potential to be an early, accurate, dynamic, screening instrument for
the renal transplant population.
Autonomic Symptom Checklist
Symptoms of autonomic nerve damage are often non-specific and vary depending
on the individual.  Symptoms generally occur after objective test measures, such as the
change in heart rate with deep breathing or the frequency domain measures of 24-hr
HRV, indicate a decline in autonomic function61.  Recognizing the difficulty of
objectively evaluating a person’s subjective symptoms, an instrument entitled the
Autonomic Symptom Checklist was developed and tested as part of this dissertation.  The
development of the Autonomic Symptom Checklist is described in Chapter 2.
Limitations of Autonomic Function Measurements
Autonomic function testing is used in both research and clinical settings.  For the
purposes of this dissertation, limitations and problems associated with examining
autonomic function will be research-oriented, although, many of the limitations apply in
the clinical area.  The essential attributes for autonomic measurement are that the tests
use noninvasive techniques, measure with precision and accuracy, and deliver
reproducible results.
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Laboratory Evoked Autonomic Function Measures
For laboratory evoked autonomic function measurements to be accurate, the tests
must be completed using a standardized methodology that requires patient participation.
For example, to obtain an accurate VR the patient must be capable of and willing to blow
into a mouthpiece against resistance for 15 seconds.  Thus, limitations of evoked bedside
measures are the patient’s ability and willingness to cooperate.
Another significant limitation is that evoked measures do not di ctly assess the
autonomic nervous system.  Researchers rely on indirect methods based on animal9 and
human models10 to assess autonomic function.  Based on the results of animal and
human models, the Valsalva maneuver and change in heart rate with deep breathing are
theorized to evaluate parasympathetic function.  The complexity of the underlying
physiology is a limitation of indirect measurements5.
24-hr Heart Rate Variability Measures
Limitations of 24-hr HRV with power spectral analysis result from problems in
obtaining and processing of the ECG signal, analyzing the ECG signal process, and
interpreting what the components (LF and HF) mean.  Twenty-four hour HRV measures
use signal processing to evaluate cardiac autonomic function.  Biomedical signals convey
information about physiologic processes, such as the heart rate, and can be used to
evaluate the biologic system.  However, acquisition of a signal is not sufficient.  To
obtain the information needed a processor transforms the signal using various
mathematical computations and statistical procedures.  Depending on the method of
analysis, certain assumptions about the data are made and these assumptions can lead to
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limitations of the measurements.  These limitations of the process need to be understood
and minimized to the extent possible.
One limitation is digital processing that occurs during data acquisition53.  The
data is digitally processed in an effort to clean the signal of noise94.   Relevant
information, such as frequency, is not readily visible in a noisy signal.  Noise usually
occurs due to background electrical activity, such as muscle movement, which masks the
waveform produced by the autonomic nervous system.  Digital processing identifies the
background electrical activity and removes it from the signal.  Methods to remove noise
include traditional linear filtering, which enhances the signal, and optimal filtering, which
smoothes the signal with an averaging technique when the signal and the noise overlap
and enhancing cannot be accomplished80.  T  continuous signal is then converted into a
discrete-time series and quantified by assigning amplitude values to each sample.  Both
processes change the characteristics of the signal and could affects the analysis95.
Another assumption is that no data exists outside the recording window.  Because data
may exist outside the window, this assumption leads to spectral leakage in the analysis.
Techniques used to solve this problem can lead to a reduction in frequency resolution
resulting in reduced accuracy of frequency measurement.
Stationarity of data relates to signal processing and is the assumption that the
signal is present at all times and does not change with time56.  Assuming stationarity of
data simplifies the analysis process and is used when analyzing HRV in both time- and
frequency-domains.  Non-stationary processing methods are complex or involve cutting
data into short durations to assure stationary.  Stationarity of data, however, is seldom
true when evaluating biological variables, and is not true when analyzing heart rate
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patterns that are generally in a constant state of change.  Because infinite data sequences
are assumed and the record is finite, estimation errors are introduced95.
Heart rate is not stationary data because it is constantly affected by balance
between the parasympathetic and sympathetic branches of the autonomic nervous system,
hormonal, and other physiologic feedback mechanisms.   However, the sympathovagal
balance is of primary concern in patients with ESRD and diabetes mellitus.  Evaluating
the HRV over a 24-hr period can provide an in-depth evaluation of the daily modulations
occurring in the autonomic nervous system.  The researcher can evaluate the effect of
such variables as changes in position, changes in respiratory rate, exercise, circadian
rhythms, sleeping and eating on fluctuations in HRV.  Some researchers use short-term
recording of HRV in order to increase control of data acquisition.  When the subject is
placed in a controlled environment for the duration of the data acquisition, stationarity of
data increases.  However, the researcher using 24-hr HRV assessments wants to evaluate
the patient’s autonomic function during the patients normal lifestyle and activities.
Recommendations53 have been made that would minimize the effects of non-
stationarity of data and other limitations on research investigations.  One requirement is a
good technical ECG recording for analysis.  Error-free and artifact-free recordings are
difficult to obtain from ambulatory 24-hr Holter recordings because patients are engaging
in everyday activities and movement of skeletal muscles causes artifact on the recordings.
Prior to processing, the data needs to be manually-edited to correct mislabeled beats53.
This results in good quality R-R intervals for analysis.  However, over-cleaning the data
can reduce frequency resolution and manual editing of long-term ECG recordings is time
consuming (1 to 10 hours) and clinically impractical.
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Thus, it is important to follow strict procedures when applying the chest
electrodes to obtain higher quality data83. Surface contact is critical because data can be
affected by muscle movement, electrode motion, and other sources which add noise to
the signal.  Encouraging the subject to keep an accurate diary of sleep, exercise, eating
and other activities during the 24-hr monitoring period will provide additional data when
interpreting the HRV measurements.  Because medications can affect heart rate
fluctuations, obtaining a record of the subject’s medications can also be useful when
interpreting data.  Repeat Holter monitoring is recommended when the data signal is of
poor quality, or the subject has an abnormal 24-hours during data acquisition, for
example, if the patient was restless due to a thunderstorm.
According to some96, 97, researchers have made too big a leap when interpreting
what different HRV spectral components and time-domain measures mean.  It has been
established9-11 that HF and LF component of HRV are associated with parasympathetic
and sympathetic influences, respectively.  However, Malik and Camm96warn that the
HRV components do not reflect autonomic tone, as is frequently assumed.  Instead, HF
and LF are markers of autonomic influences on the modulations of heart rate.  This
means that at either maximal stimulation or blockage of parasympathetic or sympathetic
activity there is no variability and no spectral components.  Thus, when a patient has a
reduction in HRV it should be interpreted as a decrease in the modulation of the heart,
not necessarily as a decrease in the tone of the autonomic system.
In summary, to diminish limitations associated with 24-hr HRV with power
spectral analysis it is important to use recommended techniques53 when obtaining,
processing, and analyzing ECG recordings.   In addition, the interpretation of results can
37
not be assumed a reflection of autonomic tone, but instead the components represent a
modulation in autonomic activity.
Autonomic Symptom Checklist
A primary limitation of the Autonomic Symptom Checklist is that it is a self-
administered instrument; thus, subject to patient interpretation.  In addition, the reliability
studies were done using a relatively small sample with very few African-Americans.  To
date, however, there are no reported studies that have demonstrated significant
differences in autonomic function based on race.
General Description of Population Under Study
Over 11,000 Americans undergo renal transplantation each year with another 800
individuals undergoing kidney-pancreas transplantation.  In 1994, diabetes mellitus was
the leading cause of renal failure worldwide1.  Prior to transplant, uremia, especially in
combination with diabetes, can cause major alterations in biological function exemplified
by severe derangements in autonomic function.  The autonomic nervous system exerts
widespread control over multiple critical body functions; therefore, the severe autonomic
neuropathies that accompany uremia and diabetes can lead to life-threatening cardiac
states38, 40, 69, 75, 93, 98, 99.  Transplantation brings about an immediate correction of
uremia and diabetes, which has been found to improve autonomic function100 and
alleviate many of the accompanying symptoms, such as gastropathy and neuropathy99.
This series of studies being reported employed a convenience sample of patients
with ESRD who were undergoing evaluation for kidney or kidney-pancreas
transplantation.  In addition, a group of healthy adults was recruited for comparison
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purposes and for establishment of normal referent values.  Each patient and healthy adult
signed an informed consent (see Appendix B) which gave permission to record
autonomic function data and to gather demographic information.  The study was
approved by the Institutional Review Board of the University of Tennessee, Memphis.
Patients were generally stratified into three groups: those with ESRD who did not
have diabetes mellitus (ESRD NonDM), those with ESRD who had type 1 diabetes
mellitus (ESRD DM), and healthy individuals.  The original diagnoses represented in the
non-diabetic ESRD group were hypertension, chronic glomerulonephritis, systemic lupus
erythematosus, polycystic kidney disease, ESRD of unknown etiology, and
miscellaneous.
The Pathology of Dysautonomia Due to Renal Failure
The prevalence of dysautonomia in both uremic and dialysis patients was found to
be as much as 50% when evaluated by evoked autonomic function tests12.
Manifestations of dysautonomia in patients with uremia are primarily thought to be
related to increased parathyroid hormone levels101, abnormalities within the
baroreceptor arc, which includes the efferent parasympathetic pathways, and reduced
end-organ responsiveness to vasoconstrictor agonists such as epinephrine12.  Thes
disturbances are associated with the uremia itself, or consequences of the uremia, and not
associated with either anemia or the state of having a chronic illness12.
Fraser and Arieff101 suggest that there may also be abnormalities in
neurotransmission in uremic patients.  One potential cause of this is thought to be a
change in uremic patients’ parathyroid hormone levels.  Parathyroid hormone increases
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both intracellular and extracellular levels of calcium and can also affect sodium levels.
Both calcium and sodium are intimately involved in neurotransmission along the axon
and at the neurosynaptic junction.  Changes in the calcium levels can affect enzymes,
which are used to provide energy for neurotransmission.  In addition, calcium pumps
used to mediate neurotransmissions at the nerve terminals can be affected, resulting in
abnormalities in processing information102.  However, researchers have not been able to
demonstrate consistently that parathyroid hormone is an uremic neurotoxin101, as some
have suggested.
In addition, some101 have suggested that uremic neuropathy is related to
anatomic evidence of nerve damage, such as loss of myelin.  Myelin is a fat-like
substance that forms a sheath around primarily large-diameter nerve fibers, such as
skeletal muscle efferents, and some small-diameter fibers, such as preganglionic
sympathetic efferents.  Myelin surrounds the nerve fiber and increases conduction rates,
thus, loss of myelin would affect electrical conduction of neurotransmission.  It is
hypothesized that this could affect the baroreceptor arc.
Reduced end-organ response to vasoconstrictor agonists, such as norepinephrine,
is thought to play a major role in the manifestations of dysautonomia, particularly in the
predialysis patient12.   It is hypothesized that postural hypotension in the uremic patient
is due to down regulation of alpha-adrenergic receptors in the peripheral blood vessels to
norepinephrine.  The resulting inability to augment peripheral vascular resistance
prevents the uremic patient from maintaining a constant blood pressure upon standing.
Again, it is unknown what specifically causes this, but these results are consistent with
the hypothesis that cumulative effects of multiple uremic toxins decrease
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neurotransmission at the synaptic gap.   In addition, excess blood levels of parathyroid
hormone could play a factor in end-organ response by stimulating an increase in tissue
production of prostacycline12.
The Pathology of Dysautonomia Due to Diabetes Mellitus
Diabetic autonomic neuropathy became recognized as an entity following a
comprehensive review by Rundles in 194560.  Although the pathogenesis, like uremic
autonomic neuropathy, has not been established, it is a common complication with a
prevalence rate of up to 56% in patients with long-standing type 1 diabetes3, 22, 103.
Even persons with newly diagnosed type 1 diabetes have a prevalence rate of up to 9%35.
Most likely diabetic autonomic neuropathy results from a prolonged exposure to
metabolic derangements similar to that postulated for somatic neuropathies18.
Metabolic derangements are thought to lead to chronic, widespread neural lesions
in the autonomic nervous system with loss of both myelinated and unmyelinated
axons14, 104.  Potential factors responsible for axon loss include an accumulation of
glucose in the central and peripheral autonomic nerves with potential slowing of
conduction, a reduction of myoinositol which is involved with lipid synthesis and reflects
a lack of insulin, and changes in myelin composition and synthesis18, 59, 105.   Recently
autoimmune reactions in both type 1 and type 2 diabetes mellitus have been postulated to
cause nerve destruction106, 107.  The hypothesis that diabetic neuropathy results from
nerve ischemia brought about by microvascular abnormalities14, 18 is controversial, but
is receiving a great deal of investigative attention.  Although studies investigating the
structural origin of ischemia are inconclusive, the functional evidence of nerve ischemia
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and hypoxia is emerging and may involve the “endothelium-dependent” nitric oxide-
mediated component14.
The Diabetic Control and Complications Trial is a landmark study that
investigated the importance of insulin-deficiency, hyperglycemia, or both in the
pathogenesis of diabetic neuropathy108.  The results of this study provided support for
the theory that an increase in blood glucose is associated with autonomic neuropathy.
Tighter control of hyperglycemia in persons with type 1 diabetes reduced the prevalence
of clinical diabetic neuropathy by 60%.
Since both uremic and diabetic autonomic neuropathy have a fragmentary
pathogenesis and several commonalties, it is difficult to distinguish between
manifestations that are uremic versus diabetic in origin.  As seen with dysautonomia due
to uremia, the clinical presentation of diabetic autonomic neuropathy is frequently non-
specific and varying in severity.  Symptoms primarily result from abnormalities within
the baroreceptor arc and the efferent parasympathetic and sympathetic pathways of the
ANS.  Generally, it is thought that cardiac parasympathetic involvement occurs early,
with sympathetic innervation being preserved.  This is reflected by diminished values of
the Valsalva ratio and change in heart rate with deep breathing, two tests of primarily
parasympathetic nerve integrity.  As the disease progresses, sympathetic nerve damage is
characterized by postural hypotension, sudomotor disturbances, and hypoglycemic
unawareness18.
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Conceptual Framework
Uremia alone, or in combination with diabetes mellitus, brings about increased
metabolic wastes and an increase in blood glucose levels resulting in changes to fibers
within the autonomic nervous system.  Specific changes that have been suggested are
demyelination of preganglionic parasympathetic and sympathetic fibers, in addition to
nerve lesion formation18, 101.  Another hypothesis14, 104 states that in diabetic
neuropathy nerve cell hypoxia due to loss of microvasculature may result in neuronal cell
degeneration and slowing of neurotransmission.  There is not a consensus on the
pathophysiology of dysautonomia because of the difficulty in dissecting and studying
autonomic nerve fibers.  Because it is much easier to examine somatic nerve fibers, much
of the pathophysiologic basis of autonomic dysfunction is based on research investigating
the somatic nervous system.  The research findings are then applied to the autonomic
nervous system.  As technological improvements simplify procedures to study the
autonomic nervous system101, earlier assumptions based on the somatic model are being
confirmed.  However, there are still many unanswered physiologic questions, such as
what determines the selection and order of nerve fiber involvement and to what
severity21.  A primary question, especially in light of potential interventions such as
transplantation, exercise, and relaxation designed to improve autonomic function, is
whether or not dysautonomia is reversible and to what extent.
Patients with ESRD experience various degrees of dysautonomia, and those with
diabetes have the greatest dysautonomia87, 93.  E rly changes of dysautonomia include
subtle decreases in heart rate variability due to deterioration in parasympathetic
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function35.  In general, decreases in 24-hr frequency-domain measures (total power, LF,
and HF) reflect the loss of autonomic modulation earlier than either evoked tests or
autonomic symptomatology48, 87, 93.   This is particularly seen in the HF, which reflects
parasympathetic activity as compared to the LF, which reflects primarily sympathetic
activity9, 10.  Twenty-four hour HRV frequency measures were found to be diminished
in studies of patients with diabetes48, 49, patients with uremia87, 93, and patients with
uremia and diabetes87, 93, 109.
As the disease worsens, further autonomic imbalances occur, resulting in an initial
increase in sympathetic activity and loss of normal sinus arrhythmia25.  At this point,
such extensive autonomic damage has occurred that maneuvers designed to evoke
responses, such as a Valsalva maneuver, can no longer elicit a normal reflex.  Thus, the
degree of dysautonomia is such that evaluation and follow-up by evoked tests of
cardiovascular autonomic function is appropriate21.  Evok d measures, particularly the
HRDB and the VR, have been used to examine persons with ESRD and diabetes since the
1960s3, 19, 20, 22-32.   These tests evaluate a complex reflex arc involving a stimulus, a
receptor, an afferent nerve, central processing, and an efferent nerve resulting in an end-
organ response6.  This involves several synapses and various neurotransmitters.  The
tests are noninvasive, relatively simple to perform5, 28 with procedures that have been
refined3, 5, and they detect an abnormality in ESRD patients who have significant
dysautonomia3.  However, they are dependent on patient cooperation and they do not
consistently reflect early changes in autonomic function48, 49, 87, 93, 99.  In addition to
early parasympathetic dysfunction as measured by HRDB and VR, during this time
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sympathetic function begins to deteriorate.  Studies using only evoked measures are not
able to detect sympathetic loss at this time, but studies using power spectral analysis are
documenting the loss49-52.
The 24-hr time-domain measures (SDNN, SDANN, PNN50, and RMSSD) are
based on standard deviations of the R-R interval.  These measures are decreased with
dysautonomia and, particularly the SDNN, have been associated with mortality in other
populations37-39.  However, preliminary work87, 110 found time-domain measures to
be less sensitive to changes in autonomic function than either frequency-domain
measures or evoked measures.  The SDNN, however, was shown to hold promise for
identifying an at-risk group for sudden death in the ESRD population93.  Another time-
domain measure, the SDANN, reflects circadian rhythmicity by statistically estimating
the changes in heart rate due to long cycles53, 83.   A poor SDANN can result from loss
of nighttime parasympathetic activity111, which has been found in patients with
diabetes42.  Both the PNN50 and the RMSSD are thought to be vagally mediated and,
thus, reflect parasympathetic modulation53.
Late in the disease process, generally after 24-hr and evoked measures document
dysautonomia, patients begin complaining of overt symptoms of dysautonomia61, 112.
The five primary categories of symptoms are orthostatic hypotension, sweating
abnormalities, gastrointestinal problems, impotence, and hypoglycemia
unawareness18, 59, 61.  Usually patients present with symptoms of either orthostatic
hypotension or impotence61.  Once symptoms occur, the patient experiences severe
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dysautonomia, which can result in total autonomic failure and death unless interventions
are instituted to change the downward spiral61.
Although the initial approach toward dysautonomia is to alleviate or control the
underlying disease process, in some circumstances such as uncontrolled diabetes this is
not possible.  For these individuals, potentially interventions to enhance autonomic
function include exercise programs, stress reduction methods such as slow deep
breathing, biofeedback techniques, and medications75, 113.  I terventions for
dysautonomia are just beginning to be investigated, and no studies with the ESRD
population could be found.  Thus, prospective studies within the ESRD population
investigating potential interventions to halt further progression of dysautonomia or to
reverse the signs and symptoms of dysautonomia are needed.
Figure 1 represents conceptually objective measures of autonomic function that
proceed to subjective measures that assess the manifestation of dysautonomia as
displayed in the center portion of the figure.  Based on the assumption that actual
symptoms occur late in the course of dysautonomia and that evoked measures and 24-hr
HRV are hierarchical in nature, the assessment of various stages of dysautonomia is
possible in ESRD patients.  The left side of the figure denotes the objective measures of
the autonomic nervous system, arranged based on suggested sensitivity.  In addition, it
includes the autonomic symptom checklist, which was developed for this series of studies
to quantify subjective symptoms.  The right side of the figure describes possible
interventions to improve autonomic function.  Interventions are based on current research
reported or under study.
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Measurement of Autonomic Function
in Renal Disease and Diabetes
Subtle decrease in
HRV with lessening
parasympathetic
modulation
Loss of evoked sinus
arrhythmia and decreasing
sympathetic activity
Changes in circadian
rhythmicity with an
increasingly fixed heart
rate and worsening cardiac
modulation.
Overt symptoms including
orthostatic hypotension,
sweating and GI problems,
impotence, and
hypoglycemia unaware
Total autonomic failure
potentially leading to…
Measures Of Cardiac
Metabolic derangement, increased blood glucose, ischemia, or
autoimmunity  lead to changes in autonomic nerve fibers including
axonal demyelination, lesion formation, and degeneration
24-hr HRV frequency-
domain (total power, LF,
HF)
Evoked cardiovascular tests
(HRDB and VR)
Symptom manifestation—
(Autonomic Symptom
Checklist)
24-hr HRV time-domain
(SDNN, SDANN, RMSSD)
Potential Interventions
Treat underlying disease process
(medications, maintain
euglycemia, transplantation)
Death
Methods to improve AF
(exercise, stress reduction,
biofeedback, slow breathing
techniques, medication)
Adaptive maneuvers to manage
symptoms (ways to stand, walk,
medication)
Figure 1.  Conceptual Framework of Dysautonomia in Uremia and Diabetes
mellitus.
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Chapter 2.  Development and Testing of the
Autonomic Symptom Checklist
Symptomatology in early dysautonomia is often vague and nonspecific; however,
dysautonomia is a common complication of end-stage renal disease and diabetes.  As
dysautonomia progresses it affects the function of numerous body organs resulting in a
variety of signs and symptoms including orthostatic hypotension, sweating abnormalities,
nocturnal diarrhea, and gastric fullness.  In addition, dysautonomia can play a prominent
role in impotence in men and hypoglycemia unawareness in individuals with diabetes17.
While laboratory evoked tests and 24-hr HRV measures provide psychometrically
validated evaluations of autonomic function, similarly validated instruments are not
readily available for assessment of subjective symptoms of dysautonomia.
In order to document relationships among objective measures of dysautonomia
and patient perceptions of their symptoms, a psychometrically validated instrument
focused on patients’ experiences of symptoms is needed.   In 1988, the American
Diabetes Association and the American Academy of Neurology recommended, in a
consensus statement,4 that a validated questionnaire assessing symptoms should be part
of the clinical criteria used when staging patients with diabetic polyneuropathy.  Thus,
the purpose of this research was to develop and test the Autonomic Symptom Checklist,
an instrument capable of documenting symptoms of dysautonomia in ESRD pat ents with
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and without diabetes and in healthy adults. The following research questions were
examined:
1. To what extent does the Autonomic Symptom Checklist demonstrate validity by
distinguishing among known groups with and without dysautonomia?
2. To what extent does the Autonomic Symptom Checklist demonstrate reliability?
2a)  in end-stage renal disease patients?
2b)  in healthy adult individuals?
3. To what extent is the Autonomic Symptom Checklist useful as an instrument for
evaluating symptoms of dysautonomia?
Introduction
A review of the genesis of dysautonomia for both ESRD patients and patients
with diabetes mellitus was presented in Chapter 1.  A brief summary is provided here.
Dysautonomia associated with uremia has been related to increased parathyroid hormone
levels, abnormalities within the baroreceptor arc, the efferent parasympathetic pathways,
and reduced end-organ responsiveness to vasoconstrictor agonists such as
norepinephrine12 and abnormalities in neurotransmission101.  Diabetic autonomic
neuropathies most likely result from prolonged exposure to a metabolic derangement
leading to chronic, widespread neural lesions with both myelinated and unmyelinated
axons being affected104.  Primary factors involved are an accumulation of glucose in the
peripheral nerves, a reduction of myoinositol, which is involved with lipid synthesis,
changes in myelin composition and synthesis59, hypoxia resulting in nerve
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ischemia14, 18, and autoimmune reactions106, 107.  Thus, individuals with ESRD with
or without diabetes experience dysautonomia and data suggest that patients with ESRD
and diabetes, regardless of type of diabetes, have the greatest degree of
dysautonomia87, 93.
The lack of knowledge regarding the physiological mechanisms of autonomic
neuropathy partially stems from the difficulties involved in studying this part of the
nervous system.  Historically, the diagnosis of autonomic neuropathy was based
primarily on symptoms that developed late in the disease process and were frequently
nonspecific.  Thus, autonomic neuropathies were thought to be uncommon in patients
with diabetes18 and ESRD20.
Postural hypotension is a primary symptom of dysautonomia61, even though it
tends to be a late clinical feature59.  It possibly indicates a lesion in the baroreceptor arc
resulting in a decrease in peripheral vascular resistance12 due to a diminished response of
the sympathetic vasoconstrictor fibers to the splanchnic bed, muscle and skin18.  This
prevents normal arteriolar vasoconstriction upon postural change from a sitting to a
standing position.  Symptoms can include dizziness, faintness, visual impairment or
syncope.  However, some patients are asymptomatic even when objective measures
document a drop of greater than 30 mmHg in systolic blood pressure upon standing18.
Thus, although an objective test can measure the amount of postural hypotension, the
symptoms that accompany this clinical feature are not always present.
Deficiencies in thermoregulation thought to be caused by sympathetic pathway
damage result in sudomotor and vasomotor abnormalities18.  Sudomotor, or sweating,
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abnormalities generally occur in a pattern of diminished or absent sweating in the lower
extremities with compensatory increased sweating in the upper trunk and head.
Gustatory sweating, or increased sweating while eating that is unrelated to a response to
spicy foods, is a less common symptom59.  Vasomotor abnormalities present vaguer
symptoms of thermoregulation dysfunction than sudomotor abnormalities.  In general,
vasomotor complaints center around the individual’s feet being either too cold or too hot.
These symptoms are thought to be caused by a failure to reflexively vasodilate or
vasoconstrict in response to body temperature changes18.
Hosking et al.59 reported that even when the entire gastrointestinal system is
involved with generalized hypotonic or hypertonic activity, the patient is often
asymptomatic.  The genesis of gastrointestinal dysfunctions, which can range from
esophageal atony to diarrhea, involves damage to the parasympathetic and sympathetic
nervous system18, in addition to possible autoimmune factors62.  Dia rhea is the most
prevalent symptom within this category59.  It is fairly characteristic and can last from
hours to days, with liquid stooling up to 20 or more times a day.  Diarrhea at night and
fecal incontinence are common.  Constipation is also a frequent complaint of patients
with dysautonomia, but it is unknown how this is related to the autonomic nervous
system18, or if it is related to other factors such as medications the patient is taking.
Symptoms of urogenital system involvement primarily include changes in the
ability to control the bladder and impotence61.  Symptoms of deficient bladder control
develop insidiously, progress slowly, and are complex to differentiate from common
complications such as a bladder infection.  This makes it difficult to evaluate urinary
changes as a symptom of dysautonomia.  Damage to the parasympathetic nervous system
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causes impotence with loss of penile erection in diabetic men with a prevalence of up to
50%18, 59, 60.  Data on female sexual function is scant.  Other urogenital symptoms that
can occur include ejaculation failure and loss of testicular pain to pressure.  Both of these
symptoms are believed to result from widespread sympathetic denervation to the pelvic
area18.  Impotence is not always included as a diagnostic feature63 because of
confounding variables, such as psychogenic factors or the influence of age and
mediations59, which can affect penile erection.
Hypoglycemia unawareness is the failure of the patient to recognize symptoms of
low blood sugar.  This involves both parasympathetic and sympathetic dysfunction,
however, the symptoms associated with hypoglycemia, including tachycardia and
headache, are sympathetic in origin18.  Thus, hypoglycemia unawareness indicates the
progression of autonomic dysfunction from parasympathetic to sympathetic involvement.
It is considered a late symptom manifestation of diabetic autonomic neuropathy and can
be particularly devastating resulting in coma and death.
In the 1970s, Ewing and Winney20 b gan using bedside autonomic function tests
to aid in interpretation of these vague symptoms; thus, the diagnosis of autonomic
neuropathies became more objective leading to increased recognition and treatment of
dysautonomia at an earlier stage.   However, the treatment of dysautonomia is not
definitive and the progression of dysautonomia still results in symptomatology.
Presently, there are valid and reliable objective, physiologic measures of
dysautonomia21, 53 however, a valid and reliable instrument to measure
symptomatology is not available.  For research purposes, a self-administered autonomic
symptomatology instrument could be used to identify when in the progression of
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dysautonomia symptoms occur.  Thus, the purpose of this investigation was to develop
and test an instrument designed to measure symptoms of dysautonomia.
Methodology
Design
A descriptive, cross-sectional design was used to examine the symptomatology of
dysautonomia experienced by ESRD patients being evaluated for a kidney or kidney-
pancreas transplant.  In addition, healthy individuals were recruited as controls.  Based on
previously published data suggesting that subjects with ESRD and diabetes have poorer
autonomic function than ESRD without diabetes87, 93, hree known groups with varying
levels of autonomic function were identified.  Validity was then determined by
comparing the autonomic function of these known groups; healthy controls, patients with
ESERD and diabetes mellitus (ESRD DM) and patients with ESRD without diabetes
mellitus (ESRD NonDM).  A correlational design using test-retest data was used to
establish reliability of the Autonomic Symptom Checklist (ASC).
 Sample
A convenience sample of 242 pre kidney or kidney-pancreas transplant patients
from a major transplantation center in the southern United States and 34 healthy controls
were enrolled.  All pretransplant subjects had ESRD, with or without diabetes, which was
severe enough to warrant referral for transplantation.  The healthy controls were recruited
from a group of students, faculty, and friends.  Each healthy control was asked a series of
questions to evaluate for potential dysautonomia and excluded if any was suspected.
Inclusion criteria for both ESRD patients and healthy controls included being over 18
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years of age.  Patients and healthy controls were excluded if they were pregnant or found
to have a co-existing neurological deficit that altered autonomic function such as spinal
cord injury, peripheral nerve trauma, and degenerative disease of the spinal cord.
Previously published data87, 93 documented the level of dysautonomia in the ESRD
group allowing stratification into three groups: healthy controls (Control, n=34), ESRD
patients without diabetes mellitus (NonDM, n=159), and ESRD subjects with diabetes
mellitus (DM, n=85).
A subgroup of control (n=15) and ESRD patients (n=7) participated in the test-
retest portion of the study.  The control subgroup was a convenience sample of those
available to retake the test within two to seven weeks (mean=4.5 weeks) of the original
testing.  The seven ESRD patients were a convenience sample chosen from a patient
group that was available by telephone during a 4-day period that corresponded to three to
five weeks (mean=5.5 weeks) from the original testing.  Because no change was observed
in objective measures of autonomic function over a two to 10 week period46, it was
thought that retesting within 5 weeks would result in scores minimally influenced by
changes in autonomic function.
The control, NonDM and DM groups (see Table 2) had no significant gender
difference and were predominately men (54%, 64% and 58%, respectively).  In addition,
there was no significant difference in mean age (Control=42 yrs., NonDM=42 yrs., and
DM=44 yrs., respectively).  The NonDM group had a significantly higher (p<0.05)
percentage of African-Americans (68%) as compared to the DM group (42%) and control
group (9%).  Previous work has suggested an inverse relationship between autonomic
function and age27, 64, 65, 114 with a lack of consensus on the relationship between
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autonomic function and gender27, 31.  No reports on the relationship between autonomic
function and race could be found.  Subgroups consisting of only men from the control,
NonDM, and DM groups were used to establish the validity of the Impotence Category.
There was no significant difference in mean age (see Table 3) among the men subgroups
(control=39 yrs., NonDM=42 yrs., DM=46 yrs.), however, the NonDM group had a
significantly higher (p<0.05) percentage of African-Americans (68%) as compared to the
DM  (50%) and the control groups (0%).
Healthy control (n=15) and ESRD patient (n=7) subgroups were identified to
establish reliability of the ASC.  There was no significant difference in mean age (see
Table 4) among the subgroups (control=41 yrs., ESRD=47 yrs.), however, the ESRD
subgroup had a significantly higher (p<0.05) percentage of African-Americans (57%) as
compared to the control group (13%).
Displayed in Table 5 are the characteristics of the ESRD DM group that were
divided into those aware of symptoms of hypoglycemia and those unaware of the
symptoms.  The Unaware group had more women (59% vs. 36%) and had a slightly
younger mean age (40 yrs. vs. 45 yrs.).  They were similar on race with the Unaware
group being 34% African-Americans and the Aware group being 41%.
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Table 2.  Characteristics of Healthy Controls, ESRD Patients with Diabetes Mellitus
(DM), ESRD Patients Without Diabetes Mellitus (NonDM), and the Total Sample
Healthy
Controls
(n=34)
ESRD with DM
(n=85)
ESRD NonDM
(n=159)
Total Sample
(n=276)
Age (mean, SD) 42 ± 9.1 44 ± 10.4 42 ± 12.1 42 ± 11.3
  Range (yrs.) 25-65 25-67 17-69 17-69
Gender (n/%)
  Women 16 (46%) 36 (42%) 57 (36%) 109 (40%)
  Men 19 (54%) 49 (58%) 102 (64%) 170 (60%)
Race (n/%)
  African-Amer. 3 (9%)* 35 (42%)* 108 (68%)* 146 (53%)
  Caucasian 31 (89%)* 48 (57%)* 50 (32%)* 129 (46%)
  Other 1 (2%) 1 (1%) 0 (0%) 2 (1%)
Note.  *=p<0.05 for groups having like symbols; ESRD=end-stage renal disease.
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Table 3.  Characteristics of Male Subgroups in the Healthy Controls, ESRD Patients
with Diabetes Mellitus (DM), ESRD Patients Without Diabetes Mellitus (NonDM),
and the Total Sample
 Healthy Controls
(n=19)
ESRD with DM
(n=48)
ESRD NonDM
(n=102)
Total  Sample
(n=169)
Age (mean, SD) 39±10.0 46±9.8 42±12.1 43 ±  114
   Range (yrs.) 25-65 30-67 18-69 18-69
Race (n/%)
  African-Amer. 0 (0%)* 24 (50%)* 68 (67%)* 92 (54%)
  Caucasian 18 (94%)* 24 (50%)* 34 (33%)* 76 (45%)
  Other 1 (6%) 0 (0%) 0 (0%) 1 (1%)
Note.  *=p<0.05 for groups having like symbols; ESRD=end-stage renal disease.
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Table 4.  Characteristics of Healthy Control and ESRD Patient Reliability
Subgroups
Healthy Controls
(n=15)
ESRD Patients
(n=7)
Age (mean, SD) 41±7.8 47±17.9
  Range 25-55 19-67
Gender (n/%)
  Women 8 (53%) 4 (57%)
  Men 7 (47%) 3 (43%)
Race (n/%)
  African-American 2 (13%)* 4 (57%)*
  Caucasian 13 (87%)* 3 (43%)*
Note.  *=p<0.05 for groups having like symbols;  ESRD=end-stage renal disease
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Table 5.  Characteristics of Hypoglycemia Unaware and Hypoglycemia Aware
Subgroups.
Hypoglycemia Unaware
(n=31)
Hypoglycemia Aware
(n=34)
Age (mean,SD) 40±8.8 45±10.9
  Range 25-64 26-67
Gender (n/%)
  Women 18 (59%) 14 (36%)
  Men 13 (41%) 25 (64%)
Race (n/%)
  African-American 11 (34%) 16 (41%)
  Caucasian 21 (66%) 22 (56%)
  Other 0 1 (3%)
Note.  No significant differences were found among groups.
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Instrument
The aims of the ASC were to recognize the perceived presence, distribution and
severity of autonomic symptoms.  Initially, the instrument was compiled using
information from several expert sources59, 61, 115.  Subsequently, a focus group met
over a five-week period for four, two hour sessions to refine the questions and simplify
the reading level of the instrument.  The focus group was comprised of people with
experience as transplant coordinators, diabetic educators, and researchers in addition, one
person had type 2 diabetes mellitus.  Following focus group discussions, the ASC was
pilot tested on four ESRD patients and further revisions were made.  Revisions included
clarifying terminology and adding a time-frame to the directions.
The revised ASC was developed as a self-administered checklist that assessed
dysautonomia symptoms in five categories with 32-items each with a 7-point Likert
scale116 (see Appendix C).  A self-administered format was chosen because, typically,
the individual’s perception of these symptoms is what alerts the provider to the
possibility of dysautonomia.  Three categories, Orthostatic Hypotension, Sudomotor
Abnormalities, and Gastrointestinal Problems, are to be completed by all respondents,
while two categories are also completed by subgroups: the Impotence category is to be
completed by men; and the Hypoglycemia Unaware is to be completed by individuals
with diabetes mellitus.
 Each of the five categories consists of four to six questions, each answered using
a seven-point Likert scale with 0 being “never” and 6 being “always”.  The individual is
asked to circle the number that indicates the severity of that symptom.  The last question
in each category is classified as an “impact” question and used to obtain a score reflecting
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patients’ perceptions of how problematic that category of symptoms is for them.  This
question was included because the presence of a symptom and the degree to which a
symptom creates problems are not always the same.  In addition, information is obtained
concerning each patient’s current medications, alcohol and caffeine intake, and tobacco
use.  These products could affect function of the autonomic nervous system21, but it is
unknown as to what extent.
The Orthostatic Hypotension category consists of five questions (30 points
possible) focused on symptoms of hypotension upon standing.  These symptoms include
rapid heartbeat, blurred vision, an upset stomach, dizziness, and clammy skin.  The
Sudomotor Abnormalities category consists of three questions (18 points possible)
focused on an increase or decrease in sweating.  The Gastrointestinal Problems category
consists of five questions (30 points possible) focusing on bowel and stomach disorders.
The Impotence category consists of four questions (24 points possible) focused on the
ability to have and maintain an erection.  The Hypoglycemia Unaware category consists
of four questions (24 points possible) focused on subjects’ ability to recognize symptoms
associated with a low blood sugar.  Each category of symptom questions is followed by
an impact question “how much of a problem are these symptoms for you?” (6 points
possible).
Patient responses are entered into the database as scored by the individual, except
for questions 4a, 4b, and 4c in the Impotence category and question 5a in the
Hypoglycemia Unawareness category, which are written in reverse fashion and,
therefore, scored in reverse fashion.  Category and index calculations are performed
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based on these values with higher scores indicating greater symptoms.  See Appendix D
for definitions and a detailed description of the calculations.
For each patient, two scores per category are reported: symptom score and impact
score.  The category symptom score was calculated by obtaining a raw score for each
category then dividing the raw score by the number of questions in that category.  Each
category symptom score has a range from 0 – 6.  The category impact score is obtained
directly from the one impact question and also ranged from 0 - 6.   Each category
symptom score and impact score can be compared across groups.
Two other scores reported are total symptom score and total impact score.  The
total symptom score (6 points possible) are the sum of category symptom scores divided
by the number of categories reported (e.g., 5 for DM women, 6 for DM men).  The total
impact score (6 points possible) is calculated by dividing the total number of points
scored on the category impact questions by the number of impact questions possible for
that group.  Both the total symptom score and the total impact score can be compared
across groups.
The ASC index score (36 points possible) is a single measure designed to reflect
the patient’s perception of experienced dysautonomia symptoms and the impact of those
symptoms on the patient.  It is calculated by multiplying the total symptom score and the
total impact score and can be compared across groups.
Procedure
Subjects with ESRD were recruited from a group of individuals being examined
for dysautonomia as part of their transplantation evaluation at the University of
Tennessee, Memphis.  At the time of evaluation the study was explained to potential
62
subjects, eligibility was ascertained, and written consent obtained (see Appendix B).
Baseline data including health history and demographic data were also obtained prior to
administration of the ASC.  The subject was asked to return the ASC with other
questionnaires they completed as part of their evaluation for transplantation.
The normal healthy controls were recruited from a group of students, faculty, and
friends at the University of Tennessee, Memphis.  Thirty-one of the healthy controls had
participated in previous autonomic function testing which documented normal autonomic
function.  For the controls with no prior autonomic function testing, demographic data
and follow-up questions from the investigator were designed to screen for physical
problems indicating potential dysautonomia.
A subgroup from both the control group and the ESRD group were identified and
asked to complete the ASC a second time.  The control subgroup (n=15) consisted of the
controls who had taken the initial test two to five weeks previously.  All who qualified
completed the retake.  The patient subgroup (n=7) consisted of patients who had initially
completed the ASC two to six weeks previously.  The ASC was re-administered by
telephone and the first seven subjects contacted by phone comprised the subgroup.  The
two to six week period between the pre and posttest allowed enough time to prevent
recall116, yet not enough time for significant change in health status to occur which
could alter symptomatology46.
Data Analysis
Content validity of the ASC was ascertained by deriving the questions in the ASC
from published works from known experts in autonomic dysfunction and diabetes.  In
addition, a group of experts participated in a focus group to review and refine the
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questions.  Univariate analysis was used to compare the equality of the groups.
Construct validity was ascertained using ANOVA tests to compare the means of the three
known groups for three of the categories (Orthostatic Hypotension, Sudomotor
Symptoms, Gastrointestinal Symptoms).  An ANOVA test on men in each of the three
groups was used to obtain a measure of validity of the Impotence Category.  Validity of
Hypoglycemia Unaware was assessed using Student’s t-test.  Patients reported to be
aware of symptoms of hypoglycemia were placed in one group; patients reported to be
unaware of symptoms were placed in a second group.  This was based on information
gathered by a clinician assessing the patients’ awareness of hypoglycemia through a
probing interview of the patient and family.  Correlational analysis was used to evaluate
reliability of the ASC.  Test-retest data were obtained on a subset of both controls and
subjects to obtain a coefficient of stability.
Results
Validity
 The focus group concurred that the refined ASC had content validity.  Construct
validity testing resulted with the DM group reporting the greatest symptomatology,
followed by the NonDM group, and with least symptoms, the control group.  This pattern
was present for all symptom categories.  There was significant difference (p< 0.0001)
among all groups for three symptom scores (orthostatic hypotension, gastrointestinal
problems, and impotence) and two impact scores (gastrointestinal problems and
impotence).  There was significant difference (p < 0.003) between healthy controls and
both ESRD groups (see Table 6) for one symptom score (sudomotor abnormalities) and
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two impact scores (orthostatic hypotension and sudomotor abnormalities).  In addition,
findings demonstrated a significant difference (p < 0.03) in symptoms between patients
with diabetes who were hypoglycemia aware and hypoglycemia unaware (Table 7).
Thus, the ASC differentiated among groups with varying levels of dysautonomia and
identified a group with increased symptoms.
Reliability
A coefficient of stability over a two to five week period was measured with a test-
retest technique using Pearson correlation116 (see Tables 8 and 9).  Within the control
subgroup, symptom score and impact score reliability coefficients ranged from 0.69
(Gastrointestinal Problems) to 0.87 (Orthostatic Hypotension) with p < 0.004.  Within the
patient subgroup, the symptom score reliability coefficients ranged from 0.59, p £ 0.03
(Sudomotor Abnormalities) to 1.00, p £ .000 (Hypoglycemia Unaware).  Because the r-
values ranged between 0.59-0.87, there was a moderate to high positive correlation and
consistency between the two tests116.  However, the reliability coefficient for the
Sudomotor Impact Score was low for patients (r=0.05, p < 0.9).
Other findings
Mean symptom and impact scores for controls, ESRD NonDM and ESRD DM
groups were reported by gender in Table 10.  Table 11 displays data ranked from highest
score (most symptom or problem) to lowest score (least symptom or problem).  All
ESRD patient groups when examined by gender have the same symptom and impact
score ranking: Impotence Category, Hypoglycemia Awareness, Gastrointestinal
Problems, Orthostatic Hypotension, and Sudomotor Disorders.
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Table 6.  Symptom and Impact Scores Comparing Healthy Controls, Patients with ESRD and Patients with both ESRD and
DM on Four Sections of the Autonomic Symptom Checklist
Orthostatic
Hypotension
Sudomotor
Abnormalities
Gastrointestinal
Problems
Impotence
Symptom
Score
Symptom
Impact Score
 Symptom
Score
Symptom
Impact
Score
 Symptom
Score
Symptom
Impact Score
Symptom ScoreSymptom
Impact Score
n 279 272 279 260 279 262 159 151
Range of
possible scores
0-6      0-6      0-6 0-6        0-6       0-6        0-6 0-6
GROUP
Control (n=35) 0.20±0.41* 0.17±0.5*† 0.44±0.8* 0.26±0.7* 0.40±0.5* 0.34±0.73* 0.71±1.1* 0.50±1.2*
(n=19; Impotence)
NonDM (n=159)
(n=102; Impotence)
0.89±1.01* 1.15±1.5† 0.75±1.1† 0.67±1.3† 1.22±1.1* 1.53±1.7* 2.53±1.6* 2.35±2.3*
DM (n=85)
(n=49; Impotence)
1.22±1.20* 1.62±1.8* 1.24±1.5*† 1.14±1.7*† 1.66±1.4* 2.27±2.1* 3.68±1.6* 3.94±2.2*
P value< 0.0001 0.0001 0.0008 0.003 0.0001 0.0001 0.0001 0.0001
Note.  * and † indicate significance for groups having like symbols.   All values are given as means±SD.  ESRD=end-stage renal disease, DM=diabetes mellitus,
NonDM=nondiabetes mellitus.
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Table 7.  Symptom and Impact Scores from the Autonomic Symptom
Checklist Which Compares Hypoglycemia Aware and Unaware
 ESRD DM Patients
Hypoglycemia
Unaware
(24 points possible)
Symptom
Score
Symptom Impact
Score
Range of scores 0-6 0-6
GROUP
Not aware (n=31) 2.40±1.0* 3.61±2.1*
Aware (n=34) 1.61±1.0* 2.48±2.0*
P value< 0.002 0.03
Note.  * indicate significance for groups having like symbols.  All values are given as
means±SD.  ESRD=end-stage renal disease, DM=diabetes mellitus, NonDM=without
diabetes mellitus.
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Table 8.  Correlations for Pre- and Posttest ASC Scores for Three Symptom
Categories
Orthostatic
Hypotension
Sudomotor
Symptoms
Gastrointestinal
Symptoms
Symptom
Score
Impact
Score
Symptom
Score
Impact
Score
Symptom
Score
Impact
Score
ESRD Sample
(n=7)
0.79 0.78 0.59 0.05 0.72 0.91
Healthy Controls
(n=15)
0.87 1.00 0.81 1.00 0.69 0.84
Note.  Values represent correlation coefficients.
Table 9.  Correlations for Pre- and Posttest ASC Scores for Impotence and
Hypoglycemia Categories.
Impotence
(Patients & Controls)
Hypoglycemia Unaware
(Diabetics only)
Symptom
Score
Impact
Score
Symptom
Score
Impact Score
n 10 10 2 2
r values 0.99 0.76 1.00   Not calculated
Note.  Values represent correlation coefficients.
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Because pretransplant kidney and kidney-pancreas patients have poorer objective
measures of autonomic function when compared to posttransplant patients, we decided,
in addition to the research questions, to examine the validity of the ASC by administering
it to posttransplant patients.  The ASC was given to independent samples of pretransplant
(n=233) and posttransplant patients (n=77, 6-12 months posttransplant).  The samples
were similar in diabetic status, age, and gender (see Table 12).  Hypoglycemia data are
not reported because all but 7 of the 29 patients with diabetes received a pancreas
transplant and no longer experienced hypoglycemia.  Posttransplant patients reported
statistically significant (p<0.05) fewer symptoms in two categories (Orthostatic
Hypotension and Gastrointestinal Problems) with essentially no difference in sudomotor
symptoms.  Index Score, which reflects both symptoms and impact of the symptoms, was
significantly (p<0.05) better for the posttransplant group.
In addition, a subset of patients with both pre and posttransplant evaluations was
identified (n=19), which was similar to the larger posttransplant sample in terms of
diabetic status, gender, and type of transplant (64% kidney only).  Although significance
was not obtained in matched patients (see Table 13), symptom improvement was seen in
the majority of individuals in this subset for Orthostatic Hypotension (10 of 19),
Gastrointestinal Problem (10 of 19), and Index Score (12 of 19).  Thus, the ASC
documents a decrease in symptoms of dysautonomia following kidney and kidney-
pancreas transplant.
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Table 10.  ASC Mean Symptom and Impact Scores by Group and Gender
Healthy Controls ESRD NonDM ESRD DM
Women
(n=16)
Men
(n=18)
Women
(n=57)
Men
(n=102)
Women
(n=36)
Men
(n=49)
Symptom Scores
   Orthostatic
   Hypotension
0.26 0.14 0.86 0.91 1.38 0.92
    Sudomotor
   Abnormalities
0.54 0.35 0.76 0.74 1.27 0.75
   Gastrointestinal
   Problem
0.41 0.56 1.24 1.21 1.95 1.22
   Impotence na 0.71 na 2.53 na 2.53
   Hypoglycemia
   Unawareness
na na na na 2.12 2.00
Impact Scores
   Orthostatic
   Hypotension
0.38 0.00 0.99 1.24 1.89 1.42
    Sudomotor
   Abnormalities
0.44 0.11 0.73 0.64 1.20 1.09
   Gastrointestinal
   Problem
0.38 0.32 1.57 1.52 2.48 2.10
   Impotence na 0.5 na 2.35 na 3.94
   Hypoglycemia
   Unawareness
na na na na 2.94 2.96
Note.  ESRD=end-stage renal disease; NonDM=nondiabetic; DM=diabetes mellitus; na=not applicable.
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Table 11.  Highest to Lowest ASC Mean Symptom and Impact Scores for ESRD Patients by Group and Gender
                        Symptom Score Impact Score
Men Women Men Women
DM NonDM DM NonDM DM NonDM DM NonDM
Impotence 2.53 2.53 na na 3.94 2.35 na na
Hypoglycemia
Unaware
2.00 na 2.12 na 2.96 na 2.94 na
Gastrointestinal
Problems
1.22 1.21 1.95 1.24 2.10 1.52 2.48 1.57
Orthostatic
Hypotension
0.92 0.91 1.38 0.86 1.42 1.24 1.89 0.99
Sudomotor Disorders 0.75 0.74 1.27 0.76 1.09 0.64 1.20 0.73
Note.  ESRD=end-stage renal disease; NonDM=nondiabetic; DM=diabetes mellitus; na=not applicable.
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Table 12.  Characteristics of Independent Samples and Matched Samples of Pre and Posttransplant ESRD Patients
NonMatched Matched
 PreTransplant PostTransplant Pre and PostTransplant
Total Group 6 mo. PostTx 12 mo. PostTx
 
n 233 68 37 31 19
Age 42.5+11.6 41.3±11.1 41.2±10.8 41.5±11.4 40.2±12.4
PreTx DM Status
  DM
  NonDM
85 (36%)
148 (64%)
29 (43%)
39 (57%)
15 (40%)
22 (60%)
14 (45%)
17 (55%)
8 (42%)
11 (58%)
Gender
  Men
  Women
140 (60%)
93 (40%)
44 (65%)
24 (35%)
24 (65%)
13 (35%)
20 (65%)
11 (35%)
11 (58%)
8 (42%)
Race
  African-Am.
  Caucasian
  Other
134 (58%)
96 (41%)
1 (1%)
19 (28%)
49 (72%)
10 (27%)
27 (73%)
9 (29%)
22 (71%)
4 (21%)
15 (79%)
Type of Tx
  Kidney alone
  Pancreas or KP
186 (80%)
47 (20%)
46 (68%)
22 (32%)
24 (64%)
13 (36%)
22 (70%)
9 (30%)
12 (64%)
7 (36%)
Note.  ESRD=end-stage renal disease; NonDM=nondiabetic; DM=diabetes mellitus;  Tx=transplant; KP=kidney-pancreas.
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Table 13.  ASC Category Mean Symptom Scores and Index Scores for Independent
and Matched Samples of Pre and Posttransplant ESRD Patients
Category Mean Symptom Scores
Group
Orthostatic Sudomotor GI ImpotenceIndex
Independent Samples
 PreTx (n=233) 0.99* 0.93 1.36* 2.98 3.03*
 PostTx (n=93) 0.72* 0.92 1.04* 2.93 1.65*
Matched
  PreTx (n=19) 0.82 0.91 1.47 1.91 2.50
  PostTx (n=19) 0.52 0.56 1.11 2.67 1.32
*p< 0.05; PreTx=Pretransplant; PostTx=Posttransplant; GI=gastrointestinal; ASC=Autonomic Symptom
Score.
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Discussion
Validity
Content validity was established by an expert panel.  Construct validity was
established by the ability of the Autonomic Symptom Checklist to significantly
differentiate among three groups with known dysautonomia.  Both the ESRD patients
with diabetes and those without diabetes were different from the control group and from
each other on orthostatic hypotension, gastrointestinal problems and impotence symptom
scores.  The sudomotor symptom score differentiated between healthy controls and
patients with ESRD and diabetes.  In addition, the groups with diabetes, which have been
shown to have the poorest evoked cardiac measures and 24-hr HRV measures of
autonomic function87, also have the highest symptom scores on all subscales.  Thus,
increased symptomatology was seen in patients with worsening physiologic autonomic
function.  In addition, when the ASC was administered to pre and posttransplant kidney
and pancreas-kidney patients, the ASC documented increased symptomatology in the
pretransplant group, which is known to have poorer objective measures of
dysautonomia41, 99, as compared to the posttransplant group.  This finding documents
the ability of the ASC to monitor changes in autonomic function and, thus, supports its
clinical utility in longitudinal research protocols.  In addition, it shows that in a small
group of kidney and kidney-pancreas posttransplant patients, symptomatology decreased
by 6 to 12 months after transplant.
Age and gender have been identified as the primary factors, outside of disease,
which may affect autonomic function.  It has been shown that with age autonomic
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function values tend to worsen27, 64, 65, 114 and that women tend to have worse values
of autonomic function than men65, 114.  In the present study, the three groups (Control,
NonDM, and DM) were essentially equivalent on both age and gender.  No studies were
found which documented any affect of race on autonomic function.  Thus, it is unknown
if, or how, the 89% Caucasian composition of the control group affected the values
obtained.
It was quite interesting that all groups ranked the symptoms and impact scores in
the same order.  Impotence appeared to be the major symptom and problem for men with
hypoglycemia unawareness ranking a close second for the patients with diabetes and first
for women with diabetes.  For symptom categories responded to by the group as a whole,
gastrointestinal problems are of major concern, with women without diabetes ranking
them first.
Reliability
Reliability was found to be moderate to high using pretest/posttest correlation
scores for symptom categories.  The fluctuation seen in the reliability coefficients could
be due to the small sample size for both the controls and patients117. Burns and
Grove116 suggest that a well-developed measurement instrument should have a
reliability of at least 0.8, whereas a newly developed instrument should have a reliability
of 0.7.  Most of the ASC categories have a reliability of at least 0.7, and meet the criteria
for reliability.
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Implications and Conclusions
The ASC is a potentially useful research instrument for monitoring symptom
changes brought about by interventions designed to improve autonomic function, such as
transplantation and exercise.  It is also important to note that a question to quantify how
important or bothersome a category of symptoms is, if present, included in each category.
Only one impact question is asked in each category (versus an impact question for each
symptom question) in an assumption that it is more important to obtain a global
quantification of the category impact and in an effort to simplify the questionnaire.  This
question is an initial effort to address quality of life of patients as it relates to symptoms
of dysautonomia.
The ASC was designed to ascertain ESRD patients’ perceptions of symptoms,
therefore, it is intended to be self-administered, and is subjective in nature.  Presently, it
is being used in a longitudinal research protocol as an instrument to obtain subjective data
in conjunction with two objective tests of autonomic function.  The ASC was not
designed to provide objective clinical signs of dysautonomia.  The ASC is easy to
administer, has a Flesch-Kincaid reading grade level of 3.3, and has only four to six
questions addressing each of the five symptom categories.  This design was thought to
improve patient compliance in completing and returning the instrument.
To increase the variability in scores, further refinements to the ASC are needed.
Potential revisions include replacing the “never” and “always” Likert anchors with more
descriptive anchors, including in the directions instructions to use the past one to two
months as a time-frame when deciding how to answer the questions, and clarifying the
wording of some of the questions.  Further studies to confirm reliability using a larger
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sample size are needed; however, r-values, even with a small sample size, were moderate
to high.
One of the advantages for use of this instrument are the individual category
symptom scores and impact scores.   Category scores consequently can be correlated with
specific physiologic measurements of dysautonomia.  For example, the Orthostatic
Hypotension symptom category can be correlated with objective laboratory evoked tests,
which evaluate systolic blood pressure change when the patient moves from a lying to a
standing position.   Thus, if a patient is experiencing symptoms of dysautonomia in only
a few categories, the categories can be identified, quantified, and compared to objective
test results.  Correlation of individual category scores or the ASC index score with
objective test measures could help identify the threshold where autonomic function test
values herald the presence of symptoms.  If specific thresholds are identified,
interventions could feasibly be designed to prevent progression to symptomatology.
The consistent finding of low symptom scores suggests a relatively asymptomatic
state, even for ESRD groups with severe dysautonomia as measured by physiologic
testing, supporting the premise that symptoms of dysautonomia occur late in the disease
process61.  For this reason, the ASC is not designed as a screening tool for
dysautonomia, but rather as a research instrument to be used in combination with other
measures of autonomic function.  Within a research environment, the ASC could be used
to discover when, in the progression of disease, do symptoms occur, and in a clinical
setting to monitor the progression of disease and effects of therapy.  To develop a
screening tool for early dysautonomia, early symptoms of dysautonomia, if they can be
identified, would have to be established.
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In conclusion, the ASC was found a valid and reliable research instrument for
assessing symptoms of dysautonomia in the ESRD transplant population.  If clinicians
could begin treating the dysautonomia prior to symptoms, the onset of symptoms with
subsequent deterioration in quality of life could possibly be delayed.  In addition, the
ASC’s clinical utility for monitoring changes in autonomic symptomatology resulting
from transplantation was established.  Thus, the ASC can be incorporated into
longitudinal research protocols. The next step in a program of research would be to
correlate physiological measures of dysautonomia to symptomatology in hopes of
identifying a threshold, which identifies the beginning of symptomatology.
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 Chapter 3.  Establishment of Referent Values for Evoked Autonomic
Function, 24-Hr Heart Rate Variability, and Autonomic
Symptomatology
In 1988, a consensus statement written by the American Diabetes Association and
the American Academy of Neurology was published118.  T  organizations
recommended that when performing evoked autonomic function tests, a battery of tests
should be used and each laboratory should standardize their own cardiovascular measures
using the population they were studying.  Each laboratory, in addition, should establish
it’s own normal referent values from an appropriate normative control population.   No
recommendations were made for testing autonomic function with 24-hr HRV analysis.
Four years later, in 1992, the two groups again met to review the current state of the art of
standardized autonomic function testing.  The second consensus group now agreed that
evoked measures were sufficiently standardized for longitudinal assessment of
cardiovascular autonomic function of patients with diabetes.  The recommended evoked
battery of tests included the change in heart rate with deep breathing and the Valsalva
maneuver21.  In addition, physiologic factors, such as respiratory rate and age, and
confounding variables, such as smoking and dehydration, which are thought to affect
tests results, were identified.   However, evaluating autonomic function using ambulatory
monitoring was only briefly mentioned with no recommendation for testing or
information on sensitivity and specificity.
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Recommendations for standardized nomenclature and methods of measurement
for heart rate variability53 were made by the Task Force of the European Society of
Cardiology and the North American Society of Pacing and Electrophysiology in 1996.
These recommendations included which time- and frequency-domain measures to report,
guidelines for standardization of ECG recording length and analysis, and technical
requirements for commercial equipment.  It is yet to be seen how these recommendations
will be utilized in clinical research.
Autonomic function testing is an evolving field.  This is reflected in the fact that
although recommendations for standardization of autonomic function testing research
methodologies have been made4, 21, 53, a standard methodology and reporting system is
not used in all laboratories.  Thus, it is difficult to compare and contrast research findings
among various studies due to different research protocols, analysis techniques, and
reporting formats.  This study was designed to establish normal, borderline, and abnormal
values for measures of autonomic function and to determine if these values can
distinguish healthy individuals from ESRD patients.  In addition, the extent to which age,
gender and presence or absence of ESRD and diabetes mellitus influence measures of
cardiovascular autonomic function was explored.  To this purpose, the following research
questions were investigated.
1. What responses to evoked cardiovascular function testing, 24-hr HRV monitoring,
and autonomic symptomatology are characteristic of
1a)  healthy adult individuals?
1b)  adult ESRD pretransplant patients?
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2. What is the relationship between age and measures of evoked cardiovascular
function, 24-hr HRV monitoring, and autonomic symptomatology for
2a) healthy adult individuals?
2b) adult ESRD pretransplant patients?
3. What is the difference between measures of evoked cardiovascular function, 24-hr
HRV monitoring, and autonomic symptomatology for
3a)  healthy adult men and women individuals?
3b)  adult men and women ESRD pretransplant patients?
4. What are the relationships among measures of autonomic function in
4a) healthy adult individuals?
4b) adult ESRD pretransplant patients?
5. What are normal, borderline, and abnormal values for evoked autonomic tests, 24-hr
HRV, and Autonomic Symptom Checklist measures?
Introduction
The heart rate response to the Valsalva maneuver and change in heart rate with
deep breathing (HRDB) are widely used, simple tests which quantify cardiovascular
autonomic function3, 4, 15.  The Valsalva ratio (VR) is determined by calculating
changes in heart rate during and following a Valsalva maneuver.  An early study19
examined the VR of 42 patients with diabetes mellitus and found this measure an
objective assessment of the state of the autonomic nervous system in diabetic patients.
At that time, Ewing defined VR values < 1.10 as abnormal, 1.11 to 1.20 as borderline,
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and values >1.21 as normal19.  Mayo Clinic73 has subsequently established control
values that are age-related (see Table 14).
In the 1970s, HRDB was reported to be a simple, accurate119, 120 and
reproducible119 method to test cardiac vagal neuropathy in diabetic patients.  Mackay,
Page, Cambridge, and Watkins63 a d Dyrberg, Benn, Christiansen, Hilsted, and Nerup22
defined HRDB as abnormal when the change in beats between inspiration and expiration
was less than 9, which was the lower limit of normal for the control group22.  For
research purposes, Ewing, Martyn, Young, and Clarke3 established the commonly
accepted values for HRDB to be <10 as abnormal, 11 to 14 as borderline, and > 15 s
normal.   Different values have been established by Mayo Clinic73 (see Table 14).
In the 1980s, researchers began describing power spectral analysis of HRV as a
quantitative method to evaluate autonomic regulation of the cardiovascular system9 and
began examining HRV in both time- and frequency-domains121.  Once HRV was
recognized as a strong and independent predictor of mortality after an acute myocardial
infarction37, 122, its clinical importance was appreciated.  Normal values for 24-hr time
and frequency measures were established by Bigger et al.2 by recruiting 274 healthy
middle-aged individuals (range 40-60 years old, mean 57+8.2 years, 74% men) (see
Table 15).  These same values were accepted as normal by the Task Force of the
European Society of Cardiology and the North American Society of Pacing and
Electrophysiology53.
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Table 14.  Varying Normal, Borderline, and Abnormal Values for Evoked Measures
Normal Borderline Abnormal
Change in HR with Deep Breathing
   Values established by Ewing et al.3   > 15 11 - 14 <10
   Control Values established by Mayo Clinic73
  10-40 yr. olds
  41-50 yr. olds
  51-60 yr. olds
  61 and over
 > 18
 > 16
 > 12
 > 8
   Values established by MacKay et al.63 and
   Dyrberg et al.22 < 9
   Values established by Naverro et al.41, 123 > 15
Valsalva Ratio
   Values established by Ewing et al.19 > 1.21 1.11 - 1.20 < 1.10
   Control Values established at Mayo Clinic73
  10-40 yr. olds
  41-50 yr. olds
  51-60 yr. olds
  61 and over
 > 1.50
 > 1.45
 > 1.45
 > 1.35
   Values established by Navarro et al.41, 123  > 1.43
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Table 15.  Characteristic Values for Healthy Middle-aged Persons (Selected 24-hr
Time- and Frequency-Domain Measures)2
Measure Healthy Subjects
(mean ± SD)
SDNN (ms) 141±39
SDANN (ms) 127±35
RMSSD (ms) 27±12
PNN50 9±7
Total powera (<0.4 Hz) 9.83±0.54
LFa (0.04-0.15 Hz) 6.45±0.68
HFa (0.15-0.40 Hz) 5.05±0.83
Note.  a =natural log (ms2).   See Table 1 for explanation of
time- and frequency-domain variables.
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Cardiovascular Autonomic Function Measures
It is well documented that autonomic function is attenuated in patients with
ESRD12, 93 and in those with diabetes mellitus3.  Valsalva ratio and HRDB, both of
which are considered tests of primarily parasympathetic function21, have bee
commonly used to evaluate autonomic function in both patient populations.  Only two
studies29, 93 were found which investigated cardiovascular autonomic function in
dialysis patients.  Chu, Tsai, Lee, and Yen29 examined 46 hemodialysis patients, 8
continuous ambulatory peritoneal dialysis patients, and 107 healthy adults.  Results of
this study found VR to be significantly less for dialysis patients as compared to the
healthy controls, whereas, the HRDB did not differ significantly.  In contrast, Hathaway,
Cashion, Milstead, Winsett, Cowan, Wicks, and Gaber93 found that both peritoneal
(n=61) and hemodialysis (n=168) subgroups had diminished HRDB, but a normal VR.
Clearly, further study is needed to document the characteristics and effect of dialysis on
cardiovascular dysautonomia.
Autonomic function has been reported diminished in ESRD patients awaiting
kidney or pancreas-kidney transplantation93.  Ewi g et al.’s values for normal HRDB
and VR were used to interpret the findings3, 18, 19.  When cardiovascular autonomic
function was evaluated by diabetic status, nondiabetic ESRD (n=184) had a normal
HRDB and VR.  In contrast, HRDB was abnormal in ESRD patients with either type 1
(n=60) or type 2 diabetes (n=34), and VR was borderline for both diabetes subgroups.   In
another study99, it was reported that following pancreas-kidney (n=23) or kidney alone
(n=16) transplantation, kidney recipients experienced nonsignificant improvement in
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HRDB and VR.  In contrast, the pancreas-kidney group demonstrated significant
improvement in VR and insignificant improvement in HRDB.  Thus, a measure thought
to be reflective of parasympathetic function (HRDB) showed less change than VR, a
measure increasingly thought to reflect some adrenergic function in addition to
parasympathetic function32.
In a 1990 study of ESRD patients with type 1 diabetes mellitus who were
awaiting pancreas transplantation, abnormal VR and HRDB were found in 75% of 232
patients123.  In a subsequent larger study, abnormal values were found in 65% of 545
patients41.  In both studies, normal values of HRDB and VR were established to be >
15.0 and >1.43, respectively41, 112, 123.
Evoked tests, HRDB and VR, have documented dysautonomia in pre and
posttransplant ESRD patients.   However, referent values tend to vary by laboratory and
study population with no consensus on which test is the most sensitive.
24-hr HRV Measures
Twenty-four hour HRV values were diminished in studies of patients with
diabetes48, 49, patients with uremia87, 93, and patients with uremia and
diabetes87, 93, 109.  Bigger, Fleiss, Rolnitzky, Steinman, and Schneider77 found 24-hr
frequency-domain measures of 68 myocardial infarction patients obtained immediately,
and at 12 months post-infarction, to be one half to two thirds the values found in a sample
of 95 healthy individuals.  These results were confirmed in a second study with 962 post-
infarction patients2.
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Power spectral analysis of HRV demonstrated poorer values in a diabetic sample
(n=23) when compared to healthy controls (n=22), and were especially pronounced in
diabetic subjects below 65 years of age50.  Within 3 weeks of renal transplantation,
Kirvela, Salmela, Toivonen, Koivusalo, and Lindgren86 obtai ed 24-hr HRV recordings
on 12 diabetic and 11 non-diabetic renal transplant patients, in addition to 12 control
patients. HRV was analyzed in time- and frequency-domains and showed poorer 24-hr
HRV in ESRD patients with diabetes than without diabetes immediately posttransplant.
Short–term ECG recordings have also been used to assess sympathovagal balance.  In a
study of 21 nondiabetic hemodialysis ESRD patients before and 8 to 12 months after
kidney transplantation, Strano, De Casstro, Urani, Ferrucci, Marcheselli, Poli, Berloco,
Calcagnini, Cerutti, and Cortesini88 found  significant improvement in low and high
frequencies.
Although in healthy adults time-domain measures do not discriminate
components from different physiologic processes, time-domain measures are strongly
correlated with the frequency-domain measures, which have been shown to
discriminate124.  Thus, in research studies, correlation of time- and frequency-domain
measures may be helpful when interpreting findings.  Bigger et al.2 found that total
power is strongly correlated with SDNN and SDANN.  In addition, three commonly used
measures of parasympathetic function, RMSSD, PNN50, and HF, are so highly
correlated46 that Bigger suggests these measures can be used interchangeably82.   It is
unknown if 24-hr measures continue to be highly correlated once the patient becomes
chronically ill.
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Twenty-four hour HRV with power spectral analysis has confirmed poorer HRV
exists for patients with chronic disease ranging from ESRD to coronary heart disease.
This is an emerging technology and referent values tend to vary by laboratory and study
population.   Referent values and values characteristic of the pre and post transplant
ESRD population need to be determined.
Physiologic Factors
In studies examining healthy individuals, the attenuation of both HRDB and VR
with increasing age, independent of gender, appears to be a consistent finding27, 31.
However, findings were inconsistent on the ability to diagnose dysautonomia in subjects
over the age of 6527 using HRDB or VR, with one study31 finding that the diagnosis of
dysautonomia was possible in subjects over 80 years of age.  Gender was shown to have
an effect on autonomic function, in some studies using evoked measures with women,
having lower values31, while not in another study27.  Findings, from studies using 24-hr
HRV measures to evaluate autonomic function, also indicate a decrease in autonomic
function with increasing age in healthy individuals2, 65.  Women have, in addition, been
found to have lower values in most measures65.
The influences of gender and age on autonomic function as measured by 24-hr
HRV65 appeared blunted in a group of 95 surviving sudden cardiac arrest patients with
only the frequency measures decreasing with age.  Bigger et al.2 recruit d 274 healthy
middle-aged individuals (57±8.2 years old, 74% men) to establish normal values for 24-
hr time- and frequency-domain measures.  Findings showed a significant decrease in low
and high frequency measures with increasing age and small, inconsistent differences
88
between men and women.  No reports were found on the influence of age and gender on
autonomic function post-transplantation.
Although normal referent values have been suggested for evoked measures of
autonomic function3, 19, normal and abnormal values for 24-hr HRV measures are just
beginning to be determined2, 53 and may vary depending on methodology and analysis
techniques.  Thus, researchers29, 112 frequently test healthy control groups for
comparisons to a sample of their population under study.  This is in accordance with
recommendations by both the American Diabetes Association and the American
Academy of Neurology4.  Using this model, the purpose of this investigation was to
establish values of evoked measures and 24-hr HRV measures, in addition to
symptomatology, which were characteristic of the ESRD pre-transplant population and a
comparison healthy control group.  From the values characteristic of healthy individuals,
normal borderline and abnormal values were determined.
Methodology
Sample
A convenience sample of ESRD patients pre-kidney or kidney-pancreas transplant
(n=363) were evaluated for dysautonomia.  In addition, a group of healthy persons
(n=158) was recruited from faculty, family and friends to determine normal values for
autonomic function in our Physiologic Function Lab and to compare healthy values to
values from ESRD patients.  Patients scheduled for pretransplant evaluation between
February 1996 through February 1998 were asked to participate.  All data obtained were
a part of the patient’s normally scheduled evaluation.  All pretransplant patients over 18
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years of age were included in the study unless they were physically unable to participate
in data collection or if they were found to have other neurologic disorders which could
affect autonomic function values.  Each patient with diabetes mellitus had blood glucose
levels checked prior to autonomic function testing.  If the blood glucose was 200 mg/dl or
greater, the testing was cancelled and rescheduled.  Demographic data included
information on current medications, alcohol and tobacco use.  Healthy control data were
collected between November 1995 through February 1998.  Subjects were considered
healthy if they reported no neurologic dysfunction or coronary heart disease.  This study
was approved by the Institutional Review Board of the University of Tennessee,
Memphis.  Each participant signed an informed consent.  Not all participants completed
all three components of the evaluation; evoked tests, 24-hr HRV tests, and the Autonomic
Symptom Checklist.
Procedure
Study participants were recruited and informed of the study.  They were then
scheduled for an appointment in the Physiologic Function Lab where the testing was
again explained, a consent form (see Appendix B) was signed, demographic data
obtained, evoked cardiovascular tests done, ASC completed, and an ambulatory Holter
monitor applied.  Participants were asked to return the Holter monitor within 36 to 48
hours.  Following data collection, analysis was completed and reviewed weekly.
Evoked Cardiovascular Tests
Evoked measures, change in heart rate with deep breathing (HRDB) and the
Valsalva ratio (VR) were obtained by tests performed in a temperature-controlled
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laboratory dedicated to performing autonomic function tests.  Environmental stimuli such
as noise and light were minimized.  A Power Macintosh 9500 computer system and
AcqKnowledge ® III BIOPAC software were used for data acquisition and analysis of
standard electrocardiogram recordings and blood pressure measurements obtained from a
DinamapTM XL (CRITIKON).   The protocols (see Appendix A) used to perform the
evoked tests were modified from the Mayo Clinic’s protocols73, and a brief overview
follows.
The HRDB value was obtained while the patient was relaxed in a recumbent
position breathing deeply and regularly for one minute at a rate of 6 breaths per minute (5
second inhale/5second exhale) which follows a two minute period of regular breathing.
The difference between the maximum and minimum heart rates was calculated (see
Appendix A).  The second test, the VR, was derived by dividing the maximum heart rate
during a seated patient’s forced expiration of 40-mm Hg for 15 seconds by the minimum
heart rate within 15 seconds after the maneuver (see Appendix A).  Reliability and
validity have been established for HRDB and VR5, 19, 23, 63.
Ambulatory 24-hr Holter Recordings
Data collection and processing of 24-hr HRV measures followed
recommendations125, and are briefly summarized here.  Analysis of 24-hr ambulatory
Holter monitor tapes was completed by Marquette Electronics Laser SXP® Ambulatory
ECG Analysis and Editing Systems with version 5.8 software program and Series 8500
Holter recording system (see Appendix A).  Each QRS complex was digitized, identified
and labeled.  The analyzed data file was then scanned and manually edited to locate and
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correct any errors in QRS labeling that would adversely affect measurement of heart rate.
Tapes were required to have > 20 hours of analyzable data and generally had > 23 hours
of analyzable data.  Using these data files, 24-hr HRV with power spectral analysis was
calculated.
The time-domain HRV calculations are placed in 2 general categories.  The first
category is derived directly from the R-R intervals and includes means and standard
deviations of the interval.  Measures in this category of the time-domain include the
SDNN and the SDANN.  The SDNN is the standard deviation of all R-R intervals during
the 24-hours and has been found to be associated with sudden cardiac death37.  The
SDANN is the standard deviation of the means of R-R intervals found in successive five
minute blocks over 24-hours and is considered the best measure of overall autonomic
balance and represents circadian rhythmicity of autonomic function75, in addi  to
estimating long-term components of HRV125.  The second category of time-domain
variables is based on the differences between adjacent R-R intervals and included the
RMSSD.   The RMSSD is the square root of the mean of the sum of squares of
differences between adjacent R-R intervals.   The RMSSD is virtually independent of
circadian rhythms and reflects alterations in autonomic function that are primarily vagally
mediated57, 125 (see Table 1).
The power spectrum is computed over the 24-hr recording interval using fast
Fourier transform for 3 frequency bands; total (0.01-1.00 Hz), low (0.04-0.15 Hz) and
high (0.15-0.40 Hz) frequency power.  Low frequency waveforms reflect modulation of
sympathetic and parasympathetic activity by baroreflex mechanisms while high
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frequency waveforms, also known as the respiratory frequency, represent modulation of
parasympathetic activity by respiration9, 10.
Autonomic Symptom Checklist
The aims of the ASC were to recognize the perceived presence, distribution and
severity of autonomic symptoms.  Initially, the instrument was compiled using
information from several expert sources59, 61, 115.  Subsequently, a focus group met
over a five-week period for four, two hour sessions to refine the questions and simplify
the reading level of the instrument.  The focus group was comprised of people with
experience as transplant coordinators, diabetic educators, and researchers in addition, one
person had type 2 diabetes mellitus.  Following focus group discussions, the ASC was
pilot tested on four ESRD patients and further revisions were made.  Revisions included
clarifying terminology and adding a time-frame to the directions.
The revised ASC was developed as a self-administered checklist that assessed
dysautonomia symptoms in five categories with 32-items each with a 7-point Likert
scale116 (see Appendix C).  A self-administered format was chosen because, typically,
the individual’s perception of these symptoms is what alerts the provider to the
possibility of dysautonomia.  Three categories, Orthostatic Hypotension, Sudomotor
Abnormalities, and Gastrointestinal Problems, are to be completed by all respondents,
while two categories are also completed by subgroups: the Impotence category is to be
completed by men; and the Hypoglycemia Unaware is to be completed by individuals
with diabetes mellitus.
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 Each of the five categories consists of four to six questions, each answered using
a seven-point Likert scale with 0 being “never” and 6 being “always”.  The individual is
asked to circle the number that indicates the severity of that symptom.  The last question
in each category is classified as an “impact” question and used to obtain a score reflecting
patients’ perceptions of how problematic that category of symptoms is for them.  This
question was included because the presence of a symptom and the degree to which a
symptom creates problems are not always the same.  In addition, information is obtained
concerning each patient’s current medications, alcohol and caffeine intake, and tobacco
use.  These products could affect function of the autonomic nervous system21, but it is
unknown as to what extent.
The Orthostatic Hypotension category consists of five questions (30 points
possible) focused on symptoms of hypotension upon standing.  These symptoms include
rapid heartbeat, blurred vision, an upset stomach, dizziness, and clammy skin.  The
Sudomotor Abnormalities category consists of three questions (18 points possible)
focused on an increase or decrease in sweating.  The Gastrointestinal Problems category
consists of five questions (30 points possible) focusing on bowel and stomach disorders.
The Impotence category consists of four questions (24 points possible) focused on the
ability to have and maintain an erection.  The Hypoglycemia Unaware category consists
of four questions (24 points possible) focused on subjects’ ability to recognize symptoms
associated with a low blood sugar.  Each category of symptom questions is followed by
an impact question “how much of a problem are these symptoms for you?” (6 points
possible).
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Patient responses are entered into the database as scored by the individual, except
for questions 4a, 4b, and 4c in the Impotence category and question 5a in the
Hypoglycemia Unawareness category, which are written in reverse fashion and,
therefore, scored in reverse fashion.  Category and index calculations are performed
based on these values with higher scores indicating greater symptoms.  See Appendix D
for definitions and a detailed description of the calculations.
For each patient, two scores per category are reported: symptom score and impact
score.  The category symptom score was calculated by obtaining a raw score for each
category then dividing the raw score by the number of questions in that category.  Each
category symptom score has a range from 0 – 6.  The category impact score is obtained
directly from the one impact question and also ranged from 0 - 6.   Each category
symptom score and impact score can be compared across groups.
Two other scores reported are total symptom score and total impact score.  The
total symptom score (6 points possible) are the sum of category symptom scores divided
by the number of categories reported (e.g., 5 for DM women, 6 for DM men).  The total
impact score (6 points possible) is calculated by dividing the total number of points
scored on the category impact questions by the number of impact questions possible for
that group.  Both the total symptom score and the total impact score can be compared
across groups.
The ASC index score (36 points possible) is a single measure designed to reflect
the patient’s perception of experienced dysautonomia symptoms and the impact of those
symptoms on the patient.  It is calculated by multiplying the total symptom score and the
total impact score and can be compared across groups.
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Data Analysis
For analysis, only one baseline pretransplant evoked test, 24-hr HRV test, and
ASC test was used for each subject in each group.  In addition, subjects with type 2
diabetes mellitus were excluded from analysis; thus, the ESRD with DM group was
composed of patients with only type 1 diabetes mellitus.  This prevented any confounding
effects that might occur due to differing physiologic mechanisms causing the
dysautonomia in type 1 and type 2 diabetes mellitus patients.  Expected values for each
study measure were determined for the healthy control group with the aim of using these
data to establish normal, abnormal, and borderline values for each of the study measures.
Using the means and SDs for each evoked and 24-hr HRV measure, values were
determined for each study measure at 2 SDs below the mean, the lower 95% confidenc
interval, and the 2.3 percentile.  These values were defined as abnormal and then
scatterplots were used to visually analyze each measure for cutpoints to determine if they
logically identified a group that was abnormal.  In addition, these cutpoint values were
applied to each study group to determine what percent of each group was classified as
normal and abnormal.  Methods for determining referent values were adapted from
several studies2, 19, 35, 63, 109.  Chi square tests were used to determine equivalence of
groups for categorical data.  One way ANOVA with preplanned multiple comparisons
using Least Square Means was used to test for differences among study groups.
Correlational analysis was used to evaluate the relationship between age, gender, and all
measures.
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Results
Results will first be reported for autonomic function and symptomatology
characteristic of healthy controls (n=158) and 2 samples of ESRD patients (ESRD with
DM, n=91; ESRD NonDM, n=272) followed by the relationships between age, gender
and autonomic function.  In addition, referent values for evoked measures, 24-hr HRV
measures, and the Autonomic Symptom Checklist will be established.
Autonomic Function of Healthy Controls and Two ESRD Samples
Although the ages of the three study groups were similar (see Table 16) with
healthy controls being slightly younger than ESRD patients with diabetes mellitus (ESRD
DM) and ESRD patients without diabetes mellitus (ESRD NonDM) groups (36.2, 39.5,
41.9; respectively;), there was a significant difference in age (p< 0.001) between the
healthy and ESRD NonDM groups.  In addition, there was a significant difference in
gender (p< 0.001) with healthy controls being primarily women (75%) as compared to
both ESRD DM (47%) and ESRD NonDM (37%) groups.   However, both healthy
controls and ESRD DM groups were 77 % Caucasian as compared to the ESRD NonDM
group which was significantly different (p< 0.001) with 56% African-American.  There
was no difference among the three groups when compared by exercise, with 29-36 % of
each group reporting that they exercise.  The ESRD NonDM group had significantly
(p£0.0001) more months of dialysis (27.7±34.4) when compared to the ESRD DM group
(8.0±12.5).
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Table 17 shows data generated in response to the research question, “what are the
evoked, 24-hr HRV, and Autonomic Symptom Checklist values characteristic of ESRD
pretransplant adult patients and healthy adult individuals?”   The average RR interval
(mean NN) was found to be longer for the healthy group (746±77) compared to the
ESRD NonDM group (724±103) and significantly longer than the ESRD DM group
(705±94; p< 0.01).  Thus, the healthy group had a slower heart rate than the other 2
groups.  Excluding the mean NN, all other measures of evoked and 24-hr HRV  were
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Table 16.  Characteristics of Healthy Controls, ESRD Pretransplant Patients, ESRD
Patients with Diabetes Mellitus (DM), and ESRD Patients Without Diabetes
Mellitus (NonDM)
ESRD
with DM
(n=91)
ESRD
NonDM
(n=272)
Total ESRD
Sample
(n=363)
Healthy
Controls
(n=158)
Characteristic
Age (yrs.) mean±SD
range
39.5±8.1
25-67
41.9±12.1*
18-69
41.3± 11.3
18-69
36.2±11.2*
18-65
Gender
  Men
  Women
n (%)
n (%)
48 (53)*
43 (47)*
172 (63)*
100 (37)*
220 (60)
143 (40)
40 (25)*
118 (75)*
Race
  African-Amer.
  Caucasian
  Other
n (%)
n (%)
n (%)
21 (23)*
70 (77)*
0
182 (67)
89 (33)
1 (0.4)
203 (56)
159 (44)
1 (0.2)
29 (19)*
121 (77)*
7 (4)
Exercise
  Yes
  No
n (%)
n (%)
27 (32)
58 (68)
99 (29)
153 (61)
126 (37)
211 (63)
43 (36)
78 (64)
Dialysis Type
  HomeHemo
  Incenter Hemo
  Peritoneal
  None
n (%)
n (%)
n (%)
n (%)
1 (1)
24 (32)
17 (23)
33 (44)
4 (2)
134 (62)
55 (26)
22 (10)
5 (2)
158 (54)
72 (25)
55 (19)
na
Months dialysis mean±SD 8.0±12.5* 27.7±34.4* 22.6±31.4 na
Years of DM mean±SD 24.8±6.9 na na
Unemployed n (%) 52 (58) 150 (55) 88 (56) unknown
Height (cm) mean±SD 168.0±9.3 169.0±10.5 168.8±10.2 unknown
Weight (kg) mean±SD 73.3±14.1 76.5±16.9 75.7±16.2 unknown
Note. *p£0.001 between groups with like symbols.  ESRD=end-stage renal disease, DM=diabetes mellitus,
NonDM=without diabetes mellitus, Hemo=hemodialysis
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significantly (p< 0.001), and, substantially, poorer in patients with ESRD compared to
healthy individuals.  In addition, almost all measures were significantly more
compromised for ESRD patients with diabetes mellitus compared to ESRD patients
without diabetes.  A higher score on the ASC index reflects a heightened perception of
dysautonomia symptoms and the impact those symptoms have on the individual.  Similar
to the objective measures, the ESRD patients reported significantly greater
symptomatology (p<0.001) than the healthy controls (0.12±0.21), with ESRD patients
with diabetes reporting greater symptomatology (4.79±5.2) than the ESRD patients
without diabetes (2.09 ± 3.3).
Relationship Between Age and Autonomic Function of Healthy Controls and Two
ESRD Samples
For each of the 3 study groups, a correlational analysis was computed for the two evoked
measures, the 3 frequency-domain measures, the 6 time-domain measures, the ASC index
and age.  Tables 18 shows the data generated in response to the research question, “Is
there a relationship between age and the evoked cardiovascular test, 24-hr HRV test, and
Autonomic Symptom Checklist values of adult ESRD patients and healthy individuals?”
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Table 17.  Comparisons of Evoked, 24-hr Heart Rate Variability, and ASC
Measures Among Healthy Controls (n=158) and ESRD Pretransplant Patients
(n=363) With (ESRD DM=91) and Without Diabetes (ESRD NonDM=272)
ESRD with
DM
ESRD
NonDM
Total ESRD
Sample
Healthy Controls
Evoked measures
  HRDB 11.2±9.9† 18.0±9.9† 16.2±10.3* 26.1±9.8*†
  VR 1.22±0.38† 1.38±0.40† 1.34±0.40* 1.68±0.40*†
24-hr HRV measures
  Total powera 4.57±1.30† 5.82±1.05† 5.51±1.24* 7.25±0.63*†
  LF a 3.10±1.70† 4.7±1.27† 4.31±1.54* 6.42±0.66*†
  HFa 2.63±1.10† 3.64±1.27† 3.39±1.26* 5.20±0.91*†
  SDNN 64±27† 88±36† 82±35* 134±33*†
  SDANN 58±23† 78±33† 73±32* 120±32*†
  SD 21±17† 33±16† 30±17* 58±15*†
  RMSSD 13.2±12.6† 19.0±12.0† 17.5±12.4* 32.8±13.0*†
  PNN50 1.62±6.30† 3.57±6.60‡ 3.09±6.54* 11.03±8.26*†‡
  Mean NN 705±94# 724±103 719±100^ 746±77^#
ASC Index 4.79±5.20† 2.09±3.30† 2.73±3.99* 0.12±0.21*†
Note. * and † and ‡ p< 0.001; ^ and # p< 0.01 for groups having like symbols;  a =natural log (ms 2).  All
values are given as mean ±SD. ESRD=end-stage renal disease, DM=diabetes mellitus, NonDM=without
diabetes mellitus. HRDB=heart rate change with deep breathing, VR=valsalva ratio. See  Tab e 1 for 24-hr
HRV measure definitions.
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As indicated in Table 18, there was an inverse relationship between age and most
measures of heart rate variability for all three groups, demonstrating that autonomic
function decreases as an individual ages.  In addition, the relationship was generally
much stronger for the healthy control group with r values primarily ranging from –0.30(p
< 0.2) to -0.60 (p < 0.003) when compared to the ESRD DM group with r values
primarily ranging from –0.03 (p < 0.68) to –0.31 (p < 0.05) or the ESRD NonDM group
with r values primarily ranging from –0.02 (p < 0.03) to –0.43 (p < 0.00).  In the healthy
individuals, the frequency-domain measures showed the strongest inverse relationship
(-0.60; p <0.003).
Relationship Between Gender and Autonomic Function of Healthy Controls and
Two ESRD Samples
Table 19 shows data generated in response to the question, “is there a gender
difference between measures of evoked cardiovascular function, 24-hr HRV monitoring,
and autonomic symptomatology for healthy adult individuals and ESRD pretransplant
adult patients?”  To answer this question, women and men were compared separately in
each of the three study groups.  As Table 19 shows, men demonstrated significantly
better values (p<0.01) than women in the healthy group for frequency-domain values of
total power and LF and for time-domain values of SDNN, SDANN, and SD.  In addition,
women had a faster heart rate (Mean NN=733±71, p<0.001) as compared to the men
(781±82).  Although the evoked measure VR tended to be higher for men when
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 Table 18.  Correlational Analysis Between Age and Evoked and 24-hr HRV Measures for Each of the Three Study Groups
Evoked Measures Frequency Measures Time Measures
                               HRDB VR  TotalPower LF HF   SDNN   SDANN SD     RMSSD    PNN50     MeanNN
Group
ESRD DM
n=91
-0.29 -0.31 -0.05 -0.00 -0.08 0.11 0.12 -0.03 -0.05 -0.05 0.13
ESRD NonDM
n=272
-0.43 -0.32 -0.32 -0.33 -0.34 -0.05 -0.02 -0.24 -0.24 -0.21 0.12
Healthy Controls
n=158
-0.45 -0.30 -0.60 -0.59 -0.60 -0.38 -0.34 -0.47 -0.48 -0.40 -0.10
Note.  ESRD=end-stage renal disease, DM=diabetes mellitus, NonDM=without diabetes mellitus. HRDB=heart rate change with deep breathing, VR=valsalva
ratio. See Table 1 for 24-hr HRV measure definitions.
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Table 19.  Comparisons Between Women and Men of Evoked, 24-hr Heart Rate Variability, and ASC Measures Among
Healthy and ESRD Patients as a Group, With (ESRD DM) and Without (ESRD NonDM) Diabetes.
ESRD with DM
(n=91)
ESRD NonDM
(n=272)
Total ESRD Sample
(n=363)
Healthy Controls
(n=158)
Women Men Women Men Women Men Women Men
n 43 48 100 172 143 220 118         40
Age 37.7±7.7 41.1±8.2 41.0±12.4 42.5±12.0 40.0±11.2 42.2±11.3 35.6±11.7 38.1±9.3
Evoked  Measures
  HRDB 12.1±10.9 10.4±9.0 18.5±10.1 17.6±9.83 16.2±9.7 16.0±10.1 26.1±10.6 26.1±8.1
  VR 1.25±0.41 1.19±0.35 1.43±0.45 1.36±0.35 1.38±0.45 1.32±0.36 1.64±0.4 1.78±0.4
24-hr Measures
  Total power a 4.58±1.29 4.58±1.33 5.84±1.08 5.81±1.04 5.47±0.1 5.54±0.08 7.16±0.61* 7.49±0.64*
   LF a 3.09±1.75 3.12±1.63 4.75±1.31 4.68±1.25 4.26±0.12 4.34±0.1 6.31±0.64* 6.71±0.66*
   HF a 2.74±1.04 2.54±1.17 3.79±1.21 3.56±1.21 3.49±1.25 3.34±1.27 5.18±0.88 5.22±1.01
   SDNN 64±22 64±31 90±34 87±36 82±33 82±37 129±31* 149±34*
   SDANN 59±20 58±25 80±33 77±34 74±31 73±33 115±45* 134±33*
   SD 20±11 22±21 34±16 33±16 30±16 31±18 56±14* 65±17*
   RMSSD 13±8 13±15 20±12 19±12 18±11 17±13 32±13 34±14
   PNN50 1.48±3.7 1.74±7.9 3.85±7.3 3.41±6.12 3.17±6.53 3.04±6.57 10.81±8.12 11.68±8.74
   Mean NN 686±77 721±105 715±98 728±106 707±93 727±105 733±71* 784±83*
ASC Index (n) 3.75±3.9 5.92±6.17 1.39±1.82* 2.48±3.84* 2.13±2.86 3.11±4.53 0.17±0.28 0.08±0.13
Note. * and † p< 0.05for groups having like symbols;  a =natural log (ms2). All values are given as mean ±SD.  ESRD=end-stage renal disease, DM=diabetes
mellitus, NonDM=without diabetes mellitus. HRDB=heart rate change with deep breathing, VR=valsalva ratio. See Table 1 for 24-hr HRV measure definitions
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compared to women, the difference failed to reach significance (p<0.10), th HRDB was
essentially the same for men and women.  In contrast, the pattern of higher values for
men compared to women was not seen in the 2 ESRD patient groups.  Instead, men and
women had similar values for most evoked and 24-hr HRV measures, all of which
indicated compromised function.  However, a significant difference (p< 0.05) was seen in
ASC index between men (2.48±3.84) and women (1.39±1.82) in the ESRD NonDM
group, with men reporting increased presence and impact of symptomatology.
Relationships Among 24-hr HRV Measures of Autonomic Function
For the healthy control group, many of the correlation coefficients among the
time- and frequency-domain measures were strong, several exceeding the r-value of 0.90
(see Table 20). The pattern of strong r-values (p < 0.000) in the healthy group for total
power and LF (r=0.99), total power and SD (r=0.97), LF and SD (r=0.95), HF and
RMMSD (r=0.94), SDNN and SDANN (r=0.97) and RMSSD and PNN50 (r=0.98) was
repeated in both ESRD groups.  However, for most values the correlation coefficient,
although still strong, decreased in the ESRD groups, with the weakest correlations seen in
the ESRD DM group (see Tables 21 and 22).
Referent Values for Evoked Measures, 24-hr HRV Measures, and Autonomic
Symptomatology
Data obtained from healthy individuals were firt exam ned for normality and
identification of outliers.  Three individuals were identified whose results from
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 Table 20.  Correlational Analysis Among  Evoked, Time- and Frequency-Domain Measures of 24-hr HRV in Healthy Controls
(n=158)
Evoked Measures Frequency Measures Time Measures
                               HRDBVR Total power  LF     HF SDNN   SDANN SD    RMSSD PNN50 MeanNN
HRDB 1.00
VR 0.13 1.00
Total power 0.26 -0.08 1.00
LF 0.29 -0.08 0.99 1.00
HF 0.40 -0.17 0.88 0.86 1.00
SDNN 0.15 -0.11 0.82 0.80 0.66 1.00
SDANN 0.18 -0.12 0.74 0.72 0.58 0.97 1.00
SD 0.15 -0.09 0.97 0.95 0.84 0.88 0.79 1.00
RMSSD 0.27 -0.09 0.89 0.86 0.94 0.74 0.66 0.89 1.00
PNN50 0.20 -0.10 0.85 0.82 0.88 0.72 0.64 0.87 0.98 1.00
MeanNN -0.07 -0.20 0.71 0.67 0.60 0.77 0.67 0.81 0.68 0.69 1.00
Note.  See Table 1 for definitions of measures
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Table 21.  Correlational Analysis Among Evoked Measures, Time- and Frequency-Domain Measures of 24-hr HRV in ESRD
DM Patients (n=91)
Evoked Measures Frequency Measures Time Measures
                               HRDBVR  Total power LF  HF SDNN SDANN SD  RMSSD PNN50 MeanNN
HRDB 1.00
VR 0.70 1.00
Total power 0.58 0.47 1.00
LF 0.61 0.48 0.97 1.00
HF 0.54 0.46 0.82 0.78 1.00
SDNN 0.38 0.32 0.63 0.63 0.60 1.00
SDANN 0.35 0.29 0.53 0.54 0.52 0.99 1.00
SD 0.51 0.45 0.93 0.92 0.84 0.68 0.57 1.00
RMMSD 0.32 0.30 0.61 0.56 0.83 0.43 0.34 0.70 1.00
PNN50 0.21 0.21 0.45 0.39 0.65 0.27 0.19 0.54 0.95 1.00
MeanNN -0.02 -0.05 0.33 0.30 0.38 0.37 0.34 0.39 0.21 0.10 1.00
Note.  See Table 1 for definitions of measures.
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Table 22.  Correlational Analysis Among Evoked Measures, Time- and Frequency-Domain Measures of 24-hr HRV in ESRD
NonDM Patients (n=272)
Evoked Measures Frequency Measures Time Measures
                               HRDBVR Total powerLF HF SDNN SDANN SD    RMSSD  PNN50     MeanNN
HRDB 1.00
VR 0.55 1.00
Total power 0.45 0.50 1.00
LF 0.47 0.50 0.98 1.00
HF 0.42 0.47 0.88 0.82 1.00
SDNN 0.28 0.41 0.73 0.70 0.65 1.00
SDANN 0.25 0.38 0.61 0.59 0.56 0.98 1.00
SD 0.37 0.45 0.94 0.90 0.84 0.78 0.65 1.00
RMMSD 0.29 0.37 0.72 0.64 0.86 0.61 0.52 0.79 1.00
PNN50 0.26 0.34 0.60 0.52 0.73 0.56 0.48 0.72 0.95 1.00
MeanNN -0.12 0.00 0.51 0.44 0.51 0.51 0.44 0.59 0.54 0.46 1.00
Note.  See Table 1 for definitions of measures
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possibility of unknown neurological problems.  In addition, the healthy control data were
examined for any individual test values that were greater than 3 SDs from the mean.
Four healthy individuals were found who had one value each (either evoked or 24-hr
HRV)  that was more than 3 SDs above the mean.  No healthy group values were found
to be 3 SDs below the mean.  Three healthy individuals were found to have ASC values
more than 3 SDs above the mean.  These values were deleted from the data and new
means and SDs were determined for those study measures.
Abnormal values were determined for each study measure using 3 different
methods; at 2 SDs below the mean2, 63, the lower 95% confidence interval109, and the
2.3 quantile35 (see Table 23).  In addition, these cutpoint values were applied to each
study group to determine what percent of each group was classified as normal and
abnormal (see Table 23).  Results showed that, for most measures, the 2.3 quantile best
discriminated between normal and abnormal values in each of the groups.  Thus, using
the cutpoints established at the 2.3 quantile in the healthy group to classify the ESRD
pretransplant groups, it was found in the ESRD DM group the frequency measures of
total power, LF, and HF and the time-domain measure of SD best separated this group
from the healthy group.  For the ESRD NonDM group, the frequency measures of total
power and LF and the time-domain measure of SD best separated this group from the
healthy group.
After abnormal values were established using the 2.3 quantile cutpoint, borderline
cutpoint values were established at the 5th quantile (see Table 24).  The values between
abnormal (2.3 quantile) and normal (> 5th quantile), were defined as borderline values.
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Table 23.   Number and Percentage of Abnormal Test Responses in Healthy
Controls, ESRD DM Patients, and ESRD NonDM Patients
ESRD with DM
n/ (%)
ESRD NonDM
n (%)
Healthy Controls
n (%)
Measure Abnormal
Value
Evoked
  HRDB
    -2SD
    95% CI
    2.3 quantile
< 6.0
< 7.0
<10.0
36/90 (40)
47/90 (52)
55/90 (61)
28/262 (11)
37/262 (14)
66/262 (25)
0/98 (0)
0/98 (0)
2/98 (2)
  VR
    -2SD
    95% CI
    2.3 quantile
< 0.88
< 0.90
< 1.06
1/82 (1)
1/82 (1)
38/82 (46)
0/249 (0)
0/249 (0)
39/249 (16)
0/96 (0)
0/96 (0)
2/96 (2)
24-hr HRV
  Total powera
    -2SD
    95% CI
    2.3 quantile
< 5.99
< 6.01
< 5.94
70/79 (89)
70/79 (89)
69/79 (87)
139/243 (57)
139/243 (57)
136/243 (56)
3/124 (2)
4/124 (3)
2/124 (3)
  LF a
    -2SD
    95% CI
    2.3 quantile
< 5.10
< 5.13
< 4.96
69/79 (87)
71/79 (90)
69/79 (87)
145/243 (60)
149/243 (61)
134/243 (55)
4/124 (3)
5/124 (4)
2/124 (2)
  HF a
    -2SD
    95% CI
    2.3 quantile
< 3.38
< 3.42
< 3.28
66/79 (84)
67/79 (85)
64/79 (81)
104/243 (43)
109/243 (45)
100/243 (41)
5/124 (4)
6/124 (5)
1/124 (1)
  SDNN
    -2SD
    95% CI
    2.3 quantile
< 68
< 69
< 78
51/79 (65)
51/79 (65)
58/79 (73)
77/243 (32)
79/243 (33)
110/243 (45)
1/123 (1)
2/123 (2)
2/123 (2)
  SDANN
    -2SD
     95% CI
     2.3 quantile
< 56
< 57
< 65
43/79 (54)
43/79 (54)
53/79 (67)
66/243 (27)
69/243 (28)
95/243 (39)
1/122 (1)
1/122 (1)
3/122 (2)
  SD
    -2SD
     95% CI
     2.3 quantile
< 28
< 29
< 30
64/79 (81)
66/79 (84)
66/79 (84)
108/243 (44)
114/243 (47)
127/243 (52)
1/123 (1)
1/123 (1)
2/123 (2)
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Table 23 (continued)
ESRD with DM
n/ (%)
ESRD NonDM
n (%)
Healthy Controls
n (%)
Measure Abnormal
Value
  RMSSD
    -2SD
    95% CI
    2.3 quantile
< 7
< 7
< 12
12/79 (15)
12/79 (15)
58/79 (73)
6/243 (2)
6/243 (2)
81/243 (33)
0/124 (0)
0/124 (0)
3/124 (2)
  PNN50
    -2SD
    95% CI
    2.3 quantile
< -5.5
< -5.2
< 0.3
0 (0)
0 (0)
53/78 (68)
0 (0)
0 (0)
75/242 (31)
0 (0)
0 (0)
3/124 (2)
  Mean NN
    -2SD
    95% CI
    2.3 quantile
< 592
< 595
< 620
6/79 (8)
7/79 (9)
12/79 (15)
18/242 (7)
20/242 (8)
37/242 (15)
1/123 (1)
1/123 (1)
2/123 (2)
  ASC Index
    -2SD
    95% CI
    2.3 quantile
> 0.50
> 0.53
> 0.91
37/49 (76)
37/49 (76)
37/49 (76)
86/156 (55)
86/156 (55)
76/156 (49)
0/32 (0)
0/32 (0)
1/32 (3)
Note. a =natural log (ms2). The 95% confidence interval was determined by the formula mean-1.96 (SD).
CI=confidence interval, ESRD=end-stage renal disease, DM=diabetes mellitus, NonDM=without diabetes
mellitus. HRDB=heart rate change with deep breathing, VR=valsalva ratio, ASC=Autonomic Symptom
Checklist. See Table 1 for 24-hr HRV measure definitions.
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Table 24.  Normal, Abnormal, and Borderline Values for 2 Evoked Measures, 3
Frequency-Domain Measures, 6 Time-Domain Measures, and the ASC Index Based
on the 2.3 and 5th Percentile Values of a Group of Healthy Individuals (n=158)
Normal Borderline Abnormal
Evoked  Measures
  HRDB ³ 12 11 £ 10
  VR ³ 1.12 1.07-1.11 £ 1.06
24-hr Measures
  Total power a ³ 6.11 5.95-6.10 £ 5.94
   LF a ³ 5.22 4.97-5.21 £ 4.96
   HF a ³ 3.45 3.29-3.44 £ 3.28
   SDNN ³ 85 79-84 £ 78
   SDANN ³ 69 66-68 £ 65
   SD ³ 33 31-32 £ 30
   RMSSD ³ 14 13 £ 12
   PNN50 ³ 0.6 0.4-0.5 £ 0.3
   Mean NN ³ 632 621-321 £ 620
ASC Index £ 0.49 0.50-0.90 ³ 0.91
Note.  a =natural log (ms2). ESRD=end-stage renal disease, DM=diabetes mellitus, NonDM=without
diabetes mellitus. HRDB=heart rate change with deep breathing, VR=valsalva ratio, ASC
Index=Autonomic Symptom Checklist Index.  See Table 1 for 24-hr HRV measure definitions.
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Discussion
Evoked cardiovascular tests, 24-hr HRV and the ASC ind x measure objective
and subjective autonomic function. The autonomic nervous system is divided into the
parasympathetic and sympathetic pathways, which function in an antagonistic manner to
maintain the balance of visceral functions and to assure the body responds in an
appropriate manner to physical and emotional stressors.  Consequences of dysautonomia
can affect normal body function, particularly the cardiovascular and gastrointestinal
systems, resulting in incapacitating symptoms such as gastroparesis and impotence6.
Severe autonomic neuropathies which are known to accompany ESRD and diabetes can
lead not only to such symptoms, but can result in sudden death3, 12, 16, 22, 59.
The recognition of morbidity and mortality in patient populations diagnosed with
dysautonomia, such as patients with coronary heart disease, ESRD, diabetes mellitus, and
sleep disorders, has stimulated technological improvement in diagnostic equipment.  New
technologies potentially provide earlier diagnosis of dysautonomia.  In addition, various
disciplines encompassing a multitude of laboratories are examining dysautonomia from
different perspectives and increased research is contributing new knowledge.  Although
standards of measurement for cardiovascular evoked tests have been established, the
specific battery of tests used tends to be dependent on the autonomic function laboratory,
the population under study, the technology available, and whether the tests are for clinical
or research purposes.  The establishment of standards for 24-hr HRV measurement and
determination of normal referent values is still in an early stage.  Thus, it is presently
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recommended that individual laboratories develop their own evoked and 24-hr HRV
referent values based on their population of study4, 5.
When the values characteristic of healthy individuals and ESRD pretransplant
patients reported in this study were determined, our findings supported previous data,
which suggested that all groups of ESRD patients have severely compromised autonomic
function and patients with ESRD and diabetes have the greatest degree of
dysautonomia12, 61, 93.  The conclusion that the combination of ESRD and diabetes
further reduces autonomic function more than ESRD alone is supported.  In addition, the
ASC Index, which reports an individual’s perception of symptoms of dysautonomia and
the symptoms impact on the individual’s life, indicated increased symptomatology in
patients with poorer autonomic function.
When examining the relationship between age and measures of dysautonomia, an
inverse relationship was found between most objective measures of dysautonomia and
age in healthy individuals, which is congruent with most studies2, 27, 31, 65.  This
relationship was either absent or weaker in the pretransplant ESRD samples.  Because HF
and LF had a strong inverse correlation with age, it appeared that both sympathetic and
parasympathetic function are involved in this relationship.  In addition, the frequency-
domain demonstrated a stronger correlation with age than the evoked measures
supporting the growing consensus that frequency-domain measures are more sensitive to
autonomic function than either evoked or time-domain measures.  The weaker
relationship observed between age and study measures in patients with ESRD was
possibly due to the disease itself.  These findings are congruent with Bigger et al.2 who
found a significant decrease in frequency measures with increasing age in healthy adults,
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yet, little association was found between age and HRV in a sample of chronic coronary
heart disease patients.  However, our study’s results, which found that both total power
and HF had a strong correlation with age (r= - 0.60; p < 0. 03) in healthy adults, were in
contrast to Bigger et al.’s finding that total power does not significantly decrease with
age.
The effect of gender on all values of evoked, 24-hr HRV, and the ASC index for
healthy individuals appears to be inconclusive, which is congruent with other
studies2, 27, 31, 65.   In the healthy control group, men had higher values than women,
particularly in measures reflective of sympathetic function (LF) and circadian rhythm
(SDNN, SDANN).  Thus, the effect of gender on measures of dysautonomia may be
related to sympathetic function.  This pattern was not seen in the ESRD pretransplant
samples in contrast to Bigger et al.2, who found a gender difference between many 24-hr
measures in patients with coronary heart disease.  However, the reported values for
coronary heart disease patients were not as compromised as those for ESRD pretransplant
patients.  Thus, it is possible that as values become compromised due to the disease
process, the difference between genders observed in healthy individuals becomes
attenuated.
Congruent with findings from other studies2, 46, 82, several measures of 24-hr
HRV were highly correlated in healthy adults.  It has been suggested that when
correlations between two variables were this high, the 2 variables can be used
interchangeably2.  Similar patterns of strong correlations among 24-hr heart rate
variability measures were seen in the two ESRD pretransplant patient samples.  Thus,
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although disease weakens correlations among values, it does not significantly affect
them.
Our results established characteristic values for evoked tests and time- and
frequency-domain measures of 24-hr HRV for our laboratory, based on a sample of 158
healthy individuals.  In general, our values are lower than those reported in the
literature2, 27, 31, 65, possibly due to our healthy controls being predominately women.
Our referent values, consequently, may be conservative.  Other factors that could cause
variation in referent values among laboratories include analysis techniques, methods of
calculation, and differences in geographic populations.  For example, the largest variation
between laboratory values of healthy adults was noted in total power, which Bigger et
al.2, 27, 31, 65measures as <0.40 Hz (total power=9.83), while our laboratory uses 0.01-
1.00 Hz (total power=7.25).  The HF and LF values, which examine the same frequency
range as Bigger et al., were much closer (see Tables 15 and 17).  Based on the values of
the healthy individuals, abnormal values were determined using 2 SDs below the mean,
the 95% confidence interval, and the 2.3 quantile.  The abnormal values established using
the 2.3 quantile appeared to be the most sensitive.  Borderline values were established
from the 2.3 quantile to the 5th quantile.
Our findings indicate that the frequency-domain measures are the most sensitive
and, thus, the best able to identify patients with dysautonomia.  This is congruent with
others2, 49, 50, 109.  For example, when comparing the percentage of abnormal test
responses in ESRD DM group to the healthy control group, it was found that total power
identified 87% of the ESRD DM sample as abnormal vs. 3% of the healthy individuals,
LF found 87% vs. 2%, and HF found 81% vs. 1%.  This is in contrast to Bigger et al.2
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who found that while LF was useful in separating healthy controls from samples of
coronary heart disease patients, HF was not useful.  The difference in findings could be
due to ESRD patients having extremely poor parasympathetic function, which is reflected
in the HF.  This is important because other studies have established an association
between compromised autonomic function37, 38, 92, particularly poor parasympathetic
function93, 126, and sudden death.
In conclusion, this study followed previously made recommendations to establish
laboratory and population dependent referent values for measures of autonomic function.
Characteristic values for healthy individuals and two samples of ESRD pretransplant
patients, in addition to normal, borderline, and abnormal values were determined for each
of the study measures.  The characteristic values of the two pretransplant ESRD samples
were found to be much poorer, especially those of the ESRD with diabetes group, than
those for the healthy individual sample.  These abnormal values were found to be
effective cutpoints for identifying a group with compromised autonomic function in the
two patient samples.  In addition, the frequency-domain measures were the more
sensitive than either the evoked or time-domain measures.  The correlation of age with
autonomic function measures and the effect of gender were examined and found to be
less significant in the patient samples and to vary in importance depending on the study
measure.  This was thought to be due to the disease process attenuating the effect of age
and gender on autonomic function.  The disease process had a minimal effect on
correlations among time- and frequency-domain variables.
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 Chapter 4.  Correlation and Sensitivity Among Three Instruments
Designed to Measure Autonomic Function
Altered cardiovascular autonomic function is a frequent complication of end-st ge
renal disease (ESRD) causing a myriad of clinical symptoms ranging from gastroparesis
and impotence to cardiac death12, 61.  It is of particular concern for patients with ESRD
and diabetes mellitus (DM) with 50% of this population dying within two years of
initiating dialysis therapy1.  Although, no universal gold-standard or battery of tests
exists to evaluate autonomic function45, several objective methods have been described
and compared as to sensitivity in the ESRD population.  Two such methods are evoked
cardiovascular measures and 24-hr heart rate variability (HRV) measures.  While
dysautonomia has been found to be relatively common in newly diagnosed type 1
diabetes mellitus patients35 when assessed with objective measures of autonomic
function, symptoms of dysautonomia are not common and are thought to occur late in the
disease process59, 61.  Our laboratory uses two objective tests, evoked and 24-hr HRV,
in addition to symptomatology to evaluate dysautonomia in ESRD patients awaiting
kidney or kidney-pancreas transplantation.  A scoring system that includes all three tests
would be useful in describing the severity of the individual’s dysautonomia, in addition to
allowing a quantitative way to monitor the progression of the disease and interventions
designed to improve autonomic function127.  However, studies have not defined the
relationships among these three measures of dysautonomia.  In addition, it is unknown to
what extent early abnormalities in objective measures of autonomic function can predict
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the onset and progression of clinical symptoms4.   The purpose of this study was to
compare and contrast three different instruments that assess autonomic function.  In
addition, we sought to establish correlations between physiologic measures of
dysautonomia and symptoms as a step toward defining a threshold where physiologic
measures herald the occurrence of symptomatology.  To this purpose, the following
research aims and questions were investigated.
1. Determine the relationships of measures within the evoked tests, 24-hr heart rate
variability tests, and the Autonomic Symptom Checklist.
1a) What are the correlations among measures of evoked cardiovascular tests?
1b) What are the correlations among measures of 24-hr heart rate variability?
1c) What are the correlations among measures within sections of the Autonomic
Symptom Checklist?
2. Compare the clinical utility of the evoked tests, 24-hr heart rate variability
monitoring, and the Autonomic Symptom Checklist.
2a) What are the correlations among the evoked scores, the time- and frequency-
domain scores of 24-hr HRV, the 24-hr heart rate variability scores, and the
Autonomic Symptom Checklist scores?
2b) What are the sensitivities for detecting dysautonomia of the evoked scores, 24-hr
heart rate variability scores, and the Autonomic Symptom Checklist scores ?
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Introduction
Dysautonomia is difficult to measure and quantify due to the dual innervation of
the ANS (sympathetic and parasympathetic pathways), the numerous reflex arcs
involved, and the anatomic dispersion of autonomic nerve fibers14.  Even with these
measurement obstacles, quantification of dysautonomia using objective physiologic
measures of autonomic function has been reported in the literature since the
1950’s3, 15-17.  Prior to that time, there were occasional references to clinical signs and
symptoms thought to indicate the presence of autonomic neuropathies18.  In the 1970s,
investigators began using a battery of bedside autonomic function tests to aid in
interpretation of these vague symptoms in both diabetic19 and uremic20 patients.  A
battery of tests has been recommended3, 21, 22 because researchers have been unable to
isolate a single best measure of autonomic function.  This battery of tests has moved from
the bedside to the laboratory and has led to improved diagnosis and treatment of
autonomic neuropathies3.
Evoked Cardiovascular Measures
Two evoked measures commonly included in a battery of tests designed to
evaluate autonomic function are the change in heart rate with deep breathing (HRDB)
and the Valsalva ratio (VR)3, 20, 22.   Both measures assess a complex reflex arc
reflecting a “beat to beat” balance of sympathetic and parasympathetic activity which can
easily be altered by physical and/or emotional stress3.   Num rous studies3, 20, 22-32, 41
have used both HRDB and VR to evaluate cardiac autonomic function in normal, uremic,
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diabetic, and transplant populations.  The high reliability, ease of administration, and
non-invasive nature of these tests make them the most popular investigative tools3.
However, there are two major limitations to evoked measures.  First, the patient must be
willing and able to cooperate with the protocol.  Second, although a procedure is
standardized, stimuli could evoke different mechanisms in different individuals, thus, the
resulting measure may not always reflect the same dysfunction33.
Although the HRDB has been shown to be the single most sensitive evoked
measure in many studies22, 25, 63, the VR has been shown to be the most sensitive in
studies of posttransplant kidney and kidney-pancreas patients99 nd newly diagnosed
diabetic patients35.   In addition, one study32 observed that some patients had a markedly
reduced HRDB with a paradoxically normal VR.  When explored further, the
investigators determined that attenuation of both measures indicated possible additional
impairment of cardiac adrenergic failure, in addition to the already suspected
parasympathetic failure.  Thus, there is a lack of consensus concerning which of these
two measures is the most sensitive.  However, when assessing autonomic function with
only evoked measures it is thought that, once the measure becomes abnormal, subjects
either remain static or deteriorate3.
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 24-hr Heart Rate Variability Measures
Twenty-four hour monitoring of heart rate variability and use of power spectral
analysis has gained interest as an alternative method to evoked tests for evaluating
autonomic function.  This method was first appreciated clinically as a strong and
independent predictor of mortality after an acute myocardial infarction37, 122.  Heart rate
variability has the potential to assess earlier stages of autonomic cardiovascular
dysfunction, in addition to examining circadian rhythmicity42, 45-47.  Test measures are
frequently reported in both the time- and frequency-domains (see Table 1).  In an early
study using 24-hr HRV measures, Ewing, Neilson, and Travis48 assessed cardiac
parasympathetic function using the PNN50 derived from 24-hr electrocardiograms
obtained from healthy subjects and diabetic patients.  The results showed the 24-hr HRV
method was better than evoked tests in detecting early cardiac parasympathetic damage.
In another study, Comi, Sora, Bianchi, Bontempi, Gianoglio, Cerutti, Micossi, and
Canal49 compared abnormalities in autonomic function found with HRV recordings to
abnormalities identified with a battery of evoked tests and found that one-fourth of the
diabetic patients with normal evoked measures had abnormal power spectral analysis
results.  Thus, researchers using HRV measures demonstrated this technique as a more
sensitive indicator of dysautonomia than evoked measures.  In addition, power spectral
analysis allowed better quantification of autonomic function into parasympathetic and
sympathetic function.  Using HRV, research of diabetic49-51 and uremic52 patients is
dispelling the previously held belief that diabetic autonomic neuropathy primarily affects
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parasympathetic function.  These studies report lower values in measures of sympathetic
activity, as well as parasympathetic activity.
Several 24-hr HRV time- and frequency-domain measures are strongly correlated
with each other46, 82.  It is thought that these strong correlations exist because of both
mathematical and physiological relationships among time- and frequency-domain
measures53.  Kleiger et al.46 obtained 24-hr HRV measures from 14 healthy individuals
(20-55 years of age) and found that certain time- and frequency-domain variables were
highly correlated and concluded that the measures may serve as surrogates for each other.
High frequency power, RMSSD, and PNN50, all considered measures of vagal function,
were strongly correlated (r>0.9) with each other and with SD.  Low frequency power was
also strongly correlated with the measures of vagal function (r>0.8) indicating that some
parasympathetic activity is reflected in low frequency power.
Bigger et al.82 examined the correlations between time- and frequency-domain
measures in 715, 24-hr HRV recordings obtained two weeks after myocardial infarction.
They found natural groupings for several of the 24-hr measures.  From Bigger et al.’s
data, Keehn83 deduced that both SDNN and SDANN are essentially equivalent to total
power (see Table 1 for measure definitions).  It was suggested82that these measures
could act as surrogates for each other.  Similar patterns of correlation among measures of
parasympathetic function (RMSSD, PNN50, and HF) were reported in an earlier study84
and in a later, larger study2.  In addition, the SDNN and the square root of total power
were almost perfectly correlated, and the time-domain measure, SDNN, was found
strongly and significantly associated with mortality in this group2, 37.
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Symptomatology
Historically, the diagnosis of autonomic neuropathy was based primarily on
clinical features including postural hypotension, intermittent diarrhea, hypoglycemic
unawareness, sweating abnormalities, gastric fullness, and impotence18, 59, which
generally occur late in the disease process.  Symptoms of autonomic dysfunction were
initially described by Rundles60 in 1945.  At that time, limited treatment options existed
for patients with uremia with or without diabetes, and complications resulting from these
diseases generally caused a shortened life expectancy.   Patients did not always live long
enough to manifest symptoms that occurred late in the disease process and symptoms of
dysautonomia were thought uncommon.  Improved medical treatment options have
lengthened a patient’s life expectancy, resulting in increased reporting of
symptomatology.  MacKay et al.63 reported that, although diabetics with autonomic
symptoms as a rule also had abnormal evoked tests, about one-third of the diabetics
without symptoms also had abnormal evoked tests.  Symptoms were, therefore, an
insensitive measure of dysautonomia when compared to evoked measures20, 63 and 24-
hr HRV measures50.  In addition, symptoms of dysautonomia, particularly orthostatic
hypotension, gastric problems and hypoglycemia unawareness, in combination with
abnormal evoked measures of autonomic function, carry a very poor prognosis61.  It is
unknown, if once a patient’s autonomic function is allowed to deteriorate to the point of
symptomatology, whether an intervention such as transplantation can improve the
dysautonomia enough to ameliorate the symptoms.  The purpose of this study was to
examine the relationships among two objective and one subjective test of autonomic
function in ESRD patients both pre and post kidney or kidney-pancreas transplant.
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Methodology
Sample
A convenience sample of patients with ESRD pre-kidney or kidney-pancreas
transplant or posttransplant (n=185) were evaluated for dysautonomia between February
1996 through February 1998.  All data obtained were a part of the patient’s normally
scheduled evaluation.  All transplant patients over 18 years of age were included in the
study unless they were physically unable to participate in data collection or if they were
found to have other neurologic disorders which could affect autonomic function.  Each
patient with diabetes mellitus had blood glucose levels checked prior to autonomic
function testing.  If the blood glucose was 200 mg/dl or over the testing was cancelled
and rescheduled.  Demographic data included information on current medications,
alcohol and tobacco use.  In addition, a group of healthy persons (n=22) was recruited
from faculty, family and friends to determine normal values for autonomic function in
our Physiologic Function Laboratory and for comparison with the ESRD patients.
Healthy control data were collected between November 1995 through February 1998.
Subjects were considered healthy if they reported no neurologic dysfunction or coronary
heart disease.  This study was approved by the Institutional Review Board of the
University of Tennessee, Memphis.  Each participant signed an informed consent (see
Appendix B).  All participants completed all evoked and 24-hr HRV tests, and the
Autonomic Symptom Checklist (ASC).
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Procedure
Study participants were recruited, the study explained, and those volunteering
scheduled for an appointment in the Physiologic Function Lab.  On the day of testing a
consent form was signed, demographic data obtained, evoked cardiovascular tests done,
ASC completed, and an ambulatory Holter monitor applied.  Participants were asked to
return the Holter monitor within 36 to 48 hours.  Following data collection, analysis was
completed and reviewed weekly.
Evoked Cardiovascular Test
Evoked measures, change in heart rate with deep breathing (HRDB) and the
Valsalva ratio (VR) were obtained by tests performed in a temperature-controlled
laboratory dedicated to performing autonomic function tests .  Environmental stimuli
such as noise and light were minimized.  A Power Macintosh 9500 computer system and
AcqKnowledge ® III BIOPAC software were used for data acquisition and analysis of
standard electrocardiogram recordings and blood pressure measurements obtained from a
DinamapTM XL (CRITIKON).   The protocols (see Appendix A) used to perform the
evoked tests were modified from Mayo Clinic’s protocols73, and a brief overview
follows.
The HRDB value was obtained while the patient was relaxed in a recumbent
position breathing deeply and regularly for one minute at a rate of 6 breaths per minute (5
second inhale/5 second exhale) which follows a two minute period of regular breathing.
The difference between the maximum and minimum heart rates was calculated .  The
second test, the VR, was derived by dividing the maximum heart rate during a seated
patient’s forced expiration of 40-mm Hg for 15 seconds by the minimum heart rate within
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15 seconds after the maneuver (see Appendix A).  Reliability and validity have been
established for HRDB and VR5, 19, 23, 63.
Ambulatory 24-hr Holter Recordings
Data collection and processing of 24-hr HRV measures followed manufacturer
recommendations83 in addition to being modified from recommendations by the Task
Force of the European Society of Cardiology and the North American Society of Pacing
and Electrophysiology125.  It is briefly summarized here.  Analysis of 24-hr ambulatory
Holter monitor tapes was completed by Marquette Electronics Laser SXP® Ambulatory
ECG Analysis and Editing Systems with version 5.8 software program and Series 8500
Holter recording system.  Each QRS complex was digitized, identified and labeled.  The
analyzed data file was then scanned and manually edited to locate and correct any errors
in QRS labeling that would adversely affect measurement of heart rate variability.  Tapes
were required to have > 20 hours of analyzable data and generally had > 23 hours of
analyzable data.  Using these data files, 24-hr HRV with power spectral analysis was
calculated (see Appendix A).
Recently, it was recommended that four measures be used for time-domain HRV
assessment; SDNN, HRV triangular index, SDANN, and RMSSD53.  Because both the
SDNN and the HRV triangular index are estimates of overall HRV53, and the SDNN is
more routinely reported in the literature37, this series of studies will report SDNN in
place of HRV triangular index.  In addition, this series of studies is part of a longitudinal
research protocol funded by the National Institute of Health and is in compliance with the
study measures as defined there76.
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The time-domain HRV calculations are placed in two general categories (see
Table 1).  The first category is derived directly from the R-R intervals and includes
means and standard deviations of the interval.  Measures in this category of the time-
domain include the SDNN and the SDANN.  The SDNN is the standard deviation of all
R-R intervals during the 24-hours and has been found to be associated with sudden
cardiac death37.  The SDANN is the standard deviation of the means of R-R intervals
found in successive five minute blocks over 24-hours and is considered the best measure
of overall autonomic balance and represents circadian rhythmicity of autonomic
function75, in addition to estimating long-term components of HRV125.  The second
category of time-domain variables is based on the differences between adjacent R-R
intervals and included the RMSSD.  The RMSSD is the square root of the mean of the
sum of squares of differences between adjacent R-R intervals and is virtually independent
of circadian rhythms.  It reflects alterations in autonomic function that are primarily
vagally mediated57, 125 (see Table 1).
The frequency-domain measures are calculated by fast Fourier transform which
indicates the relative amount of total (0.01-1.00 Hz), low (0.04-0.15 Hz) and high (0.15-
0.40 Hz) frequency power83.  Low frequency waveforms estimates sympathetic activity
along with some parasympathetic activity, while high frequency waveforms, also known
as the respiratory frequency, represents parasympathetic activity9, 10 (see Table 1).
Quality assurance data provided by the manufacturer illustrates mathematically
correct results following submission of known electronically generated cardiac signals83.
This technology has been successfully employed in clinical studies evaluating alterations
in autonomic regulatory mechanisms in patients with heart disease38, cardiac
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transplantation85, diabetic autonomic neuropathy42, 48, 86 uremia52, 87 and kidney
transplantation88. Twenty-four hour measures are highly stable in both normal
subjects46, post myocardial infarction patients55, a d patients with ventricular
arrhythmias89.  Thus, it is thought that 24-hr HRV measures may be ideal for assessing
intervention therapies53, such as transplantation110, exercise68, and deep breathing
relaxation techniques113.
Autonomic Symptom Checklist
The Autonomic Symptom Checklist (ASC) is a self-administered checklist
developed using a focus group approach and designed to recognize the perceived
presence, distribution and severity of autonomic symptoms (see Appendix C).
Development and psychometric testing have been previously described (Chapter 2), and
will be summarized here.   The ASC assesses dysautonomia symptoms in 5 categories
with 32 questions, each using a 7-point Likert scale.  Four additional questions address
daily life-style habits that may influence autonomic function. The five categories of
symptoms are postural hypotension, sudomotor abnormalities, gastrointestinal problems,
impotence, and hypoglycemia unawareness.  A question is also asked in each category to
obtain a score reflecting patients’ perceptions of how problematic symptoms are.
Validity of the ASC was established by administering it to two groups of ESRD
patients with known autonomic dysfunction, diabetic ESRD patients (n=85) and
nondiabetic ESRD patients (n=159) and to healthy controls (n=35).  The DM group
reported the greatest symptomatology, followed by the NonDM group, and with least
symptoms, the control group.  This pattern was present for all symptom categories.
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There was significant difference (p< 0.0001) among all groups for three symptom scores
(orthostatic hypotension, gastrointestinal problems, and impotence) and two impact
scores (gastrointestinal problems and impotence).  There was significant difference (p <
0.003) between healthy controls and both ESRD groups for one symptom score
(sudomotor abnormalities) and two impact scores (orthostatic hypotension and sudomotor
abnormalities.  In addition, findings demonstrated a significant difference (p < 0.03) in
symptoms between patients with diabetes who were hypoglycemia aware and
hypoglycemia unaware.  Test-retest reliability for subscales yielded moderate to high r-
values (0.59 to 1.00), except for the sudomotor subscale.  The ASC appropriately
differentiated among control and two groups with known autonomic dysfunction.  In
addition, the diabetes mellitus groups, which have been shown to have the poorest
objective measures of autonomic function, also had the highest symptom scores.  Thus,
increased symptomatology is seen in patients with worsening physiologic autonomic
function.
Data Analysis
Only pretransplant and posttransplant patients who had values for all study
measures (evoked, 24-hr HRV, and ASC ) were included in data analysis.  Pretransplant
patients with type 2 diabetes mellitus were excluded from analysis, thus, the ESRD with
DM group was composed of patients with only type 1 diabetes mellitus.  This prevented
any confounding effects due to physiologic differences that might occur by including
both type 1 and type 2 diabetes mellitus patients in one group.  Chi square tests were used
to determine equivalence of groups for categorical data.  One-way ANOVA with
preplanned multiple comparisons using Least Square Means was used to test for
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differences among study groups.  Correlational analysis was used to evaluate the
relationship between study measures and time- and frequency-domain measures.
Each individual’s HRDB and VR were assigned a value of 1 (normal), 2
(borderline), or 3 (abnormal) based on our lab’s referent values (see Table 24) determined
by healthy individuals (n=158).  These values were then summed and averaged to
calculate the Evoked Score.  Each of the time- and frequency-domain measures were
assigned a value of 1 (normal), 2 (borderline), or 3 (abnormal) based on our lab’s referent
values (see Table 24) determined by healthy individuals (n=158) and reported in
Chapter 3.  These values were then summed and averaged to calculate the 24-hr HRV
score.   To allow comparisons between sensitivity of the time- and frequency-domain
measures, an individual time-domain score and an individual frequency-domain score
were calculated by summing and averaging the values assigned to their respective
measures.  Thus, time-domain score elements were SDANN, SDNN and RMSSD;
frequency-domain score elements were total power, HF, and LF; and 24-hr HRV score
elements were SDANN, SDNN, RMSSD, total power, HF, and LF.  Each score ranged
from 1 to 3.
Several scoring systems have been suggested to grade the severity of autonomic
damage3, 41, 127.  However, not all scoring systems account for borderline values and
not all evaluate the same study measures we have assessed.  Thus, our scoring system is
modified from others and based on our experience with autonomic measurement in
ESRD patients.  Our scoring system was developed by assessing for cutpoints in the data.
Cutpoints were established for each score such that if the majority of values determining
that score were normal, then the score was normal.  If the values were equally normal and
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borderline, or there were more borderline values than abnormal values the score was
determined to be borderline.  If the values were equally borderline and abnormal, or if
there were more abnormal values, then the score was determined to be abnormal.  The
only exception was the evoked score where if both values were normal, then the score
was normal and if both values were abnormal then the score was abnormal.  All other
evoked values were determined to be borderline.  Thus, using this modified scoring
system, each of the five scores ranged from 1-3 with normal defined as 1.0-1.4,
borderline defined as 1.5-2.4, and abnormal defined as 2.5 to 3.0.
Results
The evoked measures, 24-hr HRV measures, and all sections of the ASC for a
group of ESRD pre and posttransplant individuals and healthy controls (n=290) were
visually inspected for incomplete data sets.  Fifty-three individuals were eliminated from
the study due to missing values, which left a sample size of 237 subjects.  Only one set of
tests measures was used for each individual, thus, if an ESRD transplant patient had both
pretransplant and posttransplant data, the pretransplant data (n=29) were eliminated from
the study sample.  Including the posttransplant data, in addition to having healthy
controls in the study sample, increased the variability among values.  The final study
sample (n=208) was composed of pretransplant ESRD patients (n=130), posttransplant
patients (n= 55), and healthy individuals (n=22).  The total sample had a mean age of
40.2 ± 10.4, with 84 (41%) women and 88 (43%) African-Americans.
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Correlations of Within Test Measures
A correlational analysis among the two evoked measures, HRDB and VR, showed
them to be strongly correlated (r=0.63; p < 00) in this sample of healthy individuals, pre
and posttransplant patients.  Correlations among the six time- and frequency-domain
measures were also strong (p < 0.00) with all r-values > 0.67 (see Table 25).  Correlations
were strongest (p < 0.00) among the frequency-domain measures, especially between
total power and HF (r=0.90) and total power and LF (r=0.99).  In addition, two time-
domain measures, SDANN and the SDNN, were highly correlated (r=0.99; p < 0.00).
The SDNN and the SDANN were correlated (p < 0.00) to total power at r-values of 0.79
and 0.71, respectively.  The SDANN had the lowest correlation with frequency-domain
measures (LF, r=0.69; HF, r=0.67), however, they were still strongly correlated (p <
0.00).  Data in Table 26 displayed the results of a correlational analysis examining the
relationship among the ASC symptom and impact scores for the three categories
completed by the total sample.  All symptom scores were positively correlated with all
other symptom and impact scores (r=0.27 to 0.81; p < 0. 0).  Correlations between
individual category symptom scores and their respective impact scores were high (r >
0.74; p <0.00), with the highest correlation occurring between Orthostatic Hypotension
symptom and impact scores (r=0.81; p < 0.00).  The lowest correlation (r=0.27; p < 0.00)
was seen between Sudomotor impact and Gastrointestinal symptoms. A correlational
analysis was completed on a male subgroup (n=123) examining the impact of the
Impotence category on correlations (see Table 27).  All symptom and impact scores
remained positively correlated with r-values ranging from 0.22; p < 0.01 (Impotence
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Table 25.  Correlational Analysis Among Six Time- and Frequency-Domain
Measures of 24-hr HRV in ESRD Pre and Posttransplant (n=185) and Healthy
Individuals (n=22)
Frequency Measures Time Measures
                               TotPower  LF   HF SDNN   SDANN RMSSD
TotPower 1.00
LF 0.99 1.00
HF 0.90 0.88 1.00
SDNN 0.79 0.77 0.74 1.00
SDANN 0.71 0.69 0.67 0.99 1.00
RMMSD 0.76 0.71 0.88 0.69 0.62 0.89
Note.  TotPower=Total Power, LF=low frequency, HF=high frequency,  See Table 1 for definitions of
measures.
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Table 26.  Correlational Analysis Among Measures in Three Sections of the ASC in
Pre and Posttransplant (n=185) and Healthy Individuals (n=22)
Symptom Scores Impact Scores
                               Ortho Sudo GI Ortho Sudo GI
Symptom Scores
   Ortho 1.00
   Sudo 0.41 1.00
   GI 0.55 0.34 1.00
Impact Scores
   Ortho 0.81 0.32 0.53 1.00
   Sudo 0.38 0.74 0.27 0.36 1.00
   GI 0.49 0.30 0.79 0.54 0.32 1.00
Note.  Ortho=orthostatic, Sudo=sudomotor, GI=gastrointestinal
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symptoms and Sudomotor Impact) to 0.81; p < 00 (Orthostatic Hypotension symptoms
and impact).  Impotence symptom and impact scores were moderately correlated (p <
0.01 to 0.00) with most other symptom and impact values (r=0.25 to 0.56).  A
correlational analysis examining the Hypoglycemia Unaware category (see Table 28)
was completed on a subgroup of ESRD patients with diabetes mellitus (n=30).  The
results showed that all correlations were positive, ranging from r=0.29; p < 0.12
(Sudomotor impact and Hypoglycemia Unaware symptom) to r=0.87; p <0.00
(Orthostatic symptoms and impact).  These results concur with the high r-values between
Orthostatic symptom and impact values that were found for the total sample of pre and
posttransplant ESRD patients and healthy individuals and for men subgroup sample.
Clinical Utility of Measures of Autonomic Function
To compare the evoked tests, time- and frequency-domain tests, and the ASC test
each measure within each test was assigned a value of 1 (normal), 2 (borderline) or 3
(abnormal) and a score was obtained as previously described.  To examine the sensitivity
of the five scores (evoked, time, frequency, 24-hr HRV, and ASC) the sample was
divided into three groups; healthy individuals (n=22), pretransplant patients (n=130), and
posttransplant patients (n=55).  Data from the three groups were examined to determine
the frequency of normal (1-1.4), borderline (1.5-2.4), and abnormal (2.5-3) scores for
each of the five reported study scores (evoked, time, frequency, 24-hr HRV, and ASC) as
previously described.  Characteristics of the three groups are displayed in Table 29.
There were no significant differences in age or gender among the three groups.  The
groups were significantly
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Table 25.  Correlational Analysis Among Measures in Four Sections of the ASC in Pre and Posttransplant ESRD and Healthy
Men (n=123)
Symptom Scores Impact Scores
                               OrthostaticSudomotor GI Impotence Orthostaic Sudomotor GI Impotence
Symptom Scores
   Orthostatic 1.00
   Sudomotor 0.46 1.00
   Gastrointestinal 0.56 0.43 1.00
   Impotence 0.37 0.25 0.40 1.00
Impact Scores
   Orthostatic 0.81 0.39 0.60 0.33 1.00
   Sudomotor 0.52 0.73 0.37 0.22 0.51 1.00
   Gastrointestinal 0.51 0.41 0.77 0.32 0.61 0.47 1.00
   Impotence 0.47 0.35 0.43 0.56 0.49 0.47 0.39 1.00
Note.  Orthostatic=orthostatic hypotension, GI=gastrointestinal.
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Table 26.  Correlational Analysis Among Measures in Four Sections of the ASC in Pre and Posttransplant ESRD Patients with
Diabetes Mellitus (n= 51)
Symptom Scores Impact Scores
                               OrthostaticSudomotor GI HGU OrthostaticSudomotor GI HGU
Symptom Scores
   Orthostatic 1.00
   Sudomotor 0.75 1.00
   Gastrointestinal 0.60 0.53 1.00
   HGU 0.59 0.45 0.49 1.00
Impact Scores
   Orthostatic 0.87 0.67 0.50 0.48 1.00
   Sudomotor 0.63 0.79 0.45 0.29 0.53 1.00
   Gastrointestinal 0.46 0.55 0.78 0.35 0.39 0.37 1.00
   HGU 0.51 0.51 0.44 0.74 0.49 0.36 0.44 1.00
Note.  Orthostatic=orthostatic hypotension, GI=gastrointestinal, HGU=hypoglycemia unawareness.
139
different when compared by percentage of African-Americans (Healthy individuals=0%,
PreTx=55%, PostTx=31%; p£0.001).  Because diabetes in combination with uremia
results in further autonomic function deterioration, the groups were compared by diabetic
status prior to transplantation and found to be significantly different (PreTx=23%,
PostTx=38%; p£0.03).
Table 30 displays the correlational analysis among the test scores.  All scores
were positively and strongly correlated.  It was expected that the time- and frequency-
domain scores would be highly correlated (p < 0.00) to the 24-hr HRV score (r=0.94,
r=0.95; respectively) because they were the two components of the 24-hr HRV score.
However, the time- and frequency-domain scores were also strongly correlated (r=0.78;
p < 0.00) to each other.  The evoked score was also strongly correlated (p < 0.00) with
the time-domain score, frequency-domain score, and the 24-hr HRV score (r=0.55, 0.63,
0.63; respectively).  The ASC score had only weak to moderate correlations (p < 0.01)
with all other scores (r= 0.18 to 0.29).
The results of examining the sensitivity of the five measures are displayed in
Table 31.   As the results show, the frequency-domain score found 38% of the
pretransplant patients and 42% of the posttransplant patients to have abnormal scores.
Compared to the time-domain, which indicated 30% of the pretransplant patients and
29% posttransplant patients abnormal, the frequency-domain was a more sensitive
indicator of dysautonomia.  The ASC score, in addition, was sensitive in identifying
140
Table 27.  Characteristics of Healthy Individuals, ESRD Pretransplant Patients, and
ESRD Posttransplant Patients
Healthy
Individuals
(n=22)
ESRD Pretransplant
Patients
(n=130)
Posttransplant
Patients
(n=55)
Characteristic
Age (yrs.) mean±SD
range
40.7±8.1
25-55
40.6± 10.9
19-67
39.0±10.0
20-66
Gender
  Men
  Women
n (%)
n (%)
15 (68)
7 (32)
77 (59)
53 (41)
31 (56)
24 (44)
Pretransplant
Diabetic Status
  DM
  NonDM
n (%)
n (%)
na
na
30 (23%)‡
100 (77%)‡
21 (38%)‡
34 (62%)‡
Race
  African-Amer.
  Caucasian
  Other
n (%)
n (%)
n (%)
0*
22 (100)*
0
71 (55)*
59 (45)*
0
17 (31)*
37 (67)*
1   (2)
Note. *p£0.001 ‡ p£0.03 between groups with like symbols.
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symptoms of dysautonomia (as measured by abnormal scores) in ESRD pretransplant
(59%) and posttransplant (58%) patients, which are known to have poor autonomic
function.  The evoked score was found to be the least sensitive measure of dysautonomia
as compared to the time- or frequency-domain scores, with findings reporting only 24%
abnormal scores in the pretransplant sample and 25% abnormal scores in the
posttransplant sample.  There was little difference in scores between the ESRD
pretransplant and posttransplant samples.
Discussion
Dysautonomia is a well-known complication of ESRD and diabetes3 and contributes
significantly to its mortality and morbidity1.  Research suggesting various treatment
modalities to prevent diabetic autonomic neuropathy has been reported108.  However, it
appears that the onset of dysautonomia at a sub-clinical level is already present at the
time of diagnosis35 for some patients with diabetes.  It is critical that clinicians have
access to sensitive, reliable, noninvasive, and quantitative means of identifying patients at
high risk of developing dysautonomia.  Then, if treatment modalities such as exercise and
relaxation are found that can alter the progression of dysautonomia113, they can be
applied as early as possible.
Abnormalities detected by 24-hr HRV monitoring are believed to be more
sensitive indicators of autonomic dysfunction than evoked tests, particularly in patients
with diabetes who have significantly less 24-hour R-R interval variability48. Our
findings support this, however, we also found that while the time-domain scores were
sensitive indicators of dysautonomia, the frequency-domain scores were more
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Table 28.  Correlational Analysis Among Evoked Score, Time-Domain Score,
Frequency Score, 24-hr HRV Score, and ASC Score in ESRD Pre and
Posttransplant (n=185) and Healthy Individuals (n=22)
                               Evoked ScoreTime  ScoreFrequency Score24-hr HRV Score ASC Score
Evoked Score 1.00
Time-Domain Score 0.55 1.00
Frequency-Domain Score 0.63 0.78 1.00
24-hr HRV Score 0.63 0.94 0.95 1.00
ASC Score 0.18 0.30 0.25 0.29 1.00
Note.  See Table 1 for definitions of measures.
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Table 29.  Sensitivity of Evoked, Time, Frequency, 24-hr HRV and ASC Scores in
Healthy Individuals, ESRD Pretransplant Patients, and Posttransplant Patients
Test Measures
Healthy
Individuals
(n=22)
 ESRD
Pretransplant
Patients
(n=130)
Posttransplant
Patients
(n=55)
Normal Scores (1-1.4)
  Evoked Score
  Time-Domain Score
  Frequency-Domain Score
  24-hr HRV Score
  ASC Score
n (%)
 21 (95%)
20 (91%)
19 (86%)
19 (86%)
21 (95%)
n (%)
70 (54%)
50 (38%)
40 (31%)
41 (32%)
46 (35%)
n (%)
25 (46%)
26 (47%)
23 (42%)
23 (42%)
20 (36%)
Borderline Scores (1.5-2.4)
  Evoked Score
  Time-Domain Score
  Frequency-Domain Score
  24-hr HRV Score
  ASC Score
1 (5%)
1 (9%)
3 (14%)
3 (14%)
0
29 (22%)
41 (32%)
40 (31%)
34 (26%)
8 (6%)
16 (29%)
13 (24%)
9 (16%)
9 (16%)
3 (6%)
Abnormal Scores (2.5-3.0)
  Evoked Score
  Time-Domain Score
  Frequency-Domain Score
  24-hr HRV Score
  ASC Score
0
0
0
0
1 (5%)
31 (24%)
39 (30%)
50 (38%)
55 (42%)
76 (59%)
14 (25%)
16 (29%)
23 (42%)
23 (42%)
32 (58%)
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sensitive.  In addition, the frequency measures were more capable of discriminating
between parasympathetic and sympathetic modulation53 and documented earlier changes
in autonomic function as compared to the time-domain measures.  Thus, the frequency-
domain measures may be a more clinically useful tool when examining parasympathetic
and sympathetic modulation and circadian rhythmicity in longitudinal research protocols.
Essentially no change was seen between pre and posttransplant patients on all
study scores.  Because previous studies have shown improvement in autonomic function
posttransplant99, study scores were expected to reflect this change.  When examined
closely, the posttransplant group was similar to the pretransplant group in factors that
have been shown to affect autonomic function (age and gender).  However, the
posttransplant group consisted of patients that were 6 to 24 months (6 mo., n=25; 12 mo.,
n=24; 24 mo., n=6) posttransplant.  Possibly, the restoration of autonomic function
occurs more slowly and, thus, a longer time-period than 6-24 months posttransplant is
needed to document change.  Another potential factor was the number of patients in the
posttransplant sample (38%) who had diabetes mellitus pretransplant as compared to the
number of patients in the pretransplant sample (23%) who have diabetes.  Although the
posttransplant patients no longer have diabetes, their pretransplant pathology may have
been such that the posttransplant sample were a select group with poorer
function53, 87, 93.  It may take more time than 6-24 months or larger samples with
patients who are 12-24 months posttransplant to measure improvement in autonomic
function.  Future studies examining long-term posttransplant samples need to take into
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consideration such factors as length of pretransplant diabetes and length of dialysis when
interpreting study results.
Studies2, 46 have shown high correlations between some time- and frequency-
domain measures.  It has been suggested that these measures can be used as surrogates
for each other when compared to a third measure82.  Our study findings did not support
this conclusion.  While strong intracorrelations were demonstrated among frequency-
domain measures and among time-domain measures, the r-values between measures in
the two domains were not as strong.  In conjunction with the finding that frequency-
domain measures were more sensitive than time-domain measures, the correlations
suggested that time- and frequency-domain measures cannot be used as surrogates for
each other.  However, the strong r-values suggest that the time- and frequency-domain
measures can be used to support each other.
Our study’s results also demonstrated a strong correlation between time- and
frequency-domain group scores (r=0.88), however, both groups of measures are of
clinical utility and it is not suggested that one be used in lieu of the other.  The time-
domain measures, particularly the SDNN, have been shown to be associated with
increased mortality in the non-transplant population37 and, in a preliminary study, in the
transplant population93.   Although frequency-domain measures were more sensitive
than time-domain measures, time-domain measures remain an important tool, and,
concurring with prior studies, particularly with patients with established disease.
All symptom and impact scores of the ASC were found to be positively
correlated, however, the ASC score was only weakly correlated with the evoked, time-
and frequency-domain, and 24-hr HRV scores.  Possibly the score correlations were weak
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because the ASC, while able to differentiate between normal and abnormal
symptomatology, was less sensitive to midrange symptoms.  This supposition is
supported by the high percentage of abnormal ASC scores in pre and posttransplant
patients (see Table 31).  The percentage of abnormal ASC scores implied that the ASC
was a sensitive indicator of dysautonomia and its clinical utility in monitoring
symptomatology in longitudinal studies was further supported.
Another reason for weak correlations was that the ASC was designed to evaluate
autonomic symptoms over numerous body systems, such as cardiovascular,
gastrointestinal, urogenital.  In contrast, the evoked and 24-hr HRV measures assessed
only the cardiovascular system.  Because the instruments assessed different systems,
correlations were weak.  Future studies correlating the ASC with evoked tests that assess
other body systems are recommended.
In conclusion, our findings showed 24-hr HRV monitoring to be the most
sensitive indicator of autonomic dysfunction.  We also found that while the time-domain
scores were sensitive indicators of dysautonomia, the frequency-domain scores were
more sensitive87, 93 and, thus, may be more clinically useful.  This is especially the case
when examining parasympathetic and sympathetic modulation and circadian rhythmicity
in longitudinal research protocols.  However, the time-domain measures have been
shown to be clinically useful in identifying an at-risk group for sudden death37, 93, a ,
consequently are also important clinical measures.  All category symptom and impact
scores of the ASC were found to be positively correlated.  In addition, the ASC was
found to be a sensitive indicator of dysautonomia, thus, its clinical utility in monitoring
symptomatology in longitudinal studies was further supported.
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Chapter 5.  Summary, Recommendations, and Conclusions
This series of studies was undertaken to psychometrically assess three tests of
autonomic function, two objective tests and one subjective test, and to explore
relationships among measures of autonomic function in patients with ESRD and healthy
adults.  The studies began with the development of an instrument, the Autonomic
Symptom Checklist, designed to elicit subjective symptomatology of dysautonomia and
concluded with the examination of the sensitivity and clinical utility of three autonomic
function tests.
Patients with ESRD, with or without diabetes mellitus, have been well-
documented to have poor objective values of autonomic function3.  In addi , objective
measures of autonomic function have been demonstrated as able to identify an at-risk
group for sudden death in the myocardial infarction population37, 122 and i  patients
with ESRD93.   A self-administered instrument designed to evaluate autonomic
symptomatology and to allow correlation of symptoms with objective tests would be a
useful research tool.  However, studies examining symptomatology are scant, with
autonomic symptomatology instruments assessing clinical signs in addition to subjective
symptoms25, 115, 127, 128.  Definitive symptoms are thought to occur late in the disease
process60, 61.
 Although standard protocols and referent values for evoked tests, objective
measures of autonomic function, have been suggested21, no one test or battery of tests
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has been established as the gold standard.  Instead, recommendations have been made
that autonomic function laboratories should establish batteries of tests and referent values
based on their unique population of study5, 21.  Recently, recommendations have also
been made for the standardization and interpretation of 24-hr HRV monitoring, another
objective measure of autonomic function53.  However, it is yet to be seen how the
recommendations will be applied in clinical research protocols.
Because our autonomic function laboratory was recently established, referent
values based on healthy individuals in our geographic area and comparisons of sensitivity
and clinical utility among three tests of autonomic function were needed.  A series of
three descriptive studies using samples composed of patients with ESRD and healthy
adults was used for this purpose.  Study 1, reported in Chapter 2, documented the
development and psychometric testing of the Autonomic Symptom Checklist, a self-
administered instrument for assessment of autonomic symptomatology.  Study 2, reported
in Chapter 3, established referent values for evoked tests, 24-hr HRV monitoring, and the
ASC based on values obtained from healthy individuals.  These values were then
compared to autonomic function test values determined from patients with ESRD.
Study 3, reported in Chapter 4, examined the correlation, sensitivity, and clinical utility
among three tests of autonomic function.
      The Autonomic Symptom Checklist
The ASC was developed to provide a subjective measure of autonomic
symptomatology.  This measure could then be correlated with two objective measures of
dysautonomia, the evoked test and 24-hr HRV monitoring.  The ASC is a self-
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administered checklist developed using a focus group approach and designed to
recognize the perceived presence, distribution and severity of autonomic symptoms.  The
ASC assesses dysautonomia symptoms in 5 categories with 32 total questions, each using
a 7-point Likert scale116.  Four additional questions address daily life-style habits that
may influence autonomic function21. The five categories of symptoms are postural
hypotension, sudomotor abnormalities, gastrointestinal problems, impotence, and
hypoglycemia unawareness59, 61.  In each category a question to obtain a score
reflecting patients’ perception of how problematic symptoms are is also asked.
Content validity was established by a group of experts.  Construct validity was
established by administering it to two groups of ESRD patients with known autonomic
dysfunction, diabetic ESRD patients (n=85) and nondiabetic ESRD patients (n=159) and
to healthy controls (n=35).  The DM group reported the greatest symptomatology,
followed by the NonDM group, and with least symptoms, the control group.  This pattern
was present for all symptom categories.  There was significant difference (p< 0.0001)
among all groups for three symptom scores (orthostatic hypotension, gastrointestinal
problems, and impotence) and two impact scores (gastrointestinal problems and
impotence).  There was significant difference (p < 0.003) between healthy controls and
both ESRD groups for one symptom score (sudomotor abnormalities) and two impact
scores (orthostatic hypotension and sudomotor abnormalities).  In addition, findings
demonstrated a significant difference (p < 0.03) in symptoms between patients with
diabetes who were hypoglycemia aware and hypoglycemia unaware.  Test-retest
reliability for subscales yielded moderate to high r-values (0.59 to 1.00), except for the
sudomotor subscale.  The ASC appropriately differentiated among control and two
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groups with known autonomic dysfunction.  In addition, patient groups with diabetes
mellitus, who have been shown to have the poorest objective measures of autonomic
function87, also had the highest symptom scores.  Thus, increased symptomatology is
seen in patients with worsening physiologic autonomic function.
In addition, the symptomatology of posttransplant patients (n=77) as compared to
pretransplant patients (n=233) was examined.  It was thought that with restoration of
metabolic balance and euglycemia posttransplant99, symptomatology would improve.
Findings showed the posttransplant sample had statistically significant (p£0.05) ewer
symptoms than the pretransplant sample.  This finding further supported the construct
validity of the ASC.  Thus, the results of these studies indicated the ASC is a potentially
useful research instrument for monitoring symptom changes brought about by
interventions designed to improve autonomic function.
Referent Values for Evoked Tests, 24-hr HRV Monitoring, and the ASC
This study followed previously made recommendations5, 21 to establish
laboratory and population dependent referent values for measures of autonomic function.
The evoked measures (HRDB and VR), the 24-hr HRV time- and frequency-domain
measures (total power, HF, LF, SDNN, SDANN, SD, PNN50, and RMSSD), and the
ASC index of a convenience sample of pre-kidney or kidney pancreas transplant patients
(n=363) and healthy adults (n=158) were examined.  Characteristic values for healthy
individuals and pretransplant patients, in addition to normal, borderline, and abnormal
values were determined for each of the study measures.  The characteristic values of the
two pretransplant ESRD samples (ESRD with DM, n=91; ESRD NonDM, n=272) were
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found to be much poorer, especially those of the ESRD with diabetes group, than those
for the healthy individual sample.  The abnormal values were found to be effective
cutpoints for identifying a group with compromised autonomic function in the two patient
samples.  In addition, individual frequency-domain measures were more sensitive than
either the evoked or time-domain measures.  The correlation of age with autonomic
function and the effect of gender were examined and found less significant in the patient
samples and to vary in importance depending on the measure being studied.  This was
thought to be due to the disease process attenuating the effects of age and gender on
autonomic function.  The disease process had a minimal effect on correlations among
time- and frequency-domain variables.
Correlation and Sensitivity of Measures of Autonomic Function
Data from a convenience sample of pre-kidney or kidney-pancreas transplant and
posttransplant patients (n=185) and healthy adults (n=22) were evaluated to address
correlation and sensitivity of autonomic function tests.  Our findings were congruent with
others48, 49, which showed 24-hr HRV monitoring to be the most sensitive indicator of
autonomic dysfunction.  In addition, while the time-domain scores were sensitive
indicators of dysautonomia, the frequency-domain scores were found to be more
sensitive, which is also congruent with other studies87, 93.  B cause the frequency
measures are more capable of discriminating between parasympathetic and sympathetic
modulation9 as compared to the time-domain measures, the frequency-domain measures
may be more useful clinically.  Especially when examining parasympathetic and
sympathetic modulation and circadian rhythmicity in longitudinal research protocols.
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However, the time-domain measures have been shown to be clinically useful in
identifying an at-risk group for sudden death37, 93, supporting their utility when
examining mortality.  All category symptom and impact scores of the ASC were found to
be positively correlated.  In addition, the ASC was found to be a sensitive indicator of
dysautonomia.
The onset of dysautonomia at a sub-clinical level at the time of diagnosis35 has
been documented for some patients with diabetes.  It is clinically important, therefore,
that clinicians have access to sensitive, reliable, noninvasive, and quantitative means of
identifying patients at high risk of developing dysautonomia.  This early treatment using
modalities such as exercise and relaxation113 to improve autonomic function can be
started.
Recommendations
Three areas of further exploration concerning measurement of autonomic function
were identified.  These were divided into methodological, theoretical, and clinical
recommendations.
Methodological Recommendations
1. Referent values by gender and by age group need to be established.
2. Recruitment of African-Americans for the healthy adult sample is needed to
determine if there are differences in autonomic function by racial status.
3. Focus groups of patients with ESRD are needed to:
· identify questions in the ASC that need clarification.
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· identify and discuss “early” symptoms of dysautonomia as opposed to
“late” symptoms, which are already define.
4. Because sudomotor symptom and impact scores were low, in addition to weak
correlation coefficients, this category needs to be reexamined for its
applicability in the ESRD population.
5. The high reliability coefficients found in the patients with ESRD subgroup
need to be confirmed with a larger sample size.
6. Categories of the ASC need to be correlated with other evoked tests that were
not examined in this series of studies.  For example, the orthostatic
hypotension category needs to be correlated with the evoked tilt test measure.
7. The potential clinical utility of other frequencies (ultra low, and very low)
needs to be considered by examining their measurement in samples of ESRD
transplant patients.
8. To determine whether pretransplant patients with ESRD are a select group of
ESRD patients, studies examining autonomic function in ESRD samples not
awaiting transplant are needed.
9. Studies are needed that examine long-term transplant patients to evaluate
changes in autonomic function from pretransplant.
Theoretical Recommendations
1. Clinical usefulness of the ASC was shown in this series of studies.  However,
relationships between the ASC and objective measures needs examining to
identify if a score on objective test measures could be strongly correlated with
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symptoms.  This could lead to identification of a threshold where symptoms
occur.
2. We need to further examine why our referent values are different than those
reported by other autonomic function laboratories, particularly in reference to
the frequency-domain measures.  It has been suggested that this is due to
variations in what Hertz ranges are reported by total power, LF, and HF,
however, other factors that could be involved are analysis procedure and
geographic location.
3. Frequency-domain measures from short-term recordings of HRV (5-15
minutes) are closely correlated to 24-hr HRV frequency measures54, and
excellent predictors of mortality.  If so, short-term recordings could be
feasible for longitudinal studies in the ESRD population and needs further
exploration.
4. Further studies are needed to confirm that frequency-domain measures are the
most sensitive assessment tool for measuring autonomic function.
5. Studies are needed to explore the relationships between interventions, such as
exercise and stress reduction, and autonomic function.
Clinical Recommendations
1. The ASC measured autonomic symptomatology of ESRD patients and its use
should be continued.  In addition, its ability to monitor variations in symptoms
that accompany changes in autonomic function (whether deterioration or
improvement) was evident in a small sample of pre and posttransplant patients
and needs further study in larger longitudinal studies.
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2. The identified normal, borderline, and abnormal values need to be used in the
clinical setting to further establish their clinical utility.
3. To establish clinical utility, the associations among measures of autonomic
function and sudden death, particularly the SDNN and frequency-domain
measures, need further examination in the ESRD population.
4. The effects of medications, particularly antihypertensive and antidepressants,
on autonomic function as measured by 24-hr HRV need further exploration.
5. Longitudinal follow-up studies are needed to examine the effect of
interventions, such as transplantation and exercise, on autonomic function.
Conclusions
This series of studies established the reliability and validity of the ASC, an
instrument designed to assess and monitor autonomic symptomatology.  Referent values
for evoked tests, 24-hr HRV monitoring, and the ASC were established with borderline
and abnormal values identified.  A scoring system was devised for the three sets of
autonomic function tests (evoked, 24-hr HRV, and ASC).  It was shown that 24-hr HRV
measures, particularly the frequency-domain measures, were more sensitive to
dysautonomia as compared to evoked measures.
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Appendix A
Testing and Analysis Procedures for
Evoked and 24-hr HRV Monitoring
PROTOCOL #:  02
PAGE  1  OF  2
PRE-TEST PREPARATION
1. Prepare computer for documentation:
A. Open Mac HardDrive
B. Open Folder:  BioPac
C. Open Test #1
D. At the top of screen, click on MP 100 .  Scroll down to: “Show Input Values”.  A
screen will appear in the upper right corner with scores to be used to input patient values
during testing.  Use this screen to note room temperature, blood pressures, and finger
temperature before and after the ice test.
2. At the start of each test, a dialogue box will appear asking if operator desires to 
overwrite existing data.  Click OK.
3. Tape temperature probe to theupper right corner of the computer table.  Do not allow
the temperature transducer surface (shiny side) touch any object.  This probe will
monitor the room temperature until its use with patient monitoring.
4. Insure that the room temperature is between 25° - 27°  Centigrade using the 
temperature probe value displayed on the Input Value screen.
5. Complete the patient interview/data form.  Place “NA” in areas which are not applicable.
Document patient’s health history in the right corner of the medication box:  i.e. length of
IDDM, kidney disease, HTN, dialysis, and any other appropriate information.
6. If patient is a diabetic, insure the Blood Glucose has been drawn prior to starting the
tests.  Document the results in the Pre-Test BG box on the patient interview/data form.
NOTE:  If the Blood Glucose level prior to testing is >200 or <100, recheck the level
after completing the tests and document the results in the Post Test BG box.Continuously
monitor diabetic patients during testing.  Observe for alertness, profuse diaphoresis, or
other signs/symptoms of hypoglycemia.  Treat as appropriate or seek immediate
assistance.
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7. Gather supplies:
A. Razor and Shaving Cream (if needed)
B. Soap and Water to clean skin (if needed)
C. Alcohol 2 X 2s
D. Gauze Pads
E. EKG Electrode Pads (If patient is to receive Holter monitoring following testing,
seven (7) electrodes are needed.  If Holter monitoring is not to be done, only five
(5) electrodes are needed).
F. Transparent/Non-Allergic Tape
G. Double Sided Scotch Tape
H. Scotch Tape
I. Stop Watch
J. Finger Cot
K. Paper Towels
L. Hudson RCI Disposable Mouthpiece
M. Plastic Bowl and ZipLock Bag filled with ice
N. Stool (on which to place bowl of ice water)
O. Holter Monitoring Equipment (See protocol)
8. Ensure the restraining belt is in proper position on the Tilt Table.  Cover the table pillows
with a clean blue pad.
9. Insure that the following equipment is in place and functional:
A. Dinamapä  (Determine that the correct cuff width for patient size is
attached to cable. Cuff can be changed by unscrewing the two rubber
tubes on the cuff from the equipment cables.)
B. Tilt Table with tilting control box accessible
C. Gastric Leads (white and red) located on hook on the left side of computer table
D. Donor Chair with two (2) armrests
E. EKG leads (white, red, and black) located on hook on the right side of
computer table
F. Skin Temperature Probe located on hook on the right side of computer table
G. PPG Signal Probe located on hook on the right side of computer table
H. Valsalva Pressure Monitor Apparatus
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PROTOCOL #:  06
PAGE  1 of 4
TEST # FOUR (4):  Change in Heart Rate with
Deep Breathing (HRDB)  and Valsalva Maneuver
Heart Rate Change with Deep Breathing (HRDB)
1. Attach EKG leads to patient:
ELECTRODE PLACEMENT  
LEAD COLOR LOCATION
White:  V1 (mod) Mid-Sternum-Over Manubrium    1.5 inches from clavicle
Black:   V4R Right Mid-Clavicular Line-Below Rib Cage
Red:      V4 Left Mid-Clavicular Line-Below Rib Cage
2. Patient Instructions:
Explain that they will be doing a breathing  exercise which will consist of one minute of
continuous breathing in which they will breathe in for five (5) seconds then breathe out for five
(5) seconds.
3. Practice for 1-2 breaths.  Count for the patient while you are verifying the correct timing with the
stop watch:  In-2-3-4-5 Out-2-3-4-5.
4. When you are assured that patient understands and can correctly do the test, complete the
following tasks simultaneously:
A. Note the starting point on the stop watch which will establish the start of one (1) minute.
B. Begin test by instructing patient to start deep breathing using stop watch to validate time.
Collect data for one (1) minute.
C. Create a “carrot” and document in the longitudinal box:  “Start deep breathing”.
D. Count for patient:  In -2-3-4-5 Out-2-3-4-5.
5. At completion of one (1) minute (six in and out breathing cycles), instruct patient to breathe
normally.
6. Create a carrot and document in longitudinal box:  “Stop deep breathing”.
7. Do NOT stop watch.  Continue to next test.
VALSALVA MANEUVER (VR)
1. Preparation:
A. Place the white mouthpiece into the Valsalva apparatus.
B. Position the equipment on the patient’s left side where both the patient and technician can
visualize the numbers on the meter.
2. Patient Instructions:
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A. Place the Hudson RCI disposable mouth piece in mouth and hold it with one hand.
B. Blow into the mouth piece until the pressure gauge reaches 40mmHg and maintain that
level of blowing for 5-6 seconds.  In the actual test instruct patient that they will be
maintaining the pressure level for 15 seconds.
C. Upon completion of test, they will be instructed to stop blowing.  Continue to rest quietly
and breathe normally for an additional 15 seconds.
3. Practice 1-2 times to insure patient’s level of understanding as well as ability to reach and
maintain the appropriate pressure level.  Improper mouth seal, dent res or braces may interfere
with quality of test.  Practice with rest periods until patient appears able to successfully complete
test.
4. Allow patient to rest a minimum of one (1) minute before starting test.
5. Alert patient when you are 10 seconds from starting test and instruct them to place mouthpiece in
mouth and wait until they are instructed to “Blow”.
6. Complete the following tasks simultaneously:
A. At the start time instruct patient to get a deep breathe and “Blow”.  Continue saying
“Blow” until test is over.
B. Create a “carrot” and document in the longitudinal box:  “Start Valsalva”.
C. At the point of blowing exhalation, observe watch for fifteen (15) second time frame.
7. At completion of 15 seconds, tell patient to stop blowing.  Create a “carrot” and documen :  “Stop
Valsalva”.
8. Remind patient to rest quietly/no moving/breathe normally.  Maintain quiet for an additional 15
seconds.
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PROTOCOL #:  07
PAGE  1 OF 2
24-hr HRV HOLTER MONITORING:
PATIENT PREPARATION/ELECTRODE PLACEMENT
1.To minimize electrode problems, ensure good quality by checking for expiration date. patient is
to only have Holter Monitoring , use 5 electrodes.  If Autonomic Functionis also is to be done, use
7 electrodes.
2. Apply shaving lotion and using safety razor, shave individual sites.  Shaving 
improves conductivity, holds electrode to the skin, and facilitates removal of 
electrode.
3. If skin is extremely oily, first wash designated area with soap and water.  Clean site 
with alcohol swab. Allow to air dry or dry with clean 4 X 4s.
4. Apply “dot” of liquid sandpaper, rubbing into skin with 4 X 4s, or use sandpaper squares
to further prepare each individual electrode site.
5. If patient is to only receive Holter testing, connect lead wires to each electrode prior 
to applying to patient.  If patient is to have Autonomic Function testing completed first, 
do not attach leads prior to electrode placement.
6. Apply electrodes (See picture, p 2). Tape each lead wire to the chest using a stress loop 
to prevent the wires from pulling directly on the electrode contact points.  The loops 
should be approximately 1 to 2 inches in diameter, about 2 inches from the 
electrodes (See picture below).
ELECTRODE PLACEMENT  
LEAD COLOR LOCATION
White Mid-Sternum-Over Manubrium     1.5 inches from clavicle
Green Right Mid-Clavicular Line               Below Costal Margin
Red Left Mid-Clavicular Line                 Below Costal Margin
Brown Right Mid-Axillary Line                   Below Costal Margin
Black Left Mid-Axillary Line                     Below Costal Margin
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PROTOCOL #:  08
PAGE 1 of 3
24-hr HRV HOLTER MONITORING:  RECORDER PREPARATION
1. Use a new cassette tape for each patient.  A plastic bar inserted into the tape reels
signifies no previous use. Remove the bar from the tape.  Using a pencil in the tape reel, wind the
tape forward until the blank, white pre-tape is beyond the recording site.  This procedure will
ensure that data is recorded from the onset of tape recording initiation.
2. Document patient identification information on the cassette label.
Patient’s Name
Patient’s Social Security Number
Test Date
Time Test was Initiated
Recorder Identification Number: This number is written on the outer metal case.
Patient Category:  Pre-Kidney Juvenile Women’s Study
3. Obtain a new 9-volt alkaline battery.
4. Remove outer metal case of the recorder.  Hold the top of the recorder (the end which
protrudes beyond the metal case) in one hand.  Slide the metal case off with the other hand (See
picture on page 3).
5. Install the battery by inserting it into the battery compartment with the positive (+) and
negative (-) terminals aligned according to the diagram inside the compartment.  The battery
should fit securely in the compartment with no space between the bottom of the battery and the
bottom of the compartment.
6. Slide the cassette release to the left (see picture).  The recording head assembly moves
to the OUT position.
7. Place the tape in the recorder with the full reel on the supply (left) hub.  Insert the
cassette into the recorder by placing the top edge of the cassette in first under the retaining
guides and then carefully easing the cassette down over the supply and take-up hubs and the
cassette locator pins.
8. Prepare the patient and connect the lead wires.
9. Activate the recorder by pushing the recording head assembly IN (flush with the side of
the recorder).  Visualize the take-up hub or the tape reels turning slowly.  Leave the case open
while completing the additional documentation to ensure recorder is working properly.
10. Complete the patient documentation on the diary:
Patient Name
Patient Social Security Number
Age Sex
Patient’s Medications
Date & Time test is initiated
Serial No:  (This number is the Holter Monitor number
Initials of individual completing test in the space for technician
11. Replace the recorder in the metal case and place inside the canvas purse.  Place the
Velcro tab across the cable/recorder site to prevent it from becoming dislodged.  Do not
push the inset button as it will erase tape.
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12. Patient Instructions:
A. Maintain a 24 hour diary of activities.  Especially note:
Time went to sleep-including naps
Time awoke
Remembrance of any periods of dreaming while asleep
Exercise
Home Blood Glucose Monitoring Levels <50 or >200
Time On/Off Dialysis
Stressful Experiences
B. Do not open the canvas purse or attempt to remove the case, even when the 
test is completed.
C. Wear the canvas purse by the shoulder strap or attached to a belt.
D. When the 24 hours of testing have been completed, carefully remove the 
tape over the lead wires and unsnap them from the electrodes.  Place the 
leadwires, cable, and canvas purse in the white envelope for mailing or 
return the equipment to the admissions office on first floor of Bowld 
Hospital.  Do not attempt to open the case.  Remove the electrodes and 
discard.
13. If patient wishes to mail-in equipment, provide them with a white envelope and a Fed Ex
mailing label (See example).  Identify the initials of the principle investigator for test on the form.
Maintain the “Sender’s Copy” in the Physiology Function Laboratory.  Document the monitor
number and test date on the Sender’s Copy for future tracking purposes if necessary.
14. Document patient information into Daily Log Book and on Bulletin Board:
Name
Date of Test
Patient’s Category:  Pre-KidneyJuvenile Women’s Study
Holter Number
Time Holter applied
How Holter will be returned:  Patient in town or per Federal Express
RECORDING EQUIPMENT:  INTERNAL VIEW
ITEM DESCRIPTION
A Supply Hub
B Cassette Locator Pins
C Take-Up Hub
D Battery Compartment
E Signal Test Connector for a Holter Signal Test Cable (PN 9401-901) for 5-
leadwires
F Capstan
G Recording Head Assembly
H Cassette Retaining Guides
I Cassette Release
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Evoked Tests Analysis Procedure
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HEART RATE VARIABILITY ANALYSIS PROCEDURE
1. Loading New Tapes
A.  One tape
 1.  Select #1--NEW TAPE from MAIN MENU
 2.  Select E (Enter) from the NEW TAPE MENU—press RETURN KEY
 3.  Identify an empty space (1-10), select that number when prompted—press RETURN KEY
 4.  Respond to prompts from the computer to:
a. Type patient’s name—Last name, first name, middle initial (if available)
b. Type of  tape—type letter “M”
c. Number of hours to sample—type 24 (hitting return will result in more dual channel noise being
identified)
d. Type in Sampling Parameters—Usually chose “T” for template reduction for adults, and “TP” for
pediatric patients (do not space or put comma between selections).  Additional parameters may be
chosen if needed to increase EKG size, read only one channel, etc.  Refer to Marquette Manual.
Press RETURN KEY.
5. NEW TAPE MENU reappears.  Select P (Process) and enter tape number when prompted.
  Press RETURN KEY.
6. Screen will prompt you to load tape for patient “_____” into Hard Drive Cassette reader.  Insert
tape into hard drive and press RETURN KEY to have system analyze tape (analysis takes about
20 min/tape).  You may change sampling parameter before hitting return key if desired.
  7.  Place diary and tape in upper tray beside computer monitor.
B.  Batch Loading Tapes
1. Select E(Enter) from NEW TAPE MENU
2. Perform steps 1-4 as above for each tape, making sure to select empty space (1-10) for each
tape.
3. Select P(Process) from NEW TAPE MENU—Press RETURN KEY when machine asks which
tapes to process (this will allow all tapes you “entered” to be processed)
4. Load each tape into the Hard Drive Cassette reader when prompted (takes 3-5 min/tape).
5. Press RETURN KEY after each tape loaded for machine to read tape.
6. Once batch loading is complete, the machine will analyze each tape and screen will be blank.
7. Place diary and tapes into upper tray beside computer monitor.
8. Once MAIN MENU is displayed again, operator may access tapes.
C.  Accessing Tapes (if already loaded and analyzed)
1. Select #1—NEW TAPE MENU from the MAIN MENU
2. Select R(Review) from the NEW TAPE MENU and press RETURN KEY.
3. Enter tape number to be reviewed and press RETURN KEY.
       >>will appear beside selected tape
4. Press ESC to escape to the MAIN MENU and perform functions on the selected tape
II.  Patient Information
A.  Select #2 from the MAIN MENU
B.  Enter data for all fields using RETURN key or DOWN ARROW to move from one field to
another. Data to be entered is on the patient diary.  Use military time for time tape started.
C.  Press ESC to escape to MAIN MENU.
III. Diary
A.  Select #3 from the MAIN MENU
B.  Use “I” to insert time and date of an event.  If events are already there, delete them
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C.  Once time and date are inserted, select “F” for free-form to write down the “event.” Some
symptoms can be selected by choosing a letter from the menu at the bottom of the screen
D.  Use > KEY to access the next page for diary entries; only 10 entries can be displayed
 on each page.
E.  Verify events and times entered
F.  Press ESC to return to MAIN MENU
 
IV.  QRS Morphology Review
A.  Select #4 from MAIN MENU
B.  Review each classification group in the following order:  Normal (N), Ventricular (V),
      Artifact (X), and Unclassified (?)
C.  Press TAB KEY, then symbol for classification group you wish to review
D.  Individuals who are very active (or if you did not chose template reduction (T) for sampling
parameter) tend to have more classes within group.
E.  Review the representative beat for each class, use ARROW KEY to move down one class at a
time or the > KEY to move to next page of classes
F.  Review some beats of each class until comfortable with classification, using “R” KEY and then
Up and DOWN ARROW KEYS to see beats in the class.  A six second strip which includes the
classified beat may be viewed by pressing “S” key.  Follow menu on bottom of the screen which
prompts you regarding possible choices.
G.  Reclassify beats or classes as necessary.  Follow screen prompts.  Use SPACE BAR to place
marker in the strip to relabel a beat. > or < KEYS move cursor to next computer identified beat.
RIGHT and LEFT ARROW KEYS allow you to move cursor manually to position cursor exactly
on QRS complex.
H.  Press ESC KEY to return to MAIN MENU
V.  Full Disclosure
A.  Select “F” from MAIN MENU
B.  Note Dual Channel Noise (DCN) for report
C.  If DCN is > 2 hours attempt to reduce DCN by changing sampling parameters.  This requires the
tape to reanalyzed by the machine (20 minutes).  It is recommended that you complete the
analysis with the current parameters because a reduction in DCN may not be possible even with
the sampling parameters changed.
D.  If DCN > 4 hours, even with parameter changes, notify principle investigator to see if holter needs
to be repeated.
E.  DCN is marked by brackets with channels containing noise  ( <3  >2).  DCN is programmed out
of the HRV analysis even if you manually correct the beats.  We are not relabeling beats in DCN.
F.  NOTE:  Since DCN is excluded from analysis, episodes of arrhythmias occurring during this time
will not be reported.  If this is of concern to the investigator, review of DCN can be done by
Pressing “D” for DATA WINDOW, “H” for HIGHLIGHT, and then “D” for DUAL CHANNEL
NOISE, then press RETURN KEY.  Pressing “F” for Forward, will bring the next episode of
DCN to the screen for review.  The individual strip of DCN can be selected by pressing the “S”
obtain the cursor, move the cursor to the area of DCN using the ARROW KEYS  and press the
“S” for STRIP key again.  Follow prompts on the screen.
G.  Press ESC KEY to return to MAIN MENU
VI.  Episode Review (Histograms)
A.  Select #5 from the MAIN MENU
B.  Review R-R intervals, all beats (enter 1, 1) and press RETURN KEY
C.  Review shortest RR intervals, correct any mislabeled beats by selecting “S” Strip
      Once strip appears, press SPACE BAR for cursor to appear, use > or < to move to next sensed
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      beat or ARROW KEYS to manually position cursor over QRS to relabel a beat
D. You can view the next RR interval by pressing the UP ARROW KEY, the screen will show
     the histogram at the top of the screen with the RRI length while the strip is in the middle
     of the screen.
E.  Label the “true” shortest RRI (N-N beats, not S-N beat) by pressing the “F” FILE KEY
      and the “F” again to allow you to write in “Shortest RRI”.  This will be recorded on diary
      and on cover page of report.  Press RETURN KEY to get back to histogram
F.  Once a “true” shortest RRI is found, you will move to the Longest RRI by pressing > KEY
      while viewing the histogram.  Press “S” KEY to view strip with this RRI.
G.  Continue as you did for the shortest RRI, making sure to relabel all beats.
H.  Once a “true” longest RRI if found, press “F” to file it, and “F” again to write in “Longest RRI.”
I.  Press “L” to have longest RRI placed on cover sheet
J.  Press “M” to eliminate RRI filled with artifact from histogram.  Press RETURN KEY to view
histogram
K.  While viewing histogram, press “F” File, to file histogram.
L.  Press RETURN KEY to return to HISTOGRAM MENU SELECTION,
M.  Press ESC KEY to return to MAIN MENU
VII.  Report Review
A.  Select #9—Report Review from MAIN MENU
B.  Verify patient record you want to review is in slot 0.
C.  Press H (HRV) to print one copy of the Heart Rate Variability.  Screen will go blank, Numbers 1
to 3 will light up in sequence.  Once 3 lights up, a HRV frequency graph will be depicted.  Press
ESC KEY and you will return to MAIN MENU.
D.  Select #9—Report Review from MAIN MENU
E.  Select R (Review) to review a report.
F.  Select report number of patient (should be 0 if current report) and press RETURN KEY
G.  Enter “1” when prompted to select FORMAT 1.  Will automatically show report  without return
key being used.
H.  You will see diary first.  Skim to see that entries are correct and that shortest and longest RRI are
noted on diary.
I.  Press PF4 to move to next page.
J.  Cover page will include sampling length (should be 24 hr unless holter removed early)
      and low/high/average HR.  Press PF4 to move to next page.
K.  Scroll down next page to see how the duration of each hour (DCN reduces duration in
      each hour).  Program automatically substitutes the next normal RRI into the DCN area)
      Note hours in which duration is less than 30 minutes and include under analyst comments
      on last page of report.  Press PF4 to move to next page.
L.  Continue reviewing report until reaching last page.  Document quality of tape (excellent, very
good, good, fair, poor) and analysis time in minutes.  Enter your initials and monitor number if
not already there. Under analyst comments include DCN, hours of duration less than 30 minutes,
total duration <24 hours should be indicated if occurs.  Press PF4 to move to next page.
M.  Prompt will appear asking if you want to save report--Press Y
N.  Prompt will appear asking if you want to print report—Press Y
O.  Prompt will appear asking how many copies of report to print—Press 1
P.  Prompt will appear asking how many strip copies—Press 0
Q.  Press  RETURN KEY. Report will print.  Press RETURN KEY TO get back to MAIN MENU.
R.  Select #1 NEW TAPE from MAIN MENU and press RETURN KEY
S.  Select “D” for delete from NEW TAPE MENU and enter number of tape to be deleted
T.  You will be asked if you are sure (Y/N) select appropriate letter.
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U.  Strips will be saved to hard drive (report was previously saved) and slot is now available for new
tape to be entered into that space for analysis
 
VIII.  Files
A.  Calculate low/high ratios for HRV
B.  Make one copy of entire report for lab
C.  Place original in principle investigator’s folder
D.  Place copy for lab in outer office of AFT  lab
   IX. Troubleshooting
A.  Playback error:  Tape will not load
1. remove tape from cassette reader in hard drive, reinsert, and press return
2. select playback error from MAIN MENU
B.  Diary times incorrect
1. verify start time and date are correct in #2—Patient information
2. check trends or full disclosure (enter time on full disclosure menu that you want to look at
and it will show that screen).  If there is no data on the tape for that time, a forward time
cannot be entered in the diary section.
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Appendix B
Informed Consents for Patients with Renal
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Appendix C
Autonomic Symptom Checklist
Please tell us how much of a problem the following symptoms have been to you during
the last month.  Circle one number between 0 and 6.  The number 0 means the symptom
is never a problem to you and 6 means the symptom is always a problem to you.
1. Symptoms when you stand: Never Always
a.   Do you have a rapid heartbeat when you stand? 0    1    2    3    4    5    6
b.   Do you have blurred vision when you stand? 0    1    2   3    4    5    6
c.   Do you have an upset stomach when you stand? 0    1    2    3    4    5    6
d.   Do you have dizziness when you stand? 0    1    2    3    4    5    6
e. Do you have clammy skin when you stand? 0    1    2    3    4    5    6
f.  How much of a problem are these symptoms for you? 0    1    2    3    4    5    6
Comments: ________________________________________________________________
2.   Symptoms when you sweat: Never Always
 a.   Do you have an increase in sweating in any part of your body? 0    1    2    3    4    5    6
b.   Do you have a decrease in sweating in any part of your body?0    1    2    3    4    5    6
c.   Do you sweat during or after eating? 0    1    2    3    4    5    6
d.   How much of a problem are these symptom  for you? 0    1    2    3    4    5    6
Comments: ________________________________________________________________
3.   Symptoms of bowel and stomach problems: Never Always
a.   Do you have diarrhea? 0    1    2    3    4    5    6
b.   Do you have diarrhea at night? 0    1    2    3    4    5    6
c.   Do you lose control of your bowel movements? 0    1    2    3    4    5    6
d.   Do you have trouble moving your bowels? 0    1    2    3    4    5    6
e.   Do you have stomach fullness before you are finished eating?0    1    2    3    4    5    6
f.   How much of a problem are these symptoms for you? 0    1    2    3    4    5    6
Comments:________________________________________________________________
188
4. If you are a man, please answer the following: Never Always
a.   Are you able to get an erect penis?   0    1    2    3    4    5    6
b.   Are you able to have an erect penis when you want one?0    1    2    3    4    5    6
c. Are you able to maintain the erection as long as you want? 0    1    2    3    4    5    6
d. Over time, have you noticed any changes in the firmness?      0    1 2    3    4    5    6
e.   How much of a problem are these symptoms for you? 0    1    2    3    4    5    6
Comments:________________________________________________________________
Never Always
5. If you have diabetes, please answer the following:
a.   Do you have symptoms when your blood sugar is low?0    1    2    3    4    5    6
b.   Have you had an increase in symptoms 0    1    2   3    4    5    6
c.   Have you had a decrease in symptoms 0    1    2    3    4    5    6
d.   Does it take a lower blood sugar for you to feel symptoms0    1    2    3    4    5    6
e.   How much of a problem is this for you? 0    1    2    3    4    5    6
Comments:________________________________________________________________
6.   How many drinks of beer, wine, or liquor do you have most days?  _________
7. How many servings of caffeine (soft drinks, coffee, tea, chocolate) do you have
      most days? ____
8.   Do you use tobacco products?       (a)  Yes   No
      Mark with an X all the ones you use. __  (b) cigarettes
__  (c) cigars
__  (d) chewing tobacco
__  (e) snuff
__  (f) pipes
9.   Please list all the medications you are taking.
Akc
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Appendix D
Calculation Procedure for the Autonomic Symptom Checklist
There are 3 tabulations for each individual for each category.  They are raw symptom
score/category, symptom score/category, and impact score/category.
1. Raw Symptom Score—sum of all points for that category excluding the last question,
which is the impact, question. The range of scores differs per category:
hypotension=0-30, sudomotor=0-18, GI=0-30, impotence=0-24, hypogycemia=0-24.
In all categories a higher scores indicate increased symptomatology.
2. Symptom Score—the Raw Symptom Score divided by the number of questions
possible in the category.  Range is 0-6.  In all categories a higher scores indicate
increased symptomatology.
3. Symptom Impact Score—points indicated by subject on the impact question.  Range is
0-6.  The higher the score the more that category of symptoms is a problem to the
subject.
4. Other scores
· Raw Total Symptom Score—Sum of all Raw Symptom Scores for a subject.  The
range of the Raw Total Symptom Score differs by group, thus they can not be
compared.  Diabetic women=102, diabetic men=126, nondiabetic women=78, and
nondiabetic men=102.
· Total Symptom Score—Sum of category symptom scores divided by the number of
categories available for that group to answer (eg., DM women=4, DM men=5,
NonDM women=3, NonDM men=4).  The possible range for each group is 0-6, thus
the scores can be compared across groups.
· Raw Total Impact Score—Sum of all points scored on impact questions.  The range
varies per group, thus it can not be analyzed across groups.
· Total Impact Score—Sum of the category impact scores divided by the number of
impact questions possible for that group.  The possible range for each group is 0-6,
thus the scores can be compared across groups.
· Raw Index Score—Raw Total Symptom Score multiplied by the Raw Total Impact
Score.   The range of the Raw Index Score differs by group, thus, they can not be
compared across groups.
· Index Score—Total Symptom Score multiplied by the Total Impact Score.  The
possible range for each group is 0-36, thus, the scores can be compared across groups.
akc
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